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SUMMARY 
Proteins are essential structural and functional components of cells and catalyze a 
multitude of biochemical reactions. Many proteins are subject to post-translational 
modifications in order to regulate their function and enzymatic activities. ADP-
ribosylation of proteins is catalyzed by ADP-ribosyltransferases, which transfer one 
or more ADP-ribose molecules from their co-substrate NAD+ to their target proteins. 
The best-studied mammalian ADP-ribosyltransferase is ARTD1 (also called PARP1), 
a nuclear enzyme, which binds to and is activated by damaged DNA and poly(ADP-
ribosyl)ates itself and other proteins.  
SET7/9 is a lysine methyltransferase that was initially identified as a mono-
methyltransferase for H3K4, but also methylates many non-histone proteins such as 
p53 and DNMT1. SET7/9-dependent methylation has variable functional outcomes 
e.g. protein stabilization or crosstalk with other post-translational modifications. 
In this thesis, ARTD1 and the linker histone H1 have been identified as new targets 
for SET7/9 and the influence of SET7/9 on their cellular functions has been 
characterized. We found in vitro and in vivo that SET7/9 methylates ARTD1 at K508. 
This modification was strongly inhibited by prior poly(ADP-ribosyl)ation of ARTD1, 
while the methylation did not inhibit the automodification of ARTD1 nor its 
acetylation by p300. In cells, H2O2-induced poly(ADP-ribose) formation was 
decreased after SET7/9 knockdown and increased after SET7/9 overexpression. 
Mutation of K508 to arginine reduced the activity of ARTD1 under certain conditions, 
indicating that direct methylation of ARTD1 by SET7/9 is involved in the regulation 
of its enzymatic activity. 
Furthermore, we showed that SET7/9 methylates several lysine residues (K121, K129, 
K159, K171, K177 and K192) in the C-terminal domain of linker histone variant H1.4. 
Mutation of these residues, which are located at the terminal position of six KAKme 
motifs, did not alter the nuclear distribution of H1.4.  The functional consequence of 
H1 methylation by SET7/9 has to be further elucidated. Finally, we observed that 
ARTD1-dependent histone modifications shift the substrate specificity of SET7/9 
from H3 to H1. This crosstalk supports a role of poly(ADP-ribosyl)ation as an 
additional component of the histone code.  
Taken together, the identification of these two novel SET7/9 target proteins further 
underlines the important role of SET7/9 during the cellular stress response. 
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ZUSAMMENFASSUNG 
Proteine verleihen Zellen ihre Struktur und Funktion und steuern alle biochemischen 
Prozesse. Viele Proteine werden posttranslational modifiziert, wodurch ihre Funktion 
und enzymatische Aktivität reguliert werden. Die ADP-Ribosylierung von Proteinen 
wird von ADP-Ribosyltransferasen katalysiert, welche ADP-Ribose von ihrem 
Coenzym NAD+ auf ihre Zielproteine übertragen. Die bekannteste ist ARTD1 (auch 
PARP1), ein nukleäres Enzym, welches durch DNA-Schäden aktiviert wird und 
Polymere aus ADP-Ribose auf sich selbst und andere Proteine überträgt. 
SET7/9 wurde ursprünglich als Monomethyltransferase für H3K4 entdeckt, aber 
methyliert auch Lysine von vielen Nicht-Histon-Proteinen wie p53 und DNMT1. Dies 
hat unterschiedliche Folgen für die Substrate, z. B. ihre Stabilisierung oder die 
Beeinflussung von anderen posttranslationalen Modifikationen. 
In der vorliegenden Arbeit wurden ARTD1 und das Linkerhiston H1 als neue 
Substrate für SET7/9 identifiziert und der Einfluss der Methylierung auf deren Funk-
tionen in der Zelle untersucht. Wir fanden in vitro und in vivo, dass SET7/9 ARTD1 
an K508 methyliert. Dies wurde durch vorherige Poly(ADP-Ribosyl)ierung von 
ARTD1 stark gehemmt, während die Methylierung selbst weder die Automodi-
fikation von ARTD1 noch seine Acetylierung durch p300 verringerte. In Zellen führte 
SET7/9-Knockdown zu verringerter Synthese von Poly(ADP-Ribose) nach H2O2-
Behandlung, während SET7/9-Überexpression den gegenteiligen Effekt hatte. Auch 
Mutation von K508 zu Arginin verringerte die Aktivität von ARTD1 unter bestimm-
ten Bedingungen, was darauf hindeutet, dass die Methylierung durch SET7/9 die 
enzymatische Aktivität von ARTD1 direkt beeinflusst. 
Desweiteren haben wir gezeigt, dass SET7/9 mehrere Lysine (K121, K129, K159, 
K171, K177 and K192) im C-Terminus der Linkerhiston-Variante H1.4 methyliert. 
Alle sechs Lysine liegen am Ende der Konsensus-Sequenz KAKme und ihre Mutation 
verändert die Verteilung von H1.4 im Zellkern nicht. Die genaue Funktion dieser H1-
Methylierung muss noch erforscht werden. Interessanterweise methyliert SET7/9 
nach ARTD1-abhängigen Histonmodifikationen bevorzugt H1 statt H3, was die Rolle 
der Poly(ADP-Ribosyl)ierung als Teil des Histoncodes untermauert.  
Die Identifikation von zwei neuen SET7/9-Substraten in dieser Dissertation hebt die  
wichtige Rolle von SET7/9 in zellulären Stressreaktionen hervor. 
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ABBREVIATIONS 
3-AB    3-aminobenzamide  
aa   amino acid(s) 
ADP   adenosine diphosphate 
AMD   automodification domain 
AMP   adenosine monophosphate 
AMPK   AMP-activated protein kinase 
ARH   ADP-ribosyl hydrolase 
ARTD   ADP-ribosyltransferase diphtheria toxin-like  
ATP   adenosine triphosphate 
bp   base pairs 
BER    base excision repair 
BRCT   BRCA1 C-terminus   
CDK   cyclin-dependent kinase 
CIP   calf intestinal alkaline phosphatase 
ChIP   chromatin immunoprecipitation 
CPT   camptothecin 
CTD   carboxy-terminal domain 
DAM-TIQ-A  2-dimethylaminomethyl-4H-thieno [2,3-c]isoquinolin-5-one 
DAPI   4',6-diamidino-2-phenylindole 
DBD   DNA binding domain 
DDR   DNA damage response 
DNA   deoxyribonucleic acid 
DSB   DNA double-strand break 
FAD   flavin adenine dinucleotide 
GFP   green fluorescent protein 
H2O2   hydrogen peroxide 
HDAC   histone deacteylase 
HIF   hypoxia inducible factor 
HMG   high mobility group 
HR   homologous recombination 
I!B    NF-!B inhibitor  
IKK   I!B kinase 
Abbreviations 
 6 
IR   ionizing radiation 
JmjC   Jumonji-C 
KMT   lysine methyl transferase 
LPS   lipopolysaccharide 
LSD   lysine specific demethylase 
MLFs   mouse lung fibroblasts 
MMS   methyl methanesulfonate 
NAD+    nicotinamide adenine dinucleotide  
NF-!B   nuclear factor !B 
NTD   amino-terminal domain 
PAR   poly(ADP-ribose) 
PARG   poly(ADP-ribose) glycohydrolase 
PARP    poly(ADP-ribose) polymerase  
PARylation  poly(ADP-ribosyl)ation 
PRMT   arginine methyl transferase 
SAH   S-adenosyl homocysteine 
SAM   S-adenosyl methionine 
WGR   tryptophan-glycine-arginine motif  
ZBD   zinc binding domain 
ZF   zinc finger 
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INTRODUCTION 
1. Chromatin  
In eukaryotic cells, the genetic information is packaged into chromatin, a structure 
composed of DNA and a specialized group of proteins, mainly histones (reviewed in 
[1]). The assembly of the DNA into chromatin fulfills the remarkable task to fit a 
stretch of two meters of DNA into the cell nucleus that has a diameter of only a few 
microns. On the other hand, chromatin condensation is a natural obstacle for many 
DNA-based cellular processes like transcription, replication and DNA repair. In order 
to activate or repress genes according to the changing needs of a cell, chromatin 
architecture has to be tightly regulated. To this end, chromatin is divided into 
euchromatin and heterochromatin. Euchromatin comprises less condensed genomic 
regions that are usually transcriptionally active. Heterochromatin consists of more 
tightly packed DNA and usually stays condensed throughout the cell cycle. The gene-
free regions at the centromeres and near the telomeres of the chromosomes are forms 
of constitutive heterochromatin. The formation of facultative heterochromatin, on the 
other hand, is often associated with developmental programs and X-chromosome 
inactivation in female mammalian cells.  
 
1.1. Nucleosome structure 
The smallest building unit of chromatin is the nucleosome, which consists of 147 bp 
of DNA wrapped approximately 1.7 times around an octamer of core histones. The 
octamer consists of a central H3-H4 tetramer capped by two H2A-H2B dimers. All 
core histones harbor a flexible N-terminal tail and a globular domain with a 
structurally conserved motif, the so-called histone fold. It consists of three alpha 
helices that are connected by short loops [2]. The N-terminal tails are highly enriched 
in basic amino acid residues and protrude from the nucleosome. The nucleosomes are 
connected by 20 to 80 bp of linker DNA and build the first level of compaction of the 
DNA (10nm fiber). This structure looks like “beads on a string” under an electron 
microscope.  
The core histones and especially their N-terminal tails undergo many post-
translational modifications that do not merely alter their affinity to the DNA but also 
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regulate the interaction with other proteins. These modifications allow a very 
shapeable chromatin structure, which is necessary to accommodate all cellular 
processes that take place at the DNA while retaining the ability to properly distribute 
the chromosomes to the daughter cells during cell division. 
 
1.2. Linker histone H1 
The linker histone H1 is responsible for further condensing the polynucleosomal fiber 
into a 30 nm fiber. It binds to the nucleosome at the DNA entry and exit sites and 
protects additional parts of the linker DNA (~ 20bp) from micrococcal nuclease 
digestion. The binding of H1 to nucleosomes induces the linker DNA to form a stem-
loop structure [3], which enables the higher chromatin compaction into interphase 
chromosomes. During mitosis, further coiling leads to the highly condensed state of 
the metaphase chromosomes (Fig. 1). 
                          
 
Figure 1. Chromatin structure and compaction by H1. (a) The DNA double helix is packaged into 
nucleosomes, further condensed into 30 nm fibers in presence of H1 and ultimately coiled into higher-
order structures to form the metaphase chromosomes. Picture taken from [4]. (b) Binding of linker 
histone H1 to nucleosomes induces a more closed conformation of the linker DNA. Model from [5]. 
 
1.2.1. H1 structure  
Linker histones exist in all multicellular organisms and some protists and histone H1-
like proteins were even identified in some eubacteria, but not in archaebacteria [6]. 
a b 
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The H1 from metazoans exhibits a tripartite structure composed of a central globular 
domain flanked by a short, flexible N-terminal tail and a long C-terminal tail rich in 
lysine residues. The globular domain of H1 is built by a winged helix motif [7] that is 
evolutionary unrelated to the histone fold of the core histones [6,7]. It is necessary for 
H1 function in chromatin condensation and involved in nucleosome binding [8,9]. 
While the globular domain is relatively well conserved between species, the C-
terminal domain (CTD) is much more divergent. The CTD makes up almost half of 
the H1 protein (about 100 amino acid residues) and has a highly basic amino acid 
composition. It is the amino acid composition but not the primary sequence of the 
CTD that is important for its functions in chromatin condensation [10]. The 
predominant amino acid residues of the CTD are lysines (about 40%), followed by 
alanines and prolines, while serines, threonines, valines and glycines are much less 
abundant. The CTD is almost completely devoid of highly hydrophobic and 
negatively charged amino acids. Due to this particular amino acid composition, the 
CTD is thought to be intrinsically disordered [11]. This means it has molten globule-
like properties in solution, but adopts a specific structure when associated with its 
macromolecular interaction partners [12]. Indeed, it was shown that the CTD does not 
exclusively function by neutralizing the negative charge of the linker DNA as 
previously assumed, but that the CTD can be subdivided into specific functional 
regions that are more or less important for DNA stem-loop formation and chromatin 
condensation, probably by adopting specific structural features [13]. Due to its high 
content of lysine and alanine residues, the CTD is predicted to form "-helices that 
might be initiated and interrupted by the proline residues [14,15].  
Like the CTD, the N-terminal tail of H1 is less conserved than the globular domain 
and unstructured in aqueous solution [16]. It is much shorter than the CTD, not 
required for H1 function in chromatin condensation and is thought to influence H1-
protein interactions [17] (e.g. with HP1 [18]). 
 
1.2.2. H1 variants 
The H1 family is the most divergent class of histone proteins [19]. To date, eleven 
different subtypes that are encoded by individual non-allelic genes were identified in 
mammals (reviewed in [20,21]). These H1 variants can be subgrouped based on 
different criteria such as their expression pattern or the localization of their genes on 
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different chromosomes. H1.1 to H1.5 are replication-dependent variants that are 
expressed in somatic cells during S phase of the cell cycle. In humans, these five H1 
variants are located within a large histone gene cluster on chromosome 6 [21]. H1x is 
another variant that is ubiquitously expressed, but its expression is constant  
throughout the cell cycle and is not limited to S phase [22,23]. H1.0 is considered a 
replacement variant that is only expressed after terminal differentiation in specific cell 
types [24]. The expression of the residual four H1 variants (H1t, H1T2, Hils1, H1oo) 
is restricted to germ cells [21]. 
The H1 variants mainly differ in their N- and C-terminal extensions and originated 
from a common ancestral gene by gene duplication events. In mammals, the H1 
paralogs within the same species often vary much more than the orthologs of an 
individual H1 variant in different species [25,26]. H1.2 and H1.4 are the predominant 
variants in most cell types, while H1.1 expression is rather low in most tissues [21,27]. 
The different somatic H1 subtypes also vary in their binding affinities to chromatin 
and their subnuclear localization. H1.4 and H1.5, for example, are mainly found in 
heterochromatic regions when overexpressed as GFP fusion proteins, while H1.0, 
H1.1, H1.2 and H1.3 are also present in euchromatic regions. Chromatin binding 
affinities of the H1 variants are generally correlated to the length of their CTD with 
H1.4 and H1.5 showing the highest affinity in FRAP studies. An exception is H1.0, 
which has the shortest CTD, but still exhibits moderate affinity for chromatin, 
probably due to the high content of basic amino acids within its CTD [28]. 
Despite the differences described above, none of the H1 variants seems to be essential 
in knockout studies in mice [29,30]. It is thus very likely that they have partially 
redundant functions and that the deletion of a single variant is compensated by 
increased expression of the others. Only the sequential knockout of three H1 genes 
(homologs of human H1.2, H1.3 and H1.4) in mice, which resulted in a 50% reduced 
H1 protein expression, was embryonically lethal [31]. In embryonic stem cells 
derived from these mice, the depletion of H1 resulted in a reduced H1/core histone 
ratio and reduced local chromatin compaction, but had only small effects on gene 
expression. This indicates that despite of its function in higher-order chromatin 
formation, H1 should not be regarded as a general repressor of transcription, but 
rather as a regulator of the expression of specific genes [32]. 
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1.2.3. Post-translational modifications of H1   
Like the core histones, linker histones undergo diverse post-translational 
modifications that regulate their affinity for chromatin and the interaction with other 
nuclear proteins [21,33-35]. An overview of some H1 modifications is given in Fig. 2. 
The most extensively studied modification of H1 is phosphorylation, which was 
discovered a long time ago [36]. H1 is phosphorylated at multiple serine and 
threonine residues within its N- and C-terminal tails. Most of the H1 phosphorylation 
sites lie within the CDK consensus motif (S/T)PX(K/R) which was also shown to be 
important for DNA binding of H1 [37]. The responsible kinases are CDK1 and CDK2 
[37,38], which are counteracted by protein phosphatases [39]. H1 variants contain 
unequal total numbers of CDK motifs and these sites are differentially phosphorylated 
during the cell cycle with varying functional outcomes [40]. H1 phosphorylation 
progressively increases during the cell cycle with the lowest levels in G1 phase and 
the highest levels in late G2 phase and mitosis [41,42]. The phosphorylation of only 
few sites during the S-phase of the cell cycle leads to chromatin decondensation 
required for DNA replication [43], while extensive phosphorylation of H1 during 
mitosis is linked to chromosome condensation [44]. It was shown that 
unphosphorylated H1 binds more tightly to the DNA than the low-phosphorylated 
forms [45,46], which can be explained by the negative charges that are introduced by 
the phosphorylation and lead to electric repulsion of the DNA. H1 
hyperphosphorylation during mitosis, however, induces structural changes in the CTD 
that finally lead to the opposite effect and induce the high compaction of the mitotic 
chromosomes [47].  
Apart from this cell-cycle dependent regulation and function, H1 phosphorylation also 
seems to be involved in many other cellular processes such as apoptosis, DNA 
damage signaling and gene regulation. H1 phosphorylation is associated with 
transcription by RNA polymerase I and II and in this context mimics the effects of H1 
removal and leads to chromatin relaxation [48,49]. 
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  H1.2    ----MSETAPAAPAAAPPAEKAPVKKKA-AKKAGGTP--RKASGPP-VSELITKAVAASK 52 
H1.3    ----MSETAPLAPTIPAPAEKTPVKKK--AKKAGATAGKRKASGPP-VSELITKAVAASK 53 
   H1.4    ----MSETAPAAPAAPAPAEKTPVKKKA-RKSAGAAK--RKASGPP-VSELITKAVAASK 52 
   H1.5    ----MSETAPAETATPAPVEKSPAKKKATKKAAGAGAAKRKATGPP-VSELITKAVAASK 55 
   H1.1    ----MSETVPPAPAASAAPEKPLAGKKAKKPAKAAAASKKKPAGPS-VSELIVQAASSSK 55 
   H1.0    ----MTENSTSAPAAKP--KRAKASKKS-------------TDHPK-YSDMIVAAIQAEK 40 
   H1x     MSVELEEALPVTTAEGMAKKVTKAGGSAALSPSKKRKNSKKKNQPGKYSQLVVETIRRLG 60 
                 : *  .  .:     : . .  .                 *   *:::. :      
 
    
   H1.2    ERSGVSLAALK-KALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 111 
   H1.3    ERSGVSLAALK-KALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 112 
   H1.4    ERSGVSLAALK-KALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 111 
   H1.5    ERNGLSLAALK-KALAAGGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKA 114 
   H1.1    ERGGVSLAALK-KALAAAGYDVEKNNSRIKLGIKSLVSKGTLVQTKGTGASGSFKLNKKA 114 
   H1.0    NRAGSSRQSIQ-KYIKSHYKVGENADSQIKLSIKRLVTTGVLKQTKGVGASGSFRLAKSD 99 
   H1x     ERNGSSLAKIYTEAKKVPWFDQQNGRTYLKYSIKALVQNDTLLQVKGTGANGSFKLNRKK 120 
           :* * *   :  :         ::  : :* .:* ** ...* *.**.**.***:* :.  
 
 
   H1.2    ASGEAKPKVKKAGGTKPKKPVGAAKKPKKAAGGATPKKSAKKTPKKAKKPAAATVTKKVA 171 
   H1.3    ASGEGKPKAKKAGAAKPRKPAGAAKKPKKVAGAATPKKSIKKTPKKVKKPATAAGTKKVA 172 
   H1.4    ASGEAKPKAKKAGAAKAKKPAGAAKKPKKATGAATPKKSAKKTPKKAKKPAAAAGAKK-A 170 
   H1.5    ASGEAKPKAKKAGAAKAKKPAGAT--PKKAKKAAGAKKAVKKTPKKAKKP-AAAGVKKVA 171 
   H1.1    SSVETKPGASKV--ATKTKATGASKKLKKATGAS--KKSVK-TPKKAKKP---AATRKSS 166 
   H1.0    EPKKSVAFKKTKKEIKKVATPKKASKPKKAASKAPTKKPKATPVKKAKKK--LAATPKKA 157 
   H1x     LEGGGE---RRGAPAAATAPAPTAHKAKKAAPGAAGSRRADKKPARGQKP--EQRSHKKG 175 
                              .   :   **.   :  .:       : :*        * . 
 
 
   H1.2    KSPKKAKVA-KPKKAAKS--AAKAVK-----PKAAKP-----KVVKPKKAAPKKK- 213 
   H1.3    KSAKKVKTP-QPKKAAKSPAKAKAPK-----PKAAKPKSGKPKVTKAKKAAPKKK- 221 
   H1.4    KSPKKAKAA-KPKKAPKSPAKAKAVK-----PKAAKPKTAKPKAAKPKKAAAKKK- 219 
   H1.5    KSPKKAKAAAKPKKATKSPAKPKAVKPKAAKPKAAKPKAAKPKAAKAKKAAAKKK- 226 
   H1.1    KNPKKPKTV-KPKKVAKSPAKAKAVK-----PKAAKARVTKPKTAKPKKAAPKKK- 215 
   H1.0    KKPKTVKAK-----------PVKASK-----PKKAKP--VKPKAKSSAKRAGKKK- 194 
   H1x     AGAKKDKGG-------------KAKK-----TAAAGGKKVKKAAKPSVPKVPKGRK 213 
             .*. *               ** *     .  *        .  .   . * : 
 
Figure 2. Post-translational modifications of the linker histones. Amino acid sequence alignment of 
the human somatic H1 variants (Gene bank accession numbers: H1.2: NM_005319, H1.3: 
NM_005320, H1.4: NM_005321, H1.5: NM_005322, H1.1: NM_005325, H1.0: NM_005318, H1x: 
NM_006026). The alignment was generated using ClustalW2 and similarity is indicated according to 
the ClustalW convention (asterisk: invariant, fully conserved residue; colon: highly similar residues; 
semi-colon: similar residues). The globular domain is marked by the box shaded in yellow. Residues 
described to be ADP-ribosylated are highlighted in blue, CDK phosphorylation sites in red and 
methylation sites in green. 
 
Another post-translational modification of H1 that has been discovered very early is 
poly(ADP-ribosyl)ation (PARylation)(further explained in section 2). PARylation of 
polynucleosomes induces chromatin relaxation [50,51]. H1 was shown to be the main 
histone acceptor for poly(ADP-ribose) (PAR) in vivo [52] and it was described that 
the glutamates at positions 2, 14 and 116 and the carboxyl group of the C-terminal 
lysine residue can be modified by PAR [53].  
Modern mass spectrometry technologies have been able to identify further post-
translational modifications of H1 including acetylation, methylation, ubiquitination 
and N-formylation of lysine residues [54,55], but their exact role has to be determined. 
The first methylation described in H1 was the reversible di-methylation of K26 in 
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H1.4 by EZH2 and G9a [56-58], which serves as a docking site for HP1 and thereby 
induces transcriptional repression [18]. This methyl transferase (as well as the closely 
related enzyme GLP1) methylates H1 in a variant-specific manner [59]: While H1.4 is 
preferentially methylated in its NTD, H1.2, H1.3, H1.5 and H1.0 are methylated in 
their CTDs (K187 in H1.2). This variant-specific methylation of H1 also has different 
functional outcomes. Only the di-methylation of H1.4K26 but not the one of 
H1.2K187 can serve as a docking site for HP1 and be reversed by JMJD2/KDM4 
proteins [58,59].  
 
2. Poly(ADP-ribosyl)ation 
ADP-ribosylation is an ancient post-translational modification of proteins during 
which the ADP-ribose moiety from the co-substrate nicotinamide adenine 
dinucleotide (NAD+) is transferred onto specific amino acid side chains of acceptor 
proteins or attached to pre-existing protein-linked ADP-ribose units. The transfer of 
only one ADP-ribose unit is termed mono-ADP-ribosylation, whereas the attachment 
of linear or branched ADP-ribose polymers is termed PARylation. Mono-ADP-
ribosylation is widely spread in eukaryotes, but it was originally identified as the 
mechanism of action of bacterial toxins such as the Corynebacterium diphteriae toxin, 
which ADP-ribosylates the unusual amino acid diphthamide in the eukaryotic 
elongation factor-2 and thereby inhibits host cell protein translation [60,61]. 
PARylation is common in higher eukaryotes, apart from yeast, and was also found in 
some archaebacteria and dinoflagellates [62,63]. 
 
2.1. Enzymatic mechanism of PARylation 
NAD+ is mainly known as a coenzyme for redox reactions in which it alternates 
between the two redox states NAD+ and NADH, but it also serves as ADP-ribose 
donor during ADP-ribosylation of proteins. ADP-ribosyltransferases (ARTs) are the 
enzymes responsible for this post-translational modification. They cleave the high-
energy bond between the nicotinamide and ADP-ribose moieties of NAD+ and 
transfer the ADP-ribose unit to the acceptor protein, while nicotinamide is released as 
byproduct (Fig. 3). PARylation of proteins can be divided into at least three distinct 
reactions [64]: 1) the initiation, i.e. the attachment of the first ADP-ribose moiety to 
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the side chains of specific amino acids; 2) the elongation, i.e. the transfer of further 
ADP-ribose units to the pre-existing ones which generates linear ADP-ribose chains 
linked through glycosidic ribose-ribose bonds; 3) branching, i.e. the generation of 
branching points at irregular intervals. ADP-ribose chains vary in length and can 
reach 200 to 400 ADP-ribose units in vitro and in vivo [65]. Branching occurs on 
average every 20 to 50 ADP-ribose units [66]. 
 
Figure 3. PARylation of proteins. ARTD1 and other members of the ARTD family successively 
transfer ADP-ribose units from their cofactor NAD+ to lysine, arginine or glutamate residues of their 
target proteins thereby generating long linear and branched chains of ADP-ribose. This happens in 
three individual steps that create different chemical linkages: 1. Initiation 2. Elongation 3. Branching 
after every 20 to 50 ADP-ribose units. PARG degrades the ADP-ribose polymers with exoglysidic (a) 
and endoglycosidic (b) activity thereby creating free ADP-ribose monomers and free PAR, respectively. 
The most proximal ADP-ribose unit is removed by an ADP-ribosyl protein lyase. Distinct enzymes 
might be required for cleaving the bonds between ADP-ribose and the different amino acid side chains. 
Modified from [67]. 
 
In vivo, PARylation of proteins is transient as ARTs are counteracted by enzymes that 
cleave PAR. The extent of PARylation is thus determined by the equilibrium between 
enzymatic activities producing PAR and the ones degrading it. Poly(ADP-ribose) 
glycohydrolase (PARG) and ADP-ribosyl hydrolase 3 (ARH3) are able to hydrolyze 
the glycosidic bond between two ADP-ribose molecules [68,69]. PARG knockout 
leads to accumulation of PAR and thereby causes embryonic lethality in mice and 
Drosophila [70,71] indicating that PARG is the major PAR-degrading enzyme in 
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cells. The first ADP-ribose molecule is attached to the protein by different chemical 
linkages depending on the acceptor amino acids. ARH1 was shown to cleave off 
ADP-ribose molecules bound to arginine side chains [72] but it is currently not clear, 
which enzymes remove ADP-ribose moieties linked to lysine or glutamate residues 
[73]. 
As PAR is a very bulky and negatively charged polymer, the attachment of PAR to 
proteins often has a big impact on their structure, function or localization. In addition, 
many proteins also interact with PAR in a non-covalent manner. To this end, several 
conserved PAR binding modules have evolved including a short PAR-binding motif, 
which contains mainly basic and hydrophobic amino acid residues and is present in 
many DNA damage checkpoint proteins [74], a PAR-binding zinc finger domain [75] 
and the macrodomains [76].  
 
2.2. ARTD family 
Apart from the sirtuins, which are NAD+-dependent deacetylases that partially also 
exhibit mono-ADP-ribosyltransferase activities, mammalian ARTs can be divided 
into two groups according to their similarity to the bacterial diphteria and cholera 
toxins - the ARTDs and ARTCs, respectively. The ARTDs were formerly known as 
poly(ADP-ribose) polymerases (PARPs). However, this name is inappropriate since 
the term polymerase usually refers to template-dependent enzymes such as RNA and 
DNA polymerases and because not all ARTDs have confirmed PARylation activities. 
In fact, it is likely that some of them merely act as mono-ADP-ribosyltransferases and 
others might be completely devoid of ADP-ribosyltransferase activity. Therefore, a 
new unified nomenclature with the family name ARTD for diphtheria toxin-like ART 
has been proposed [77]. 
In humans, 18 ARTD proteins have been identified so far [77]. ARTD1 (formerly 
known as PARP1) is the proto-type and best-studied member of the ARTD family. It 
is a nuclear, chromatin-associated enzyme that is very abundant (1 x 106 molecules on 
average per cell) and responsible for most (about 90%) of the cellular PAR generation 
[78,79]. ARTD1 is implicated in a huge number of cellular processes such as the 
DNA damage response, cell cycle regulation, gene expression, differentiation and 
aging. The major target of ARTD1 is ARTD1 itself, but it also modifies other nuclear 
proteins including core and linker histones, transcription factors and DNA repair 
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proteins. The enzymatic activity of ARTD1 is low under basal conditions, but it is 
greatly enhanced upon ARTD1 binding to DNA strand breaks. As a result, cellular 
PAR levels can increase 10 to 500 fold in response to DNA damage [80]. PAR 
formed upon genotoxic stress has a half-life in the range of few minutes [81]. This 
rapid turnover indicates that PAR-catabolizing enzymes like PARG immediately start 
to degrade DNA-damage induced PAR.  
The other members of the ARTD family were identified through their “PARP 
signature”, a highly conserved 50 amino acid motif within their catalytic domain that 
is responsible for NAD+ binding [82]. ARTD2 shares the highest sequence homology 
with ARTD1 (40% identity between hARTD1 and hARTD2 catalytic domains) [83]. 
Similar to ARTD1, it is activated in a DNA-dependent manner and exhibits 
automodification activity [84].  
PARylation activity of ARTDs is thought to depend on the presence of an 
evolutionary conserved H-Y-E catalytic triad, three amino acid residues critical for 
the mono-ADP-ribosylation and PARylation activities of ARTD proteins [77,85]. The 
catalytic glutamate residue in this motif (E988 in ARTD1) is required for ADP-ribose 
chain elongation [86,87], whereas chain initiation and thus mono-ADP-ribosylation is 
also possible without this residue. ARTD1 lacking an acidic amino acid residue at this 
position displays only weak mono-ADP-ribosylation but no polymerization activity. 
The histidine and tyrosine residues in this catalytic triad are involved in NAD+ 
binding. According to the presence of these catalytic residues, ARTDs can be 
subdivided into three classes [85]: (1) enzymes with putative PARylation activity 
(ARTDs 1 to 6, which all contain the complete H-Y-E motif); (2) enzymes with 
putative mono-ADP-ribosyltransferase activity (all members lacking only the 
catalytic glutamate residue) and (3) catalytically inactive ARTD family members 
(ARTD9 and ARTD13, which lack the histidine and glutamate residue). Indeed, no 
auto-ADP-ribosylation of ARTD9 and ARTD13 has been described so far [88] and 
ARTD10 and ARTD8 displayed only mono-ADP-ribosylation activity [85], while 
synthesis of ADP-ribose oligomers and polymers has been confirmed for ARTDs 1, 2, 
4 and 5 [84,89-91].  
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2.3. ARTD1 structure 
ARTD1 is a ~113 kDa enzyme and composed of 1014 amino acids. It contains three 
major functional units: an N-terminal DNA-binding domain (DBD), a central 
automodification domain (AMD) and a C-terminal catalytic domain. The DBD 
harbors three zinc binding domains (ZFI, ZFII and ZBD III), which are required for 
the DNA-dependent activation of ARTD1, and a nuclear localization sequence (NLS). 
The automodification domain contains several confirmed automodification sites 
(K498, K521, K524) [89] and a BRCT motif (named after the C-terminal domain of 
breast cancer susceptibility protein 1 (BRCA1)), which promotes protein-protein 
interactions and is found in many proteins involved in the DNA damage response. 
The catalytic domain includes a WGR motif (named after the most conserved amino 
acid sequence in this motif) and an NAD+ binding fold, which is required for the 
enzymatic activity of ARTD1. The structure of ARTD1 is depicted in Fig. 4. 
 
 
 
Figure 4. Scheme depicting the modular architecture of ARTD1. DBD: DNA binding domain; 
AMD: automodification domain; CAT: catalytic domain; ZFI and II: zinc finger I and II; NLS: nuclear 
localization signal; ZBD: zinc binding domain; BRCT: BRCA1 C-terminus. 
 
2.4. Cellular functions of ARTD1  
As mentioned above, ARTD1 is involved in many cellular functions such as NAD+ 
metabolism, chromatin structure and gene expression, DNA damage signaling and 
repair, cell cycle regulation and cell death. On the physiological level, ARTD1 is 
implicated in processes like adipogenesis, aging, inflammatory responses and 
sensitivity to genotoxic agents. 
ARTD1 knockout mice are viable and fertile but exhibit increased sensitivity to 
ionizing radiation and other genotoxic agents [92,93]. Interestingly, ARTD1 gene 
disruption in mice conferred resistance to some oxidative stress-related disease 
models such as LPS-induced septic shock and streptozotocin-induced diabetes [94,95]. 
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The relatively mild phenotype of ARTD1 knockout in mice can be explained by 
functional redundancy with other ARTDs especially ARTD2, as ARTD1/ARTD2 
double-knockout is embryonically lethal in mice [96]. dARTD is essential in 
Drosophila, which possesses only two ARTD proteins (one ARTD1 homolog 
(dARTD) and tankyrase) [97]. 
 
2.4.1. Chromatin structure and transcription 
As mentioned previously, core histones and linker histones are targets of ARTD1 and 
their PARylation induces decondensation of higher-order chromatin structures 
[50,51,98]. Further evidence that ARTD1 regulates chromatin structure comes from 
studies with in vitro-assembled chromatin, in which addition of ARTD1 induces 
chromatin compaction and transcriptional repression [99]. This effect is dependent on 
its DBD and catalytic domain and can be reversed by the addition of NAD+, which 
leads to ARTD1 automodification and its subsequent release from nucleosomes [100]. 
In Drosophila, ARTD1 is required for local chromatin loosening during gene 
induction [101]. This is accompanied by accumulation of PAR at these sites. A role 
for ARTD1 in chromatin composition and gene regulation was further supported by 
the finding that ARTD1 is enriched at actively transcribed gene promoters and might 
serve to exclude H1 from these sites, as H1 showed a reciprocal chromatin binding 
pattern to ARTD1 and was increased at ARTD1-regulated genes upon ARTD1 
depletion [102]. 
Apart from its function in chromatin modulation, ARTD1 also acts as a classical 
cofactor for diverse sequence-specific transcription factors such as nuclear factor !B 
(NF-!B), TATA-binding protein, hypoxia inducible factor 1 (HIF1) and nuclear 
receptors [103-106]. It can function as a transcriptional activator or repressor, 
depending on the cellular context and the genes analyzed [107]. In some cases, 
ARTD1 was shown to PARylate the corresponding transcription factor or other 
components of the transcriptional machinery [104,108,109], but the enzymatic 
activity of ARTD1 is not always required for its function as transcriptional 
coregulator [110,111]. The exact mechanism of gene-specific transcriptional 
regulation by ARTD1 is not clear and depends on the transcription factor with which 
it cooperates. The recruitment of ARTD1 to target promoters might occur via the 
interaction with the corresponding transcription factors. According to a study in 
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Drosophila, however, inactive dARTD is already present at the 5’ end of the Hsp70 
locus before heat shock and becomes activated upon heat shock leading to its 
redistribution throughout the Hsp70 locus [112]. Furthermore, it was shown that 
ARTD1 and PARG localize to promoters of both positively and negatively regulated 
target genes in the absence of a stimulus and regulate gene expression under basal 
conditions [113]. 
During hormone-regulated gene induction, topoisomerase II# was shown to induce a 
transient nucleosome-specific DNA double-strand break (DSB), which in turn 
activated the enzymatic activity of ARTD1, a requirement for subsequent 
H1/HMGB1 exchange and gene activation [114]. 
Finally, ARTD1 was also shown to PARylate the insulator protein CTCF and might 
thereby help to limit the activity of enhancers to discrete genomic regions and prevent 
the spread of heterochromatin [115]. 
 
2.4.2. DNA damage response 
The cell is constantly threatened by diverse types of DNA damage, including DNA 
single and DSBs, chemical modification (e.g. oxidation and alkylation) of bases and 
base mismatches, generated by endogenous and exogenous sources. The term DNA 
damage response (DDR) summarizes all cellular processes necessary to detect, signal 
and remove DNA damage as well as the induction of the appropriate cell cycle 
checkpoint or apoptotic responses, if the DNA damage is too extensive to maintain 
genome integrity.  
ARTD1 binds to a variety of aberrant DNA structures such as single and DSBs, 
cruciforms, crossovers and supercoils, which allosterically induce its enzymatic 
activity [116]. This is one of the reasons, why ARTD1 was mainly regarded as a DDR 
protein in the past. This was further supported by its rapid recruitment to sites of 
DNA damage in vivo, which is required for the accumulation of repair factors like 
XRCC1 and the MRN complex [117,118], and by its  interactions with XRCC1 
[119,120], DNA ligase III" [121], DNA polymerase # [122] and other proteins of the 
DNA repair machinery. Many DNA repair factors also possess PAR-binding domains 
and are thought to be recruited to DNA lesions in a PAR-dependent manner 
[74,75,123,124]. Thus, ARTD1 and PAR are implicated in diverse DNA repair 
pathways especially in base excision repair [122,125,126]. Other studies, however, 
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showed that DNA repair pathways are efficient in cells lacking ARTD1 [127-129]. 
This is supported by the finding that ARTD1 knockout mice are viable, fertile and 
display no increased predisposition to develop spontaneous tumors [92]. Thus, 
ARTD1 seems to be dispensable for DNA repair under normal physiological 
conditions and the exact role of ARTD1 in DNA damage signaling and repair has to 
be further elucidated in the future. 
 
2.4.3. Cell death 
Overactivation of ARTD1, e.g. in response to excessive oxidative stress, can deplete 
cellular NAD+ and ATP levels and thereby promote cell-death [130,131]. It was 
proposed that ARTD1-mediated cell-death – known as parthanatos [132] – is initiated 
by the accumulation of PAR in the cytosol due to massive nuclear ARTD1 activity. 
Cytoplasmic PAR binds to apoptosis-inducing factor, which is subsequently released 
from the outer mitochondrial membrane and translocates to the nucleus, where it 
induces DNA fragmentation and caspase-independent cell-death [133].  
During apoptosis, ARTD1 is cleaved by caspases, especially caspase 3, at their 
consensus motif DEVD after D214 [134,135]. This cleavage, which produces two 
ARTD1 fragments of 24 and 89 kDa, inactivates ARTD1 and is thought to be 
required to avoid overactivation of ARTD1 in response to apoptosis-induced DNA 
fragmentation to preserve cellular ATP levels [136]. This is important, as apoptosis is 
an ATP-dependent process. However, ARTD1 cleavage is not an absolute 
requirement for apoptosis because knockin mice harboring a caspase-resistant non-
cleavable version of ARTD1 (D214N) develop normally [137]. Interestingly, these 
mice display a defect in NF-!B-dependent gene expression and are resistant to LPS-
induced endotoxic shock and other inflammatory disease models indicating that 
ARTD1 cleavage, although a hallmark of apoptosis, has other non-apoptotic functions.  
 
2.5. Post-translational modifications of ARTD1 
One of the most important post-translational modifications of ARTD1 is its NAD+-
dependent automodification at certain residues within its DBD and AMD (K498, 
K521, K524) [89]. PARylation of ARTD1 induces its dissociation from DNA, 
probably due to electric repulsion between the negative charges of PAR and DNA. As 
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the interaction with damaged DNA induces ARTD1 enzymatic activity, PAR-
dependent repulsion from the DNA creates a negative feedback loop that limits its 
activity to a certain extent.  
However, ARTD1 is also subject to trans-modifications by other enzymes. It was, for 
example, shown that the mitogen-activated protein kinases ERK1/2 phosphorylate 
ARTD1 at the adjacent sites S372 and T373 and thereby potentiate its DNA damage-
induced enzymatic activity [138]. Other kinases identified to phosphorylate ARTD1 
at undefined sites are JNK1 (required for sustained ARTD1 activation during 
exposure to H2O2 [139]), AMPK (increased ARTD1 activity [140]) and protein kinase 
C (decreased ARTD1 DNA binding and enzymatic activity [141]). ARTD1 is also 
acetylated by p300/CBP, two components of transcriptional coactivator complexes, in 
response to inflammatory stimuli [142]. They acetylate ARTD1 at five different 
lysine residues within its AMD (K498, K505, K508, K521, K524), which is necessary 
for ARTD1 interaction with p50 and its coactivator function in NF-!B-dependent 
gene expression.  
Apart from these small chemical modifications, ARTD1 is also subject to the covalent 
attachment of polypeptides such as small ubiquitin-like modifier (SUMO) and 
ubiquitin itself. SUMOylation of ARTD1 at K486 by the SUMO E3 ligase PIAS$ 
restrains its coactivator function in HIF1-dependent gene expression [143] and, upon 
heat shock, is required for its subsequent ubiquitination by RNF4 and full hsp70 
transcriptional activation [144].  
Notably, many of these post-translational modifications occur on the same or nearby 
residues within the AMD, thus creating a platform for vivid crosstalk. Acetylation of 
ARTD1, for example, affects three residues that are also important for its PARylation 
and therefore is likely to reduce its automodification. 
 
2.6. ARTD inhibitors 
Pharmacological inhibition of ARTDs was shown to induce synthetic lethality in 
homologous recombination (HR) deficient cell lines [145,146]. HR is an important 
error-free DSB repair mechanism and requires the tumor suppressor proteins BRCA1 
and BRCA2. Mutation of BRCA1/2 underlies many cases of heritable ovarian, breast 
and prostate cancer and thus ARTD inhibitors are currently tested as single agents or 
in combination with chemotherapy to treat these and other types of cancers. It is 
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thought that ARTD1 inhibition interferes with single-strand break repair and thus 
leads to accumulation of endogenously generated single-strand breaks, which are 
converted to DSBs during replication. ARTD inhibitors would therefore be toxic for 
HR-deficient cancer cells as they cannot repair these DSBs in an appropriate manner, 
but not for normal HR-proficient cells. This hypothesis, however, is challenged by 
studies that show no increased formation of DNA strand breaks in ARTD inhibitor 
treated cells [147,148]. It is thus very likely that other mechanisms also contribute to 
the toxic effects of ARTD inhibitors e.g. their negative influence on NF-!B-
dependent anti-apoptotic gene expression [149,150]. 
Another clinical application of ARTD inhibitors lies in a number of 
pathophysiological conditions where ARTD1 hyperactivation might have detrimental 
effects e.g. during cerebrial ischemia/reperfusion in patients suffering a stroke or in 
inflammatory disorders [151,152]. 
Most inhibitors of ARDT1 are analogs of its byproduct nicotinamide and thus also 
inhibit other NAD+-dependent enzymes, especially other members of the ARTD 
family. Therefore, they should be called ARTD inhibitors and not ARTD1 inhibitors. 
3-aminobenzamide (3-AB) was one of the earliest substances known to inhibit 
ARTD1 and used in many in vitro and in vivo studies to analyze the effects of 
ARTD1 inhibition. Its low potency and specificity, however, preclude its therapeutic 
utilization. During the last years, other ARTD inhibitors with increased potency and 
less off-target effects have been developed and several of them are presently analyzed 
in clinical trials [153]. These include, for example, olaparib (AstraZeneca) and 
ABT-888 (Abott), which have already completed several Phase II trials as single 
agents or potentiators of chemotherapy against different types of cancers.   
 
3. Protein methylation 
Protein methylation mainly targets lysine and arginine residues. While either one or 
two methyl groups can be transferred to the side chain of an arginine, resulting in 
mono- and symmetrically or assymetrically di-methylated arginine (depending on 
whether one methyl group is transferred to each of the terminal nitrogen atoms or two 
methyl groups are transferred to the same nitrogen), lysine methylation can take place 
in three different degrees: mono-, di- and trimethylation [154,155] (Fig. 5).  
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Figure 5. Arginine and lysine methylation. Arginines can be mono- or dimethylated while one to 
three methyl groups can be transferred to lysine residues. Picture modified from [156]. 
 
Unlike other post-translational modifications like acetylation and phosphorylation, 
methylation does not alter the overall charge of an amino acid and therefore cannot 
act through electro-static mechanisms. It does, however, change the size and 
hydrophobicity of the side chain in a manner proportional to the degree of the 
methylation. As a consequence, it can generate or destroy intra- and intermolecular 
binding sites and thereby influence the enzymatic activity, localization and interaction 
profile of a protein.  
Protein methylation was most extensively studied on histone tails. While histone 
acetylation is generally linked to active transcription, histone methylation can either 
activate or repress gene expression, depending on the methylation state and residue 
that is modified. K4, K36 and K79 on H3 are methylation sites linked to active gene 
expression, whereas methylation of K9 and K27 on H3 and K20 on H4 is associated 
with transcriptionally silenced chromatin [157]. Due to the vast array of histone post-
translational modifications that can act in a sequential and combinatorial manner, the 
histone code was proposed [158]. According to this hypothesis, distinct post-
translational modifications on core histone tails operate alone or in combination to 
recruit other proteins (“readers”), which alter the chromatin structure and thereby 
promote or repress gene expression and other DNA-dependent processes.  
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Several protein interaction motifs that recognize specific methylated lysine residues 
on histone tails and other cellular proteins have been identified. These include the 
chromo- and tudor domains as well as the WD40 and MBT (malignant brain tumor) 
repeats [159,160]. These domains bind to methylated lysine residues within a certain 
amino acid context and are usually able to distinguish between different methylation 
states (mono-, di- or trimethylation), which increases the coding potential of this 
modification. 
 
3.1. Enzymatic mechanism of protein methylation 
The enzymes that carry out protein methylation in cells are termed arginine 
methyltransferases (PRMTs) and lysine methyltransferases (KMTs), depending on the 
residues, which they target. They catalyze the transfer of the methyl group from their 
cofactor S-adenosyl methionine (SAM) to the acceptor amino acid and thus generate a 
methylated arginine or lysine residue and the byproduct S-adenosyl homocysteine 
(SAH). The regeneration of SAM occurs via the hydrolysis of SAH to homocysteine 
and adenosine.  Homocysteine is then remethylated to form methionine, which finally 
needs to be activated by methionine adenosyltransferase [161]. The metabolic cost for 
this cycle is high (12 ATP equivalents) [162]. Thus, reactions consuming SAM are 
much more expensive for the cell then e.g. protein phosphorylation which requires 
only one ATP molecule.  
 
3.2. SET domain protein KMTs 
Protein lysine methylation is carried out by SET domain containing enzymes 
(reviewed in [163-165]). The only exception known so far is Dot1 in yeast (and its 
homologs in other organisms), which is responsible for H3K79 methylation and does 
not harbor any domain structurally related to the SET domain [166].  The name of the 
SET domain is derived from the three Drosophila melanogaster proteins in which it 
was first identified, suppressor of variegation (Su(var)3-9) [167], enhancer of zeste 
(E(z)) [168] and trithorax [169].  
The SET domain is a conserved sequence motif of about 130 amino acids and harbors 
the catalytically active site of the KMTs. The structures of several SET domains have 
been solved. They are not related to the active sites of other SAM-dependent enzymes 
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[170]. The SET domain is comprised of several small #-sheets that surround a knot-
like structure [171]. The regions adjacent to the SET domain are called preSET (or N-
SET) and postSET (or C-SET) domains, respectively, and are also required for 
enzymatic activity [172-174]. Together with the SET domain they form the peptide 
binding cleft and the SAM binding pocket, which are connected through a 
hydrophobic channel that accommodates the side chain of the target lysine and brings 
it in close proximity to the methyl donor to allow the methyl transfer [174-176]. The 
peptide binding cleft is responsible for substrate recognition by forming hydrogen 
bonds and other interactions with the amino acids flanking the target residue 
[177,178]. This explains the overall low sequence similarity between KMTs with 
different substrate specificities. The product specificity also lies within the SET 
domain. Certain residues that define the size and geometry of the narrow target lysine 
channel determine if one or several methyl groups can be transferred [175,179,180].   
SET domain containing proteins have been found in all eukaryotes analyzed so far 
[164] and many of them are involved in chromatin regulation by methylating histones 
and other chromatin-associated proteins. In humans, more than ninety members of the 
SET domain protein family with diverse substrate and product specificities have been 
annotated [181], emphasizing the importance of lysine methylation as a mode of post-
translational protein regulation in cells.  
 
3.3. Identification and structure of the KMT SET7/9 
SET7/9 (also SET7, SET9 or SETD7) was identified a decade ago independently by 
two groups as a mono-methyltransferase for H3K4 [182,183]. Both groups found that 
H3K4 methylation by SET7/9 inhibits subsequent H3K9 methylation by SUV39H1. 
SET7/9 was therefore linked to transcriptional activation, which was strengthened by 
the fact that H3K4 methylation by SET7/9 displaces the histone deacetylase NuRD 
complex [183] and promotes acetylation of H3 and H4 by p300 [182]. The KMT 
activity of SET7/9 towards H3 in nucleosomes, however, is weak, suggesting that 
other factors might be involved in SET7/9-dependent H3K4 methylation in vivo or 
that histone proteins are not the main substrates of SET7/9.  
SET7/9 knockdown was shown to affect the expression of a subset of genes, which 
partially coincided with a decrease in local H3K4 methylation [184-186]. Depletion 
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of SET7/9 did not result in changes of global H3K4 levels, further indicating that H3 
is not the main target of SET7/9 [187]. 
Several crystal structures of SET7/9, either free or in complex with its cofactor 
product SAH, were resolved in the presence and absence of substrate peptides 
[172,175,177,188,189]. These structures revealed that SET7/9 lacks the cysteine-rich 
pre- and postSET domains found in other methyltransferases such as the SUV39 
family [164]. Nevertheless, the regions flanking the SET domain of SET7/9 are 
required for its enzymatic activity and especially the residues C-terminally to the SET 
domain are involved in the formation of the substrate binding cleft.  
 
3.4. Non-histone targets of SET7/9 
A few years after the discovery of the mono-methyltransferase activity towards H3K4, 
it became apparent that SET7/9 also modifies many non-histone proteins with diverse 
functional outcomes. TAF10, a component of the general transcription factor complex 
TFIID, was the first non-histone target shown to be methylated by SET7/9 [190], 
resulting in increased interaction with RNA polymerase II and elevated expression of 
some genes.  
A comparison of known SET7/9 targets and a substrate specificity analysis based on 
peptide array methylation [191] showed that SET7/9 methylates the consensus motif 
[K>R][S>KYARTPN][Kme] and prefers lysine residues within net positively charged 
regions. SET7/9 mainly acts as a mono-methyltransferase, although dimethylation has 
been described in some cases [191,192]. Most of the substrate proteins of SET7/9 are 
transcription factors, nuclear receptors and other chromatin-associated proteins 
involved in gene regulation. Monomethylation by SET7/9 negatively or positively 
influences their stability and transcriptional activity, crosstalks with other post-
translational modifications or regulates the interaction with other proteins (see table 1). 
The most extensively studied non-histone substrate of SET7/9 is p53, which is 
methylated at K372 in response to DNA damage [193]. SET7/9-dependent 
methylation of p53 was shown to induce its subsequent acetylation and stabilization, a 
prerequisite for efficient p53-dependent gene expression and cell cycle arrest upon 
genotoxic stress [194,195]. However, these studies were performed in human cancer 
cell lines in which p53 is often deregulated. Kurash et al. confirmed the role of 
SET7/9 in p53 regulation and tumor suppression in SET7/9 knockout mice [195], but 
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in two other SET7/9 knockout mouse models, p53-mediated DNA damage response 
was not compromised [187,196]. Thus, it is controversial whether SET7/9-dependent 
methylation of p53 is important for p53 activity in nontransformed cells.  
SET7/9 knockout mice (obtained by disruption of either exon 1 [196] or exon 5-8 
[187]) were born at normal Mendelian ratios, survived to adulthood and displayed no 
obvious phenotypic abnormalities or increased tumor predisposition. 
 
Substrate Target site Function of the methylation Ref.s 
TAF 10 K189 increased affinity to RNA polymerase II [190] 
p53 K372 increased acetylation, stability and transcriptional activity [193-195] 
ER K302 increased stability and transcriptional activity [197] 
DNMT1 K142 decreased stability and DNA methylation [198]  
RelA K314, K315 degradation of DNA-bound RelA [199]  
  K37 increased transcriptional activity  [200]  
pRb K873 stimulates HP1 binding, cell cycle arrest  [201]  
  K810 prevents phosphorylation of pRb, cell cycle arrest [202]  
E2F1 K185 decreased stability [203]  
AR K632 induces intramolecular interactions, enhanced transcriptional activity [204] 
 
Table 1. Human SET7/9 target proteins. Overview of identified SET7/9 substrates and their target 
lysine residues. The diverse functional outcomes of the methylation are indicated.  
 
 
3.5. Reversal of lysine methylation 
Histone methylation was regarded as a very stable or even irreversible epigenetic 
modification for a long time and it was thought that turnover of histone methyl marks 
mainly occurs via histone tail clipping or replacement of the whole histone [156,205]. 
Then it was shown that peptidyl arginine deiminase PAD4 antagonizes arginine 
methylation by converting methylated arginines to citrullin [206,207]. This does, 
however, not restore the original unmethylated state of the protein.  
Only recently, enzymes that are able to reverse lysine methylation were identified, 
which demonstrates that, like other post-translational modifications, lysine 
methylation is a reversible, dynamic process (reviewed in [156,208]). Lysine 
demethylases can be divided into two different groups, the LSD family with only two 
members identified in humans so far (LSD1 and LSD2) and the Jumonji-C (JmjC) 
domain family. LSD1 and LSD2 are FAD-dependent amine oxidases that are only 
Introduction 
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able to demethylate mono- and dimethylated lysine residues [209,210]. JmjC domain 
containing demethylases are Fe2+-dependent dioxygenases that use another catalytic 
mechanism involving the oxidative decarboxylation of "-ketoglutarate [211]. They 
are also able to demethylate trimethylated lysine residues. Both enzyme families 
create formaldehyde as a byproduct of the demethylation and exhibit a high substrate 
specificity for certain lysine residues and methyl states within the histone tails, which 
can shift upon interaction with different auxiliary factors [212-214]. Lysine 
demethylases are often affiliated with larger macromolecular complexes, which also 
contain other chromatin modifying enzymes such as histone deacetylases and methyl 
transferases. 
Similar to lysine methylation, lysine demethylation reaches beyond histones. LSD1, 
for example, is able to demethylate p53 [215] and DNMT1 [216] as well. 
 
3.6. Inhibitors of lysine methylation and demethylation 
KMTs can be inhibited by compounds mimicking their cofactor SAM. These small-
molecule inhibitors, however, often lack specificity, as they usually also inhibit other 
cellular SAM-dependent enzymes such as DNA and arginine methyl transferases 
[217]. The optimal inhibitor would not only have to be able to distinguish between 
KMTs and other SAM-dependent enzymes, but should also be selective among the 
various KMTs. Only few compounds with relatively narrow specificity have been 
described e.g. chaetocin, a mycotoxin selective for H3K9 specific KTMs like 
SUV39H1 and G9a [218]. For SET7/9, a bisubstrate-inhibitor was identified [219], 
but no SET7/9 specific inhibitors are commercially available yet. 
LSD1 and LSD2 are related to other types of FAD-dependent amine oxidases such as 
the monoamine oxidases (MAO-A and MAO-B). It was thus not surprising that small-
molecule inhibitors known to inhibit MAOs also exhibited activity towards LSDs. 
Two such molecules are tranylcypromine (TCP), which irreversibly inhibits LSD1 
[220,221] and LSD2 [210], and - albeit with lower potency - pargyline [214].  
  
Introduction 
 29 
4. Aim of the thesis 
SET7/9 is a lysine mono-methyltransferase that modifies H3K4 as well as many non-
histone proteins and regulates the activity of several proteins such as p53, pRb and 
E2F1 in response to DNA damage and other stresses. Based on these findings, we 
hypothesized that SET7/9 also methylates other nuclear proteins that are involved in 
the genotoxic stress response. 
ARTD1 and the linker histone H1 are two chromatin-associated proteins that 
influence many DNA-related processes. It was the aim of this thesis to investigate if 
ARTD1 and H1 are methylated by SET7/9 in vitro and in vivo and how this 
modification affects their function. 
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RESULTS 
5. Overview of published and submitted manuscripts 
5.1. Set7/9-dependent methylation of ARTD1 at K508 enhances poly-ADP-ribose 
formation 
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Journal:  manuscript in preparation 
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the figures and revision of the manuscript. MB helped with cloning 
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restrains transcriptional coactivator function 
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Hottiger 
Journal:  FASEB J. 2009 Jul 31.  
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Contribution: Localization of SUMO2/3 and ARTD1 and detection of PAR upon 
H2O2 treatment by immunofluorescence (Suppl. Figure 4). 
 
5.4. Inflammasome activated caspase 7 cleaves PARP1 to enhance the expression 
of a subset of NF-!B target genes 
 
Authors:  Süheda Erener, Virginie Petrilli, Ingrid Kassner, Roberta Minotti, 
Rosa Castillo, Raffaella Santoro, Paul O. Hassa, Jürg Tschopp and 
Michael O. Hottiger 
Journal:  Mol Cell. 2012 Mar 29.  
Contribution:  Planning, performing and evaluating the following experiments: 
preparation of nuclear and cytoplasmic extracts after LPS stimulation 
and detection of activated caspase 7 by Western blot (Figure 3B), 
determination of RelA localization after LPS stimulation by 
immunofluorescence (Suppl. Figures 2C and 4D), detection of caspase 
3 activation upon LPS treatment (Suppl. Figure 3D). Preparation of the 
corresponding figures and proof-reading of the manuscript. 
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ABSTRACT 
ADP-ribosyltransferase diphtheria toxin-like 1 (ARTD1, formerly named PARP1) is localized in the 
nucleus, where it ADP-ribosylates specific target proteins. The post-translational protein modification 
(PTM) with a single ADP-ribose unit or with polymeric ADP-ribose (PAR) chains regulates protein 
function as well as protein-protein interactions and is implicated in many biological processes and 
diseases.  
SET7/9 (also called Setd7 or KMT7) is a protein methyltransferase that catalyzes lysine 
monomethylation of histones, but also methylates many non-histone target proteins such as p53 or 
DNMT1.  
Here, we identify ARTD1 as a new SET7/9 target protein that is methylated at K508 in vitro and in 
vivo. ARTD1 auto-modification inhibits its methylation by SET7/9, while auto-poly-ADP-
ribosylation is not impaired by prior methylation of ARTD1. Moreover, ARTD1 methylation by 
SET7/9 enhances the synthesis of polymeric ADP-ribose (PAR) upon oxidative stress and stimulates 
the recruitment of ARTD1 to chromatin in vivo. Together, these results reveal a novel mechanism for 
the regulation of cellular ARTD1 activity by SET7/9 to assure efficient PAR formation upon cellular 
stress. 
 
 
Running title: ARTD1 methylation at K508 by SET7/9 
 
Key words: PARP-1, SET7/9, lysine methylation, poly-ADP-ribosylation, post-translational 
modification 
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INTRODUCTION 
ADP-ribosyltransferase diphtheria toxin-like 1 (ARTD1, formerly named PARP1, 1) is a nuclear 
protein that post-translationally modifies proteins by transferring the ADP-ribose moiety from NAD+ 
to specific amino acid residues of target proteins. It is the best described member of the ADP-
ribosyltransferase (ART) protein family, which currently comprises 22 human enzymes 1. ARTD1 is 
not only the main nuclear ART, but also the primary acceptor for polymeric ADP-ribose (PAR). 
ARTD1 can be ADP-ribosylated at specific lysine residues and is also modified by acetylation and 
sumoylation between the amino acid residues 481 and 525 2-4. Protein modification with a single 
ADP-ribose unit or with PAR chains regulates protein function and is implicated in biological 
processes such as transcriptional control, cell differentiation or cell cycle regulation 5, 6. Many cellular 
functions of ARTD1 are brought about by complex formation with partner proteins or the ADP-
ribosylation of target proteins in the cell nucleus 5, 7. For example, histones or transcription factors are 
poly-ADP-ribosylated by ARTD1, which causes concomitant changes in chromatin structure and 
DNA metabolism 8, 9.  
Genotoxic and cellular stresses activate ARTD1 enzyme activity 10. However, the detailed upstream 
mechanisms leading to the activation of ARTD1 and the involvement of PTMs modulating ARTD1 
activity are little understood. In vitro, the DNA-dependent interaction between the amino-terminal 
DNA-binding domain and the catalytic domain of ARTD1 increased Vmax and decreased the Km for 
NAD+  4. The amount of DNA in this study was kept at a saturating 1:1 ratio (DNA:ARTD1 dimer). It 
is currently not clear whether ARTD1 activity and the subsequent PAR formation under non-
saturating DNA levels depends on additional regulatory mechanisms. 
SET7/9 (also called Setd7 or KMT7) was discovered as a histone methyltransferase that causes mono-
methylation of histone 3 lysine 4 (H3K4me1) 11 and is thereby involved in the regulation of 
euchromatic gene expression 12-14. However, SET7/9 has only weak activity on nucleosomes 15, which 
implies that the main targets of the enzyme are non-histone proteins. In agreement with this 
hypothesis, numerous non-histone proteins such as Dnmt1 (reduction in stability), p53 (activation and 
stabilization), TAF10 (increased affinity for polymerase II), estrogen receptor " (activation and 
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stabilization), pRb, p65, MyoD and Tat protein of HIV1 are methylated by SET7/916-24. In addition, a 
recent study identified up to 90 new non-histone SET7/9 target peptides and a strong methylation of 
free H2A and H2B tails 25. This promiscuous targeting of SET7/9 to different substrates suggests a 
low specificity of the enzyme. Set7/9 knockout mice are viable and fertile and loss of Set7/9 does not 
seem to impair p53-dependent cell-cycle arrest or apoptosis following DNA damage 26, 27, although 
Set7/9 was originally thought to regulate p53 activity in human cells 17. SET7/9 preferentially 
modifies positively charged amino acid regions and methylates the last lysine residue in the motif 
[K>R] [S>KYARTPN] [K] 25. Peptides that do not perfectly match this sequence can be methylated to 
a lesser extent. In cells, a strong interaction of acceptor proteins with the SET7/9 methyltransferase 
might stimulate the transfer of a methyl group to weak target sites. Hence, a weaker methylation does 
not have to imply a lower biological importance 25.  
SET7/9 mediated monomethylation is a reversible PTM that can be removed by demethylases such as 
the lysine specific demethylase 1 (LSD1) and its homolog LSD2. Both proteins are flavin-dependent 
demethylases that are specific for mono- and di-methylated lysines and which are part of histone 
modification complexes that control cell specific gene expression 28, 29.  
The study presented here identifies ARTD1 as a new SET7/9 target protein that is methylated at K508, 
which enhances synthesis of PAR especially at low DNA concentrations. These results add an 
additional regulator element to cellular ADP-ribosylation, which affects ARTD1 enzymatic activity 
under oxidative stress conditions.   
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RESULTS 
ARTD1 activity is regulated by SET7/9 activity in vivo 
In order to test the hypothesis that SET7/9 regulates the enzymatic activity of ARTD1, we first 
confirmed that both enzymes are localized in the nucleus of U2OS cells (Figure S1A). Moreover, 
SET7/9 was knocked down in U2OS cells (Figure S1A, B) and PAR formation following oxidative 
stress by H2O2 was determined. Indeed, siSET7/9 treated cells formed less PAR than cells transfected 
with a control siRNA (Figure 1A, B), suggesting that SET7/9 regulates PAR formation in vivo. To 
further analyze the influence of SET7/9 on ARTD1 enzymatic activity in cells, nuclear extracts from 
siRNA treated U2OS cells (control siRNA or siRNA directed against SET7/9 or ARTD1) were 
prepared and auto-ADP-ribosylation of ARTD1 was tested in vitro in the presence or absence of 
exogenous DNA. Down-regulation of SET7/9 reduced the basal ARTD1 activity to levels only 
slightly above those in siARTD1 cells (in absence of exogenous DNA, Figure 1C, D). This effect was 
also seen, but to a lesser extent, when ARTD1 activity was stimulated by an excess of exogenous 
DNA (Figure1 C, D). In agreement with these findings, overexpression of Flag-tagged wildtype (WT) 
SET7/9 enhanced PAR formation upon H2O2 treatment and even in unstimulated cells, while the 
enzymatically inactive SET7/9 mutant H297A did not show this effect (Figure 1E, F). Finally, we 
monitored PAR formation in live cells via time-lapse imaging of the recruitment of GFP-labeled 
macroH2A to laser microirradiated sites 30. Down-regulation of SET7/9 resulted in a significant 
reduction of macroH2A-specific signal at the irradiated region, indicative of reduced PAR synthesis 
(Figure S1D). Together, these results suggest that SET7/9 stimulates ARTD1-dependent PAR 
formation in U2OS cells in a manner that depends on the methylation of proteins. 
 
ARTD1 is methylated in vitro and in vivo at K508 by SET7/9  
To determine whether SET7/9 stimulates ARTD1 activity and PAR formation by direct methylation 
of ARTD1, in vitro methylation assays were performed. SET7/9 methylated the known substrate 
histone H3 as well as full-length ARTD1 in vitro, while neither GST nor ARTD2, another member 
from the ARTD family, were modified (Figure 2A). To localize the modification site, purified 
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ARTD1 fragments covering the whole amino acid sequence were methylated by SET7/9 in vitro 
(Figure 2B). The potential SET7/9 modification site(s) in ARTD1 could be narrowed down to the 
automodification domain (AD) consisting of amino acids 373-524, which was strongly methylated in 
vitro, while all other tested ARTD1 fragments (containing the DBD, WGR or CAT domain) were not 
methylated (Figure 2B). In silico analysis identified lysine 508 (K508) as the putative target site as it 
was the only lysine residue within this region matching the published [KR] [STA] [K(me)] consensus 
motif for SET7/9-dependent methylation18. Mutation of K508 to arginine (K508R) indeed abolished 
SET7/9-dependent methylation in the ARTD1 automodification domain of the full-length ARTD1 
(Figure 2C). SET7/9-dependent methylation of ARTD1 K508 was confirmed by mass spectrometric 
analysis of recombinant ARTD1 (373-524) that was incubated with SET7/9 in presence or absence of 
SAM as methyl donor (Figure S2A, B). To confirm the methylation of ARTD1 K508 in vivo, a 
polyclonal antibody against a synthetic ARTD1 peptide containing the mono-methylated K508 was 
generated. The anti-meARTD1 antibody specifically detected in vitro the modified peptides (Figure 
S2C) and SET7/9-mediated methylation of full-length ARTD1 at K508 (Figure S2D), while the 
methylation deficient K508R mutant was not detected (Figure 2D). Moreover, upon overexpression of 
SET7/9 the same antibody specifically detected the methylation of ARTD1 in vivo (Figure 2E and F). 
Together, these results indicated that ARTD1 is methylated in vitro and in vivo by SET7/9 and 
identified K508 as the main target site for SET7/9-dependent methylation of ARTD1. 
 
ARTD1 auto-modification inhibits its methylation by SET7/9 
Interestingly, the SET7/9 target residue K508 lies within a heavily modified region (aa 486-524) of 
the ARTD1 automodification domain that comprises five acetylation and three ADP-ribosylation sites 
as well as one lysine residue that becomes sumoylated (Figure S3A). Modification of ARTD11 with 
SUMO did not affect its ADP-ribosylation activity but completely abrogated p300-mediated 
acetylation of ARTD1, revealing an intriguing crosstalk of sumoylation and acetylation on ARTD1. 
Crosstalk between different PTMs of the same modified amino acid residue has been documented in 
particular for modifications comprising the histone code31-33. It was thus tested whether there is 
crosstalk between SET7/9-dependent methylation, PARylation and acetylation of ARTD1 in vitro. 
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Prior stimulation of recombinant ARTD1 with DNA in the presence of NAD+ and subsequent auto-
modification completely inhibited methylation by SET7/9 (Figure 3A). Inhibition of ADP-
ribosylation by 3-aminobenzamide from the beginning (3-AB; +) reverted this effect on ARTD1 
methylation, while 3-AB addition after the auto-modification but before methylation (3-AB; ±) did 
not abolish methylation per se (Figure 3A). Consequently, these experiments suggested that auto-
ADP-ribosylation of ARTD1, but not a possible ADP-ribosylation of SET7/9 by ARTD1, prevented 
subsequent methylation. The sharp band of methylated ARTD1 running at the height of unmodified 
ARTD1 strengthened the conclusion that SET7/9 only methylated ARTD1 that was not ADP-
ribosylated.  
In contrast, auto-poly-ADP-ribosylation of ARTD1 was not impaired by prior methylation of ARTD1 
as indicated by the smear of methylated ARTD1 upon incubation with radiolabelled NAD+ and DNA 
(Figure 3B). Similarly, methylation of the 373-524 ARTD1 fragment by SET7/9 did not affect 
subsequent acetylation by p300 (Figure 3C, left panel). The experiment was controlled with the 
enzymatically inactive H297A SET7/9 mutant and methylation of ARTD1 was confirmed in a parallel 
experiment using 14C-SAM (Figure3C, right panel).  
These results suggested that SET7/9-dependent methylation of ARTD1 is subject to crosstalk with 
ARTD1 auto-modification, while neither PARylation itself nor acetylation are impaired by the 
methyl-modification of K508. 
 
SET7/9-dependent methylation of ARTD1 as K508 regulates ADP-ribosylation in vivo 
To elucidate whether SET7/9-dependent methylation of ARTD1 at K508 is directly responsible for 
the observed influence of SET7/9 on ARTD1-dependent PAR formation in vivo (Figure 1), ARTD1-/- 
MLFs were stably genetically complemented with WT ARTD1 or with the two methylation deficient 
mutants (K508A and K508R), which were comparably expressed and only detected in the nucleus 
(NE, Figure 4A). Nuclear extracts containing WT or mutant ARTD1 were incubated with 
radioactively labeled NAD+, but without exogenous DNA, and ARTD1 auto-ADP-ribosylation was 
assessed. The methylation deficient ARTD1 mutants K508A and K508R exhibited markedly reduced 
activity in comparison to the WT control (Figure 4B and S3B). Upon addition of excess DNA, the 
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methylation deficient ARTD1 proteins K508A and K508R still exhibited reduced enzymatic activity, 
but the effect was less pronounced as compared to conditions without exogenous DNA (Figure 4C 
and S3C). This indicated that the methylation deficient ARTD1 mutants (K508A and K508R) are 
enzymatically less active and provided further evidence that SET7/9-dependent methylation of 
ARTD1 affects its activity. 
 
Mutation of K508 affects ARTD1 recruitment to chromatin 
The results described above suggested that the methylation of ARTD1 at K508 mainly affects its 
enzymatic activity by regulating its stimulation by DNA (Figure 1C and 4B). This should 
consequently lead to a more efficient recruitment of WT ARTD1 to sites of DNA damage within the 
nucleus as compared to the methylation deficient ARTD1 mutant. We thus first analyzed whether the 
affinity of ARTD1 to chromatin would be affected under normal (non-genotoxic stress) conditions. 
ARTD1 affinity was not affected by SET7/9 down-regulation and could thus not have caused this 
effect (Figure S3C). In order to study if ARTD methylation affected the recruitment of ARTD1 to 
sites of DNA damage, cells expressing EGFP-tagged WT and methylation deficient ARTD1 were 
analyzed by localized femtosecond laser irradiation 34. This method allows studying the kinetics of the 
recruitment of proteins to sites of DNA damage. The nature of the lesion can be influenced via the 
irradiation wavelength: At 775 nm, both DNA strand breaks and UV photoproducts are generated, 
while at 1050 nm mainly DNA strand breaks are produced 34.  Interestingly, recruitment of the K508R 
mutant ARTD1 was lower than of WT ARTD1 if cells were irradiated with femtosecond pulses at ! = 
775 nm (Figure 4D). 34. On the other hand, irradiation at a wavelength of 1050 nm caused similar 
recruitment of WT and K508R ARTD1 (Figure S3D). The kinetics of release of WT and K508R 
ARTD1 from the irradiated sites was comparable (data not shown). These results strongly suggest that 
SET7/9 regulates the recruitment of ARTD1 to damaged DNA in a DNA lesion-specific manner. 
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DISCUSSION  
The results presented here suggest that SET7/9 methylates ARTD1 in vivo and in vitro at lysine K508. 
The K508 was identified as the target site for SET7/9-dependent methylation by site-directed 
mutagenesis and mass spectrometry as well as with a specific polyclonal antibody raised against this 
methylated site. Methylation of ARTD1 by SET7/9 did not prevent its consecutive ADP-ribosylation, 
but affected ARTD1 recruitment to sites of local DNA damage in vivo. Prior auto-ADP-ribosylation 
of ARTD1 impaired its methylation by SET7/9. Knockdown of SET7/9 or the expression of 
methylation deficient ARTD1 in cells lacking WT ARTD1 caused reduced PAR formation in vitro 
and in vivo. Moreover, overexpression of SET7/9, but not its enzymatic inactive mutant enhanced 
PAR formation in untreated (basal) and H2O2 treated cells. These findings define a new SET7/9 
methylation target and reveal a previously unknown mechanism for the regulation of ARTD1 activity 
in cells. 
The effect of ARTD1 methylation on PAR formation was most apparent if no exogenous DNA was 
added to the reactions using lysates of cells with either knockdown of SET7/9 or genetically 
complemented with a methylation deficient ARTD1 mutant (the cell lysate did contain low amounts 
of DNA). The effect was much weaker under conditions of saturating DNA concentrations (1:1 ration 
DNA:ARTD1 dimer), which may hint at a regulatory effect on ARTD1 activation by DNA. We have 
already provided evidence that DNA double strand breaks are recognized and bound by the DBD of 
ARTD1, which subsequently binds to the CAT domain to induce structural changes within the 
catalytic cleft in order to increase the affinity for NAD+ and stabilize reaction intermediates 4. The 
identified SET7/9-dependent methylation site at K508 of ARTD1 lies within the central 
automodification domain 4. It is at first glance surprising that ARTD1 is methylated in the AD and not 
in one of the zinc fingers of the DNA binding domain or in the catalytic domain of ARTD1, but 
nevertheless affected in its enzymatic activity. However, the AD harbours the ADP-ribose acceptor 
sites indicating that this domain has to enter the catalytic cleft of ARTD1 to be subsequently modified. 
SET7/9-dependent methylation may sensitize ARTD1 for automodification by stabilizing the 
automodification domain in the catalytic domain of ARTD1 under non-genotoxic conditions or in the 
presence of minimal DNA damage (fewer DNA lesions compared to ARTD1 molecules). 
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Alternatively, methylation might induce structural changes, which affect the binding of the DBD to 
the CAT and thus sensitise the enzyme for a special type of DNA damage (see below). Likewise, 
methylated ARTD1 could exhibit higher affinity for its substrate NAD+ and therefore show increased 
catalytic activity. Based on this hypothesis, methylation of ARTD1 at K508 by SET7/9 serves as a 
sensitization step that assures basal ARTD1 activity under low-stress conditions.  
The AD represents a PTM hotspot that is also modified by ADP-ribosylation, acetylation and 
sumoylation 2-4. Interestingly, prior auto-modification of recombinant ARTD1 inhibited subsequent 
methylation by SET7/9 most likely through steric hindrance (Figure 3A), which is in agreement with 
earlier studies providing evidence that the adjacent lysines 498, 521 and 524 are the acceptor sides for 
ADP-ribose 4. However, the SET7/9-mediated methylation of ARTD1 did not influence the auto-
ADP-ribosylation, indicating that the methylation would not affect the positioning of this domain into 
the catalytic domain. The functional relevance of this crosstalk needs to be further defined. It is 
intriguing to speculate that ARTD1 automodification would hamper K508 methylation to avoid an 
additional enhancement of its activity through this modification. Moreover, this could explain the 
inefficiency of SET7/9-dependent methylation to further activate already stimulated ARTD1 and hints 
again at a sensitization function of SET7/9 for ARTD1 under non-stimulatory conditions. 
The overall affinity of K508R mutant ARTD1 for (undamaged) chromatin in vivo was not affected. In 
contrast, different recruitment of WT and K508R ARTD1 to sites of local damage in the nucleus was 
observed in vivo. Interestingly, WT and K508R ARTD1 showed similar recruitment upon irradiation 
at a wavelength of 1050 nm, while a clear reduction was observed for the mutant after treatment with 
laser pulses at 775 nm (Figures 4D and S3D). This effect was likely due to differences in the number 
of lesions induced by 775 nm vs. 1050 nm irradiation. The latter wavelength is specific for the 
induction of DNA strand breaks but achieves a lower overall damage than 775 nm at the irradiation 
conditions employed here 34. Alternatively, a higher affinity for a certain type of lesion or chromatin 
alteration (qualitative difference) of the methylated ARTD1 protein, as compared to the unmethylated 
or the non-methylatable mutant, could also contribute to this behaviour. 
Based on the results described here, SET7/9-dependent methylation of ARTD1 at K508 is proposed 
as a mechanism to sensitize ARTD1 and thus assure the efficient activation under genotoxic stress. 
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However, the factors and conditions regulating the enzymatic activity of SET7/9 are currently not 
known.  
ARTD1 methylation at K508 could be detected in extracts of cells overexpressing SET7/9, while 
neither treatment with LPS or TNF nor induction of DNA damage by topoisomerase inhibitors could 
enhance ARTD1 methylation as discernible by the antibody (data not shown). This indicates either 
low endogenous levels of ARTD1 K508 methylation or further di- and trimethylation at this residue 
by other methyl transferases. Here, SET7/9 strongly affected ARTD1 activity in the presence of low 
amounts of DNA and upon stimulation by H2O2, although we do not know whether this was due to 
oxidative damage of the DNA. Whether SET7/9 is similarly required for the response to other signals 
(e.g. MNNG or PMA) remains to be investigated. The fact that SET7/9 is not required for cell cycle 
arrest or p53 stabilization suggests that the methylation-dependent stimulation of PAR formation is 
not required for these aspects but serves for other, yet to be identified, signalling pathways. Most 
importantly, the results presented here may indicate DNA-damage independent induction of ARTD1 
activity in vivo and suggest that ARTD1 methylation stimulates ADP-ribosylation in response to other 
cellular stresses that do not necessarily involve DNA damage 5.  
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MATERIAL and METHODS 
Plasmids and protein expression 
pGEX-SET7/9 (52-366) and pcDNA3-SET7/9 (full-length/WT and H297A) were kindly provided by 
D. Reinberg (Howard Hughes Medical Institute, NYU School of Medicine, New York, USA). 
pcDNA4-Flag-HA-SET7/9 was created by subcloning SET7/9 into pcDNA4. pCMV-HA-PARP1 and 
pRRL-vectors were described previously 2. All point mutations were inserted by site-directed 
mutagenesis. The construct encoding macroH2A-EGFP was kindly provided by A. Ladurner 
(Department of Physiological Chemistry, Ludwig-Maximilians-Universität (LMU) Munich, Munich, 
Germany). 
The baculovirus expression vector BacPak8 (Clontech, Mountain View, CA, USA) was used for the 
expression of recombinant proteins in Sf21 insect cells, as described previously 35. Recombinant GST-
tagged proteins were expressed in E.coli. All recombinant proteins were purified by a one step affinity 
chromatography using ProBond resin (Invitrogen, Zug, Switzerland) for His-tagged and glutathione 
sepharose (GE Healthcare, Zurich, Switzerland) for GST-tagged proteins, according to the 
manufacturer‘s recommendations.  
 
Antibodies and siRNAs 
The following antibodies were used for immunoblotting: rabbit PARP-1 (H-250, Santa Cruz, 
Heidelberg, Germany); rabbit poly(ADP-ribose) (LP96-10, BD Biosciences, Allschwil, Switzerland); 
rabbit SET7/9 (#2815, Cell Signaling); mouse Flag (M2, Sigma-Aldrich, Buchs, Switzerland); mouse 
tubulin (T6199, Sigma); rabbit PARP (mono methyl K508) (ab92986) was generated in collaboration 
with Abcam (Cambridge, UK) using a synthetic ARTD1 peptide containing the methylated lysine 
residue (LSKKSK(me1)GQVKE). 
The following FlexiTube siRNAs (QIAGEN, Hombrechtikon, Switzerland) were used in RNAi 
experiments: AllStars Negative Control, Hs_SET7_3 and Hs_PARP1_6. 
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Tissue culture and transfections 
U2OS cells were cultured in Dulbecco’s modified eagle medium (PAA Laboratories, Pasching, 
Austria) supplemented with 10% FCS and penicillin/streptomycin. MLFs were cultured in the same 
medium supplemented in addition with non-essential amino acids (Gibco/Invitrogen). Transfections 
with the indicated plasmids were performed with TransIT®-LT1 (Mirus Bio, Madison, WI, USA) 
according to the manufacturer’s instructions and cells were harvested after 48 hrs. Knockdown was 
achieved by reverse transfection of 16 nM siRNA using RNAiMAX (Invitrogen) according to the 
manufacturer’s protocol. Cells were harvested after three days. Cells were treated with 1 mM H2O2 in 
PBS containing 1 mM MgCl2 for 10 min and with 0.5 %M Adr in normal medium. 
Complementation of ARTD1 knockout MLFs was achieved by retroviral transduction with pRRL-
myc-PARP1 vectors containing a blasticidine resistance marker or the corresponding empty vector. 
Generation of viruses and transduction of cells was done as described earlier 36. 
 
In vitro methylation assays 
1 %g substrate protein was incubated with 1 %g bacterially purified GST-SET7/9 in presence of 0.03 
%Ci [14C]-SAM (PerkinElmer) or 0.8 mM cold SAM (Sigma-Aldrich) in methylation buffer (50 mM 
Tris-HCl pH8.0, 50 mM NaCl, 10% glycerol, 1 mM PMSF, 1 mM DTT) or PAR buffer (see section 
below) for 1 h at 30° C. Reactions were stopped by boiling in 10X SDS-loading buffer and separated 
by SDS-PAGE. Gels were stained with Coomassie Blue, incubated in 1 M sodium salicylate for 20 
min, dried, and exposed on X-ray films at -80° C. For mass spectrometric analysis, ARTD1 fragment 
373-524 was methylated as described above, separated by SDS-PAGE, excised from the gel and 
digested with Glu-C. Peptides were analyzed by MALDI-MS. 
 
Sequential in vitro modification assays 
Sequential ADP-ribosylation and methylation assays were performed in PAR buffer (50 mM Tris-HCl, 
4 mM MgCl2, 250 %M DTT, 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml leupeptin). 10 pmol 
recombinant ARTD1 was methylated with 1 %g recombinant GST-SET7/9 as described above. The 
ADP-ribosylation was then started by addition of 5 pmol activating DNA and 400 %M cold NAD+ 
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(Sigma, after methylation with [14C]-SAM) or 100 %M NAD+ spiked with [32P]-NAD+ (Perkin Elmer, 
after methylation with cold SAM). ADP-ribosylation reactions were incubated for 5 min at 30° C, 
stopped by addition of 10X SDS-loading buffer and proteins were separated by SDS-PAGE. Hot 
methylation/ADP-ribosylation was assayed by autoradiography of the Coomassie stained, dried gels, 
while cold modifications were controlled by immunoblotting with the indicated antibodies.  
In the reverse experiment, 10 pmol ARTD1 was first incubated with activating DNA and 100 %M 
NAD+ for 5 min on ice. 3-AB (Sigma-Aldrich) was added in a concentration of 8 mM to stop the 
ADP ribosylation before the methylation was started by addition of 1 %g SET7/9 and [14C]-SAM. The 
activating DNA used in all assays was an annealed double-stranded oligomer (5’-GGAATTCC-3’). 
For sequential methylation/acetylation, 1 %g ARTD1 fragment (373-524) was methylated as described 
above. Acetylation was then started by addition of 20 %l HAT reaction mix (50 mM Tris-HCl pH 8.0, 
50 mM NaCl, 10% glycerol, 1 mM DTT, 1 mM sodium butyrate, 1 mM PMSF, 0.5 %g p300, 75 %M 
[14C]-AcCoA) and allowed to proceed for 1 h at 30°C. 
 
Cellular extracts and ARTD1 activity assays 
Whole cell extracts were prepared in lysis buffer (50 mM Tris-HCl pH7.5, 400 mM NaCl, 1%Triton, 
25 mM NaF). Chromatin fractions were prepared as described elsewhere 37. 
Nuclear extracts from U2OS cells and complemented MLFs were generated as described earlier 38, 39. 
5 %g nuclear extracts were incubated in 30 %l reaction buffer (50 mM Tris-HCl, 4 mM MgCl2, 1 
mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml leupeptin, 250 nM [32P]-NAD+) in absence or presence of 
5 pmol activating DNA for 20 min at 30°C. Proteins were separated by SDS-PAGE and ADP-
ribosylation was analyzed by autoradiography. Quantifications were done using the software 
ImageQuant. 
 
Induction of local DNA damage and imaging setup 
Local DNA damage was induced by femtosecond laser irradiation and recruitment of fluorescently 
tagged proteins was recorded as described previously using a LSM 5 Pascal confocal microscope 34, 40. 
Briefly, cells were irradiated with femtosecond laser pulses through a 40x oil immersion lens with a 
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numerical aperture of 1.3 (EC-Plan-Neo-Fluar, Carl Zeiss) along a 6 µm track within the nucleus, 
followed by fluorescence imaging at 488 nm. The maximum peak irradiance in the focal plane was 
330 GW/cm2 (pulse duration 200 fs, repetition rate 40 MHz) for excitation at 775 nm and 1200 
GW/cm2 (pulse duration 85 fs, repetition rate 107 MHz) at 1050 nm. Time series of fluorescence 
images were quantified with ImageJ (http://rsb.info.nih.gov/ij) as described 40, 41.  
 
SUPPLEMENTAL DATA 
Supplemental material includes 3 supplementary figures. 
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FIGURE LEGENDS 
Figure 1. ARTD1 activity is influenced by SET7/9 in vivo. U2OS cells were transfected with 
scrambled siRNA (scr) or siRNA targeting SET7/9. (A) Three days after knockdown, the cells were 
treated with or without 1mM H2O2 for 5 min and PAR formation was analyzed by Western blot. (B) 
Quantification of (A). (C) ARTD1 activity was analyzed in nuclear extracts from U2OS cells after 
knockdown of SET7/9 and ARTD1 for three days by radioactive ADP-ribosylation assays. Upper 
panels: autoradiographies, lower panels: Coomassie stained gels. (D) Quantification of (C). (E) H2O2-
induced PAR formation was analyzed after overexpression of Flag-SET7/9 WT or H297A as in (A). 
(F) Quantification of (E).  
 
Figure 2. ARTD1 is methylated at K508 by SET7/9 in vitro and in vivo. (A) GST, ARTD1, 
ARTD2 and H3 were incubated with SET7/9 and 14C-labeled SAM in an in vitro methylation assay, 
separated by SDS-PAGE and analyzed by autoradiography. (B) Full-length ARTD1 and fragments 
covering the whole protein were incubated in an in vitro methylation assay and analyzed by 
autoradiography. (C) Decreasing amounts of WT ARTD1 and K508R ARTD1 were methylated by 
SET7/9 and analyzed by autoradiography. Left: ARTD1 automodification domain (aa 373-524), right: 
full length WT or methylation deficient K508 ARTD1 mutant (D) In vitro methylation of WT and 
K508R ARTD1 was assessed in cells overexpressing SET7/9 (+) with an anti-meARTD1 antibody. 
(E) U2OS cells were transfected with scrambled siRNA (scr) or siRNA directed against ARTD1. One 
day, later cells were transfected with an empty vector or with a plasmid containing WT SET7/9. 
Whole cell extracts were analyzed by Western blot at day 3 after knockdown using an antibody 
directed against a peptide carrying the methylated lysine residue of ARTD1. (F) U2OS cells were co-
transfected with HA-ARTD1 (WT or K508R) and EGFP or Flag-HA-SET7/9 (WT or H297A). After 
immunoprecipitation (IP) with an anti-HA antibody, whole cell extracts and IP samples were analyzed 
by Western blotting with the indicated antibodies. 
 
Figure 3. ARTD1 methylation by SET7/9 does not influence its PARylation or acetylation but is 
inhibited by ARTD1 automodification. (A) Recombinant ARTD1 was methylated by SET7/9 after 
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ADP-ribosylation in presence or absence of DNA and 3AB. ±: 3-AB was added after the ADP-
ribosylation reaction. (B) ARTD1 was first incubated with SET7/9 in presence or absence of 14C-
SAM and afterwards incubated with activating DNA and cold NAD+ to allow automodification. (C) 
ARTD1 (373-524) was first incubated with WT  SET7/9 or an enzymatic dead mutant (H297A) in 
presence of cold SAM and afterwards acetylated with p300 and 14C-AcCoA (left). Methylation was 
controlled with 14C-SAM (right).   
 
Figure 4. ARTD1 recruitment to chromatin and enzymatic activity after SET7/9 knockdown 
and K508 mutation.     
(A) ARTD1 knockout MLFs were stably complemented with WT ARTD1 or two methylation 
deficient mutants. Cells were then fractionated and cytoplasmic (CE) and nuclear extracts (NE) were 
analyzed by Western blot. (B) ARTD1 activity in NE from (A) was analyzed by radioactive PAR 
assay. (C) ARTD1 activity in NE from complemented MLFs as in (A) but in presence of 5 pmol 
activating DNA. (D) Recruitment of WT and K508R ARTD1 to sites of local DNA damage induced 
by femtosecond laser irradiation a ! = 775 nm. 
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LEGENDS OF SUPPLEMENTARY FIGURES 
Figure S1. (A) U2OS cells expressing GFP-tagged SET7/9 and mCherry-tagged ARTD1 were 
analyzed by fluorescence microscopy. (B) U2OS cells were transfected with scrambled siRNA (scr) 
or siRNA targeting SET7/9. (C) Effect of SET7/9 depletion with three different siRNAs on mRNA 
levels. (D) Recruitment of macroH2A-EGFP to sites of local DNA damage induced by femtosecond 
laser irradiation at ! = 1050 nm. 
 
Figure S2. (A) Mass spectrometric analysis of recombinant ARTD1 (373-524) incubated with 
SET7/9 in presence and absence of SAM. (B) MS/MS scan of ion with m/z 3119.72 according to 
ARTD1 peptide 485 – 514 identifying lysine 508 as the methylated residue. (C) Dot blot with non 
methylated (nm) and methylated (met) ARTD1 peptides at the indicated concentrations. Two different 
antibody batches were tested. (D) Validation of a peptide specific antibody directed against the 
methylated K508 in ARTD1. A specific signal for K508 ARTD1 methylation was observed upon in 
vitro methylation with WT SET7/9. 
 
Figure S3. (A) Schematic representation of the ARTD1 domain structure and the important 
methylation, sumoylation, acetylation and ADP-ribosylation sites in the automodification domain of 
ARTD1. (B-C) ARTD1 knockout MLFs were stably complemented with WT ARTD1 or two 
methylation deficient mutants. Cells were then fractionated and cytoplasmic (CE) and nuclear extracts 
(NE) were analyzed by Western blot. (B) Quantification of ARTD1 activity in NE of complemented 
MLFs (shown in Figure 4B). (C) Quantification of ARTD1 activity in NE from complemented MLFs 
in presence of 5 pmol activating DNA (shown in Figure 4C). (D) Recruitment of WT and K508R 
ARTD1 to sites of local DNA damage induced by femtosecond laser irradiation at ! = 1050 nm.  
! !
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5.2. Crosstalk between Set7/9-dependent methylation and ARTD1-mediated ADP-
ribosylation of histone H1.4 
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ABSTRACT 
Crosstalk between different histone post-translational modifications (PTMs) fine-tunes and 
regulates the cellular response to different external signals. ADP-ribose modification by 
cellular ADP-ribosyltransferases such as ARTD1 was recently added as a PTM of the histone 
code. All 5 histone proteins were described to be ADP-ribosylated in vitro and in vivo. 
However, the crosstalk of ADP-ribosylation with other modifications is little understood. 
Here, we identified histone H1.4 as a new target for SET7/9, which is methylated at the last 
lysine residues of the six KAK motifs in the C-terminal domain (K121, K129, K159, K171, 
K177 and K192). Interestingly, H1 competed with histone H3, a known SET7/9 target 
protein, for SET7/9-dependent methylation. Using isolated histones it was found that H3 is 
preferably ADP-ribosylated, which allowed subsequent methylation of H1. Extended poly-
ADP-ribosylation (PARylation) of histones (including H1) by ARTD1 prevented the 
methylation of H1 by SET7/9, suggesting an interesting mechanism by which ARTD1 
activity and the level of histone PARylation influence methylation and potentially other 
chromatin-associated processes.  
Together, these findings illustrate a new function and target for SET7/9-dependent 
methylation and support the role of ADP-ribosylation as an element of the histone code, 
which likely regulates chromatin-responses.  
 
 
Key words: PARP-1, SET7/9, lysine methylation, poly-ADP-ribosylation, post-translational 
modification
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INTRODUCTION 
Histones are highly alkaline proteins found in cell nuclei that package and order the DNA 
into structural units called nucleosomes (Campos & Reinberg, 2009). Five major families of 
histones exist: H1 (H5), H2A, H2B, H3, and H4. Two copies of the core histones H2A, H2B, 
H3 and H4 form the octameric nucleosome core particles (Kornberg & Lorch, 1999). Unlike 
the other histones, only one copy of the linker histone H1 is present and thus stabilizes the 
DNA, which is wrapped around the core nucleosome (Annunziato, 2008). The H1 linker 
histone binds to both, the nucleosome and the "linker DNA" (approximately 20-80 
nucleotides in length) region between nucleosomes. Many experiments addressing H1 
function have been performed with purified, processed chromatin under low-salt conditions, 
but the in vivo role of H1 is less certain. Cellular studies have shown that overexpression of 
H1 can cause aberrant nuclear morphology and chromatin structure and that depending on the 
gene H1 can serve as both a positive and negative regulator of transcription (Shen & 
Gorovsky, 1996). Similar to the core histones, H1 is also composed of three domains 
(Ramakrishnan et al, 1993). The N-terminus is a short, flexible segment rich in basic amino 
acids, the central domain exhibits a globular structure composed of a winged helix motif 
(Ramakrishnan et al, 1993) and the C-terminus is predominantly composed of lysine, alanine 
and proline residues and is the main determinant for the H1 binding to chromatin (Hendzel et 
al, 2004). The interaction of H1 with the nucleosome and additional DNA stretches at the 
entry/exit of the nucleosome forms the chromatosome and leads to higher order chromatin 
structure (Happel & Doenecke, 2009). Among the five histones of the nucleosome, the linker 
histone H1 is the least conserved. In the human genome, 11 genes encoding H1 variants have 
been identified and are transcribed either ubiquitously or in a cell type specific manner 
(Happel & Doenecke, 2009; Izzo et al, 2008). The study described here focuses on histone 
H1.4, which represents a histone variant that is expressed in somatic cells during S phase. 
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Together with H1.2 it is the predominant histone variant in most cell types. Similar to the 
core histones, linker histones are subject to extensive post-translational modifications 
(PTMs), including phosphorylations, methylations and acetylations (Raghuram et al, 2009).  
SET7/9 (also SET7, SET9, SETD7 or KMT7) is a mono-methyltransferase for lysine at 
position 4 of histone H3 (H3K4) (Nishioka et al, 2002; Wang et al, 2001) that was linked to 
transcriptional activation. It methylates the consensus motif [K>R][S>KYARTPN][Kme] and 
prefers lysine residues within positively charged regions (Dhayalan et al, 2011). However, 
SET7/9 exhibits only weak lysine methyltransferase activity towards H3 in nucleosomes, 
suggesting that other factors might be involved in SET7/9-dependent H3K4 methylation in 
vivo or that histone proteins are not the main substrates of SET7/9. Lysine methylation can be 
reversed by demethylases of the LSD family or the Jumonji-C domain family of proteins 
(Klose & Zhang, 2007; Mosammaparast & Shi, 2010). 
In contrast to the canonical PTMs of the histone code such as methylation, ADP-ribosylation 
is much less studied. ADP-ribosylation comprises the transfer of the ADP-ribose moiety from 
the co-substrate nicotinamide adenine dinucleotide (NAD+) onto specific amino acid side 
chains of acceptor proteins or to pre-existing protein-linked ADP-ribose units by ADP-
ribosyltransferases (ARTs). Mammalian ARTs can be divided into two groups according to 
their similarity to the bacterial diphteria and cholera toxins - the ARTDs and ARTCs, 
respectively. The ARTDs were formerly known as poly(ADP-ribose) polymerases (PARPs) 
(Hottiger et al, 2010). ARTD1 (PARP1) is the best-studied member of the ARTD family and 
represents a highly abundant (on average 1 x 106 molecules per cell), nuclear, chromatin-
associated enzyme that is responsible for most (about 90%) of the cellular PAR generation 
(D'Amours et al, 1999; Yamanaka et al, 1988). It is implicated in many and different cellular 
processes such as the DNA damage response, cell cycle regulation, gene expression, 
differentiation and aging. The major target of ARTD1 is ARTD1 itself, but it also modifies 
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other nuclear proteins including all five histone proteins in vitro and in vivo (Hottiger, 2011). 
In native chromatin, histone H1 is the main ADP-ribose acceptor, but depending on the 
chromatin composition and the accessibility of different histones, the ADP-ribosylation 
pattern of histones varies (Adamietz & Hilz, 1976; Huletsky et al, 1989). The identity of the 
ADP-ribose acceptor sites has been debated extensively and different amino acids have been 
put forward as ADP-ribose acceptors. More recently glutamate and lysine residues were 
identified as ADP-ribose acceptor sites based on mass spectrometry (Altmeyer et al, 2009; 
Tao et al, 2009). Importantly, mass spectrometry and electron-transfer dissociation (ETD) 
identified for the first time, lysine K13 of histone H2A, K30 of H2B, K27 and K37 of H3 as 
well as K16 of H4 as ADP-ribose acceptor sites (catalysed by ARTD1) (Messner et al, 2010).  
Crosstalk between different PTMs occurs directly by competition for acceptor sites or 
indirectly by changes in the accessibility of chromatin for modifying enzymes. The 
observation that specific lysine residues serve as ADP-ribose acceptors is important because 
the same amino acid residues are potential acetylation and methylation sites (Kouzarides, 
2007). It is therefore likely that competition for acceptor sites between different histone 
PTMs such as ADP-ribosylation, acetylation, methylation and phosphorylation causes 
crosstalk (Hottiger, 2011). This has been demonstrated by the finding that acetylation of 
lysine residue K16 of histone H4 inhibits ADP-ribosylation in vitro (Messner et al, 2010), 
which suggests that different crosstalk likely exists in vivo as well. Similarly, H1.4 K26 
dimethylation and AuroraB-mediated phosphorylation of S27 have been reported to interfere 
with each other (Hergeth et al, 2011). Whether or not other modifications of the histone code 
such as methylations or phosphorylation also crosstalk with ADP-ribosylation has not been 
studied before. 
Here, we define the linker histone H1.4 as a novel target of SET7/9-dependent methylation, 
identify lysines K121, K129, K159, K171, K177 and K192 as methyl acceptor sites and 
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describe crosstalk between H1.4 methylation and ADP-ribosylation as well as competition 
with histone H3 methylation.  
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RESULTS 
The C-terminus of linker histone H1.4 is methylated by SET7/9 
In vitro methylation experiments with the histone H3 methyltransferase SET7/9 and ADP-
ribosylated histones as acceptors revealed that linker histone H1 was unexpectedly strongly 
methylated (Figure 1A). Therefore, SET7/9-dependent methylation of the new target H1 was 
characterized in more detail. Interestingly, full-length histone H1.4 was not methylated in the 
presence of plasmid DNA, while a H1.4 variant lacking the C-terminus (&CT) was not 
methylated at all (Figure 1B). These results suggested that H1.4 is methylated at the CTD, 
which was described to bind to DNA, and that SET7/9 likely methylates soluble H1.4 that is 
not part of the chromatin structure. In order to locate the methylation site in histone H1.4, 
recombinant, C-terminally truncated, HIS-tagged H1.4 fragments as well as short fragments 
of the C-terminal domain (CTD) were analyzed (Figure 1C). Full length H1.4 (aa 1-219) was 
strongly methylated, while partial truncation of the CTD (1-189 or 1-156) caused reduced 
SET7/9-dependent methylation (Figure 1D). Deletion of the entire CTD (&CTD, aa 1-113) 
completely abolished H1.4 methylation  (Figure 1D). To further pinpoint the methylation 
sites in the H1.4 CTD, three H1.4 fragments covering the whole CTD were expressed as 
GST-fusion proteins (aa 114-144, 145-189, 190-219, Figure 1C), purified and used in 
methylation assays. All three fragments were methylated by SET7/9, albeit to different 
degree (Figure 1E). Fragment 190-219 showed the strongest methylation, while the fragment 
from amino acids 114-144 showed only weak methylation, suggesting that multiple SET7/9-
dependent methylation sites are present in the CTD of H1.4. These results clearly 
demonstrated that the linker histone H1.4 is methylated by SET7/9 in vitro. The differences 
in the degree of SET7/9-dependent methylation of different H1.4 fragments indicated 
multiple methylation sites in the H1.4 CTD.  
 
  70 
Linker histone H1.4 is methylated at six lysine residues of the C-terminal domain 
In order to define all SET7/9 methylation sites of the H1.4 CTD, the three fragments (114-
144, 145-189, 190-219) were further mutagenized. Since the strongest methylation was seen 
for fragments 145-189 and 190-219, these peptides were subjected to a cluster mutation 
approach. Seven sequence clusters that comprised all potential lysine methylation sites were 
defined and in each of these seven clusters all lysines were mutated to arginines (Figure 
S1A). Of the seven cluster mutants, methylation of the cluster 4 and cluster 6 mutant proteins 
was comparable to the wildtype protein (Figure S1B), which indicated that the lysine residues 
located in these two clusters are not methylated by SET7/9. The remaining clusters 1, 2, 3, 5 
and 7, as well as the fragment 114-144 were computationally analyzed in order to identify 
putative SET7/9 target site matching the [KR][STA]K consensus motif for SET7/9-
dependent methylation (Couture et al, 2006). This in silico analysis identified six lysines at 
positions 121, 129, 159, 171, 177 and 192, which all represented the last lysine of the KAK* 
motif (Figure S1A).  
Only the mutation of all three lysines (K159, K171, K177) of the fragment 145-189 
completely abolished methylation of the protein fragment (Figure S1C). Similarly, the 
K192R mutation abrogated the SET7/9-dependent methylation of the fragment 190-219 
(Figure S1D). Interestingly, combination of the K159R, K171R, K177R and K192R 
mutations in full-length H1.4 did not completely prevent its methylation (Figure 2). Only 
upon the additional mutation of K121 and K129 of the fragment 114-144 to arginines, 
SET7/9-dependent methylation of full-length H1.4 could no longer be observed (Figure 2). 
The mapping of the methylation sites in the H1.4 CTD thus identified the KAK* motif and 
the six lysines K121, K129, K159, K171, K177 and K192 as the targets for SET7/9-
dependent methylation of this linker histone variant. 
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Poly-ADP-ribosylation of histones prevents methylation by SET7/9 
Besides its originally described target histone H3, SET7/9 also methylates H1.4 and non 
histone proteins. Interestingly, ARTD1 is methylated at lysine K508 by SET7/9, which 
enhances its enzymatic activity and which is inhibited by ARTD1 auto-PARylation (Kassner 
et al). It was therefore tested if PARylation of core histones also impairs consecutive SET7/9-
dependent methylation. Calf histones were PARylated for different time periods and then 
subjected to methylation assays with SET7/9 and radio-labelled S-adenosyl-L-[methyl-
14C]methionine (14C-SAM) as methyl donor. In the absence of PARylation, mainly core 
histones were methylated, while only a faint signal was observed for the linker histone H1 
(Figure 3A). A short PARylation reaction strongly reduced the consecutive methylation of 
core histones, while H1 methylation was drastically increased. More extensive PARylation (> 
2 min) prevented methylation of both, core and linker histones. These results confirmed that 
core and linker histones are methylated by SET7/9 and suggested strong crosstalk and 
competition between methylation and PARylation and between core and linker histones.  
SET7/9 was described as a specific histone H3 methyltransferase (Nishioka et al, 2002; 
Wang et al, 2001). In order to elucidate the nature of the competition and crosstalk described 
above, PARylation and methylation of the histones H3 and H1 were therefore studied in more 
detail. Recombinant H3 or a mixture of H1 was incubated with ARTD1, NAD+ and with or 
without DNA (to stimulate ARTD1) and 3-AB (to inhibit ARTD1). Both, H3 and H1 were 
methylated if ARTD1 was inactive due to the lack of stimulation by DNA (lane 1) or because 
of inhibition by 3-AB (lane 4) (Figure 3B, C). PARylation of SET7/9 was not the cause for 
this effect, because the methyltransferase was only added after the PARylation reaction and 
addition or omission of 3-AB did not affect the result (Figure 3C, lanes 2 and 3). The addition 
of previously PARylated ARTD1 to H1 methylation reactions did not inhibit SET7/9 activity 
(Figure 3D). These results suggested that H1.4 and H3 are only methylated by SET7/9 in the 
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absence of PARylation and that ARTD1-dependent PARylation might modulate which 
histone protein is methylated. To test this hypothesis, in vitro competition experiments with 
or without PARylation of H1.4 and H3 were performed. As shown before (Figure 3B, C), H1 
and H3 were strongly methylated by SET7/9 if present alone (Figure 4, lanes 1 and 5). 
However, H1 and H3 competed with each other when present in the same reaction and thus 
lead to a reduced methylation signal (lanes 2-4). Prior PARylation of histone H3 completely 
abolished its competing activity for SET7/9-dependent H1 methylation (lanes 6-7).  
It was thus concluded that PARylation of H1 and H3 by ARTD1 abolishes consecutive 
SET7/9-dependent methylation and that non-PARylated H1.4 and H3 compete for SET7/9. 
These results suggest that differential PARylation of histone proteins by ARTD1 can 
indirectly influence histone methylation and thus the histone code by determining which 
target proteins are modified. 
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DISCUSSION  
This study describes the linker histone H1.4 as a new target for the H3K4 mono-
methyltransferase SET7/9. Full-length histone H1.4 was methylated by SET7/9 at the lysine 
residues K121, K129, K159, K171, K177 and K192 of the KAK motifs of the CTD, which 
suggests a strong preference of SET7/9 for this recognition sequence. However, some of the 
KAK motifs seemed preferentially methylated, which may indicate a sequential modification 
of the different acceptor sites or indicate differences in the accessibility of the different 
methylation sites.  
The addition of plasmid DNA abolished SET7/9-dependent methylation of target proteins, 
indicating that incorporation into the nucleosome structure and DNA binding may prevent 
methylation. This could be explained by DNA-induced conformational changes of the H1 
CTD and by charge neutralization through DNA, as SET7/9 is known to prefer lysine 
residues in a positively charged context. Likewise, methylation may directly influence the 
binding of H1 to DNA and its function in chromatin compaction, especially as the six lysine 
residues targeted by SET7/9 all reside in the CTD of H1.4, which is important for chromatin 
binding (Caterino & Hayes, 2011). These findings may indicate that the SET7/9-dependent 
methylation regulates free histones and possibly their turnover and exchange, which extends 
the scope of the histone code outside of the chromatin realm. 
Covalent histone modifications can alter chromatin structure and thereby define 
transcriptionally active or inactive states of chromatin (Jenuwein & Allis, 2001). Compared 
with core histones, little is known about the modifications and the corresponding modifiers of 
the linker histones. One possible function of H1 methylation by SET7/9 might thus be the 
stimulation or repression of other post-translational modifications. Crosstalk between K26 
dimethylation and AuroraB-mediated phosphorylation of S27 has been reported previously 
(Hergeth et al, 2011). In addition, the H1.4 CTD is the target of acetylation, ADP-
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ribosylation and phosphorylation (Ogata et al, 1980; Wisniewski et al, 2007). Interestingly, 
the four last KAK motifs, which displayed the strongest methylation in in vitro methylation 
assays with SET7/9, are located in close proximity to well-known CDK phosphorylation sites 
and two acetylated lysine residues (Figure 5A), which suggests the potential for significant 
crosstalk between acetylation, methylation and phosphorylation. Two of the sites in this 
region, S172 and S187, are not exclusively phosphorylated during mitosis and their 
phosphorylation in interphase correlated with transcription and chromatin relaxation (Zheng 
et al, 2010). These results indicate that significant crosstalk between different histone 
modifications of H1.4 may fulfill important functions. However, in most cases the modifying 
enzymes are currently not known and thus the biological and cellular functions of these 
modifications have not been elucidated in detail yet. 
ARTD1 and histone ADP-ribosylation were previously suggested as components of the 
histone code (Hottiger, 2011; Messner & Hottiger, 2011). The results described here provide 
a further line of evidence for this hypothesis. We show that ARTD1-dependent PARylation 
of histones influences their subsequent methylation by SET7/9. Compared to 
phosphorylation, which strongly reduces methylation if in proximity of SET7/9 target lysine 
residues (Dhayalan et al, 2011), PARylation is a much more bulky modification with more 
negative charges and therefore also inhibited histone methylation by SET7/9. Based on our 
experiments, we know that SET7/9 methylates both, H1 and H3. Yet, when both histones are 
present, H3 is preferred over H1. Strikingly, PARylation did not merely inhibit SET7/9-
dependent methylation of histones, but completely shifted its substrate-specificity from H3 to 
H1 (Figure 5B). These observations could be explained by sequential PARylation events, 
where ARTD1 modifies H3 before H1. PARylation of H3 would then inhibit its subsequent 
methylation by SET7/9 and its competition as a SET7/9 target with H1.  
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This ARTD1-dependent regulation of the substrate specificity of another histone modifying 
enzyme may be an exciting mechanism to explain how ARTD1 influences chromatin-
associated processes such as transcription. It is also important to note that progressive 
PARylation of histones also inhibited the methylation of H1, documenting that different 
outcomes for SET7/9-dependent histone methylation can occur depending on the extent of 
ARTD1 activity.  
The complexity of ARTD1-dependent histone modifications is increased by the facts that (1) 
ARTD1 can modify all core histones and the linker histones (Messner et al, 2010) and (2) the 
size and quality (e.g. branching or length) of the polymers may differ under varying 
conditions and depending on the substrate histone. Therefore, future studies should not 
merely focus on the influence of ARTD1 and PARylation on other histone modifications but 
also on how ARTD1-dependent histone methylation itself is regulated. In this regard, it will 
also be interesting to investigate if SET7/9-dependent ARTD1 methylation may influence its 
substrate choice and trans-PARylation activities. 
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MATERIAL and METHODS 
Plasmids and protein expression 
pGEX-SET7/9 (52-366) and pET28b-H1.4 (fl) bacterial expression vectors were kind gifts 
from D. Reinberg and R. Schneider, respectively. H1.4 full-length and deletions mutants 
were subcloned into pET-28a to add the N-terminal His-tag. C-terminal H1.4 fragments were 
cloned into pGEX6P1. All point mutations were inserted by site-directed mutagenesis. 
Cluster mutants were created by overlapping PCR with the corresponding primers.  
The baculovirus expression vector BacPak8 (Clontech, Mountain View, CA, USA) was used 
for the expression of recombinant ARTD1 in Sf21 insect cells, as described previously 
(Hassa et al, 2003). GST- and His-tagged histone proteins were expressed in E.coli. All 
recombinant proteins were purified by a one step affinity chromatography using ProBond 
resin (Invitrogen) for His-tagged and glutathione sepharose (GE Healthcare) for GST-tagged 
proteins, according to the manufacturer‘s recommendations. His-H1.4(fl) proteins were 
purified as described elsewhere (Weiss et al, 2010). 
 
Reagents 
Lyophilized histones or H1 mix from calf thymus was purchased from Roche and 
resolubilized in water. Recombinant H3 was a kind gift from T. J. Richmond. 3-AB (Sigma-
Aldrich) was prepared freshly in water.  
 
In vitro methylation assays 
If not stated otherwise, approximately 1 %g histone proteins were incubated with 1 %g 
bacterially purified GST-SET7/9 in presence of 0.03 %Ci [14C]-SAM (PerkinElmer) in 
methylation buffer (50 mM Tris-HCl pH8.0, 50 mM NaCl, 10% glycerol, 1 mM PMSF, 1 
mM DTT) for 10 to 60 min at 30°C in a 25%l reaction. For DNA inhibition assays, histones 
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were preincubated with or without 0.5 %g plasmid DNA (pcDNA) and then methylated for 15 
min. Reactions were stopped by addition of 10X SDS-loading buffer, boiled and separated by 
SDS-PAGE. Gels were stained with Coomassie Blue, incubated in 1 M sodium salicylate for 
20 min, dried, and exposed on X-ray films at -80° C.  
 
Sequential ADP-ribosylation and methylation assays 
Sequential modification assays were performed in PAR buffer (50 mM Tris-HCl, 50 mM 
NaCl, 4 mM MgCl2, 250 %M DTT, 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml leupeptin).  
10 pmol ARTD1 was incubated with or without 2.5 %g histone mix or 1 %g individual 
histones in presence or absence of 5 pmol activating DNA and 160 %M NAD+ (Sigma-
Aldrich) for 15 min at 30°C. 8 mM 3-AB (Sigma-Aldrich) or 0.2 mM PJ-34 were added to 
inhibit ARTD1 activity either before the ADP-ribosylation or afterwards where indicated. 
The methylation was then started by addition of 1 %g SET7/9 and 0.03 %Ci [14C]-SAM and 
allowed to proceed for 1hr at 30°C. Autoradiography was performed as described above. The 
activating DNA used in all assays was an annealed double-stranded oligomer (5’-
GGAATTCC-3’).  
 
SUPPLEMENTAL DATA 
Supplemental material includes 3 supplementary figures. 
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FIGURE LEGENDS 
 
Figure 1. Linker histones are methylated by SET7/9. (A) Calf histone mix was first ADP-
ribosylated by ARTD1 for 1 min. Then, after addition of PARP inhibitor PJ-34, histones were 
incubated with SET7/9 in presence of methyl donor [14C]-SAM. Proteins were separated by 
SDS-PAGE, stained with Coomassie blue (lower panel) and methylation was analyzed by 
autoradiography (upper pannel). The asterisk marks the shift of automodified ARTD1. (B) 
His-tagged H1.4 FL and a deletion mutant without the CTD (&CTD) were in vitro methylated 
by SET7/9 in the presence or absence of plasmid DNA. (C) Schematic depiction of H1.4 WT 
protein and constructs. NTD: N-terminal domain, GD: globular domain, CTD: C-terminal 
domain, &CT: H1.4 construct completely lacking the C-terminus. (D) Recombinant His-
tagged H1.4 full-length (FL) and deletion mutants were in vitro methylated by SET7/9 and 
analyzed as described in A. (E) H1.4 C-terminal fragments were expressed as GST fusion 
proteins and in vitro methylated by SET7/9. Methylation was analyzed by autoradiography as 
in A. 
 
Figure 2. Full-length H1.4 is methylated at six lysine residues by SET7/9. Mutation of the 
four lysine residues K159, K171, K177 and K192 (K4R) in WT H1.4 reduces SET7/9-
dependent methylation. The additional mutation of K121 and K129 (K6R) abolishes 
methylation of full-length H1.4 by SET7/9. The lower panel shows the Coomassie stained gel 
and methylation is visualized by autoradiography in the upper panel. Of each sample, two 
elutions were analyzed. 
  
Figure 3. Poly-ADP-ribosylated histones are not methylated by SET7/9. (A) Calf histone 
mix was first ADP-ribosylated by ARTD1 for the indicated times. Then, after addition of 
PARP inhibitor PJ-34, histones were incubated with SET7/9 in presence of methyl donor 
  83 
[14C]-SAM. Proteins were separated by SDS-PAGE, stained with Coomassie blue (bottom) 
and methylation was analyzed by autoradiography (top). The asterisk marks the shift of 
automodified ARTD1.  (B) H3 was incubated with ARTD1 and 160 %M NAD+. Activating 
DNA and PARP inhibitor 3-AB were present during the reaction as indicated. Methylation 
was then started by addition of SET7/9 and 14C-SAM. ±: 3-AB was added directly before 
addition of SET7/9 after the PAR reaction. (C) Influence of ARTD1 on H1 methylation as in 
B. (D) Presence of ADP-ribose polymers or nicotinamide does not disturb H1 methylation by 
SET7/9. ARTD1 was automodified for the indicated times and then inhibited by addition of 
3-AB. H1 was then methylated by SET7/9 in presence of the PAR reactions and 14C-SAM. 
 
Figure 4. H3 and H1 compete for methylation by SET7/9. H1 was methylated in presence of 
the indicated molar ratios of H3. In lanes 6 and 7, H3 was incubated with ARTD1 and NAD+ 
in presence or absence of 3-AB before addition of H1 and the methylation reaction.  
 
Figure 5. (A) Summary of known post-translational modification sites of H1.4. (B) Model of 
sequential ADP-ribosylation of histone H3 and H1 by ARTD1. 
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LEGENDS OF SUPPLEMENTARY FIGURES 
Figure S1. H1.4 CTD is methylated at KAK* motifs. (A) Amino acid sequences of C-
terminal H1.4 fragments. Boxes represent the lysine clusters which were mutated to arginines 
in B. Grey boxes mark the clusters that markedly influence methylation. KAK* motifs are 
highlighted in dark grey and the methylated lysines are bold. (B) Cluster mutant approach to 
identify methylation sites in H1.4 CTD, which contains 43 lysine residues as potential target 
sites. Clusters were mutated one by one in the corresponding C-terminal fragment and 
methylation efficiency by SET7/9 was tested in vitro. (C) Methylation of C-terminal 
fragments by SET7/9 was tested in vitro after mutation of single lysine residues in KAK* 
motifs. (D) Methylation of H1.4 (145-189) double and triple mutants by SET7/9. 
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ABSTRACT Poly(ADP-ribose) polymerase 1 (PARP1)
is a chromatin-associated nuclear protein and functions
as a molecular stress sensor. At the cellular level,
PARP1 has been implicated in a wide range of pro-
cesses, such as maintenance of genome stability, cell
death, and transcription. PARP1 functions as a tran-
scriptional coactivator of nuclear factor !B (NF-!B)
and hypoxia inducible factor 1 (HIF1). In proteomic
studies, PARP1 was found to be modified by small
ubiquitin-like modifiers (SUMOs). Here, we character-
ize PARP1 as a substrate for modification by SUMO1
and SUMO3, both in vitro and in vivo. PARP1 is
sumoylated at the single lysine residue K486 within its
automodification domain. Interestingly, modification
of PARP1 with SUMO does not affect its ADP-ribosy-
lation activity but completely abrogates p300-mediated
acetylation of PARP1, revealing an intriguing crosstalk
of sumoylation and acetylation on PARP1. Genetic
complementation of PARP1-depleted cells with wild-
type and sumoylation-deficient PARP1 revealed that
SUMO modification of PARP1 restrains its transcrip-
tional coactivator function and subsequently reduces
gene expression of distinct PARP1-regulated target
genes. Messner, S., Schuermann, D., Altmeyer, M.,
Kassner, I., Schmidt, D., Scha¨r, P., Mu¨ller, S., and
Hottiger, M. O. Sumoylation of poly(ADP-ribose) poly-
merase 1 inhibits its acetylation and restrains transcrip-
tional coactivator function. FASEB J. 23, 000–000
(2009). www.fasebj.org
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Poly(ADP-ribose) polymerase 1 (PARP1) is an abun-
dant nuclear chromatin-associated multifunctional en-
zyme found in higher eukaryotes that belongs to a
family of 5 “bona fide” PARP enzymes (1). PARP1 has an
amino-terminal DNA-binding domain (DBD) contain-
ing 3 zinc finger motifs, as well as a central automodi-
fication domain (AMD), which functions as a target of
direct covalent automodification. The carboxyl-termi-
nal catalytic domain polymerizes linear or branched
chains of ADP-ribose from the donor nicotinamide
adenine dinucleotide (NAD!). ADP-ribose is mainly
attached on PARP1, but also other proteins are modi-
fied (2). Together, the DBD and the automodification
domain allow PARP1 to interact with genomic DNA
and chromatin. Although originally characterized as a
key factor in DNA single strand-break repair, a wealth
of studies over the past decade have demonstrated a
role of PARP1 in the regulation of gene expression
under basal, signal-activated, and stress-activated condi-
tions (1, 3). Recent studies have highlighted the role of
PARP1 in distinct modes of transcriptional regulation
and provided novel insight into the cellular signaling
systems that interface with PARP1 in the nucleus (4).
The basal enzymatic activity of PARP1 is very low, but
it is stimulated dramatically under conditions of cellu-
lar stress (2, 3). Activation of PARP1 results in the
synthesis of poly(ADP-ribose) (PAR) from NAD! and
the release of nicotinamide as a reaction by-product
(1). Following PARP1 activation, intracellular PAR lev-
els can rise 10- to 500-fold (1), caused by a mechanism
that remains to be resolved. Very recently, we identified
3 lysine residues in the automodification domain of
PARP1 as acceptor sites for auto-ADP-ribosylation (5).
PARP1 is the main acceptor for poly(ADP-ribosyl)ation
in vivo, and automodification of PARP1 abolishes its
affinity for NAD! and DNA (5). Remarkably, the same
3 ribosylated lysines (K498, K521, K524) were previ-
ously identified as targets for acetylation by the histone
acetyltransferase p300 (6). Acetylation of PARP1 has
been reported to be important for its transactivation
activity (6). Recently, we also highlighted the role of
PARP1 as a transcriptional coactivator of hypoxia in-
ducible factor 1-" (HIF1-"). On hypoxic induction of
cells, PARP1 was shown to interact with HIF1-" and to
regulate the transcriptional activity of HIF1-"-depen-
dent genes (7).
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Another post-translational protein modification in
response to cellular stresses is the conjugation of small
ubiquitin-like modifiers (SUMOs) (8). SUMOs regulate
diverse cellular processes, including cell-cycle progres-
sion, genome stability, intracellular trafficking, and
transcription (9, 10). In many cases, SUMO conjuga-
tion alters localization and/or activity of the substrate
by providing a new protein-protein interaction inter-
face. However, in certain cases, SUMO modification
can also prevent distinct protein-protein interactions.
Mammalian cells express three SUMO paralogs:
SUMO2 and SUMO3, which are 96% identical and only
differ by three N-terminal residues, and SUMO1, which
is 45% identical to SUMO2/3. Moreover, SUMO2/3
proteins are able to form chains, which SUMO1 cannot
(11). Although virtually all of the SUMO1 is engaged in
conjugates, there is a free pool of the more abundant
SUMO2/3 that is utilized when cells are stressed by
heat shock or ethanol exposure (12). It is clear that
proteins can be modified selectively by SUMO1 and
SUMO2/3. Growing evidence suggests that SUMO2/3
and SUMO1 have some unique biological functions
(12–14).
SUMO family proteins are conjugated to target ly-
sines via a cascade of the E1-activating enzyme (SAE1/
SAE2), the E2-conjugating enzyme Ubc9, and E3
SUMO ligases (8, 10). The SUMO E2 protein Ubc9
often recognizes the consensus sequence !KxE/D
(where ! is a large hydrophobic amino acid, such as
isoleucine or valine, and x is any amino acid) in the
target protein and catalyzes SUMO conjugation (8).
Generally, sumoylation with SAE1/SAE2 and Ubc9 only
is rather inefficient, and additional proteins known as
SUMO E3 ligases are often required to accelerate this
reaction (10). A family of deconjugation enzymes,
SENPs, is responsible for the removal of SUMO from
target lysines (15), which accounts for the transient
nature of this modification. In human cells, six mem-
bers of this family (SENP1-3 and SENP5-7) have been
identified. Importantly distinct members exhibit para-
log specificity and show a characteristic subcellular
localization, indicating that spatial control is an impor-
tant regulatory concept of SENP activity.
Several proteomic studies to identify substrates for
SUMO conjugation have been reported (16–18). In
this context, PARP1 was detected to be sumoylated in
HEK293 cells and in K562 cells. SUMO modification of
proteins that regulate transcription has been associated
with dynamic regulation of gene expression (9, 19). A
large number of transcriptional regulators, including
transcription factors, cofactors, and chromatin-modify-
ing enzymes, have been found to be substrates of
SUMO modification. Generally, a SUMO-modified fac-
tor exists in a dynamic distribution between the SUMO-
modified and unmodified forms, and although the
SUMO-modified form of a protein is often difficult to
detect, it can have a great impact on transcriptional
activation (9, 10). Sumoylation of transcription factors
has generally been correlated with transcriptional re-
pression (9, 10). The specific effects, however, have to
be determined experimentally for each case.
In this study, we characterize the modification of
PARP1 through SUMO1 and SUMO3. The modifica-
tion primarily occurs at a lysine residue within the
automodification domain of PARP1. The attachment
site is close to hotspots of other post-translational
modifications of PARP1, such as ADP-ribosylation and
acetylation. This proximity led us to investigate a po-
tential crosstalk of these modifications. Sumoylation of
PARP1 inhibits its acetylation through p300, and cor-
respondingly, a sumoylation-deficient PARP1 mutant
has a higher acetylation status than wild-type PARP1. In
addition, a PARP1 sumoylation-deficient cell line exhib-
its increased transcriptional activity of genes under the
control of transcription factor HIF1-".
MATERIALS AND METHODS
Chemicals and antibodies
Protein G sepharose and glutathione sepharose 4B were
purchased from GE Healthcare (Les Ulis, France), 32P-NAD#
and 35S-methionine were from PerkinElmer (Boston, MA,
USA). NAD#, trichostatin A (TSA), acetyl-coenzyme A, 3AB,
ATP, anti-tubulin, and anti-Flag (M2) were obtained from
Sigma-Aldrich (Milan, Italy). Anti-p300 (C20) was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and
anti-HA antibody 16B12 from Covance (Evansville, IL, USA).
Anti-myc antibody (9E10) was purchased from Roche (Basel,
Switzerland), SUMO2/3 (18H8) was obtained from Cell
Signaling (Beverly, MA, USA), and His antibody was from
Qiagen (Valencia, Spain). Monoclonal CAIX antibody super-
natant from hybridoma was a gift from D. Stiehl (University of
Zurich, Zurich, Switzerland). Anti-PARP1 was produced in
this laboratory; anti-acetyl-PARP1 was generated in collabora-
tion with the monoclonal antibody core facility at the EMBL
Monterotondo (Monterotondo, Italy).
Cell culture and transfection
HEK293T and K562 cells were grown under standard condi-
tions. Transfections were carried out with the calcium phos-
phate method. Whole-cell extracts were prepared as de-
scribed previously (20) with 10 mM NEM and/or HDAC
inhibitors (2 $M TSA, 5 mM NAM, 1 mM Na-butyrate).
Nuclear extracts were prepared as described previously (6).
Plasmids
The baculovirus expression vectors pQE-TriSystem (Qiagen)
and BacPak8 (Clontech, Mountain View, CA, USA) were used
for the expression of recombinant proteins in Sf21 insect
cells, as described previously (21). pcDNA-myc-SUMO1, myc-
SUMO3, and myc-Ubc9 expression plasmids were kindly
provided by R. T. Hay (University of Dundee, Dundee, UK).
PARP1 was cloned into a pCMV-HA vector with NheI/NotI
restriction enzymes. pCU vector with Ubc9 was a kind gift
from R. Niedenthal (Hannover Medical School, Hannover,
Germany). PARP1 was cloned into pCU with NheI/SmaI
restriction enzymes, generating a 15-aa linker between PARP1
and Ubc9. pCMV-Flag-p300 was used for expression in mam-
malian cells. Plasmids for SUMO proteases SENP1-6 were in
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pCI-Flag backbone. Short hairpin RNA was cloned and ex-
pressed in pSUPER vector.
Cloning, expression, and purification of recombinant
proteins
Wild-type hPARP1 (National Center for Biotechnology Infor-
mation ID: BC037545) was cloned and expressed as amino-
terminal HA-tagged and carboxyl-terminal His-tagged pro-
tein. HA-PARP1, HA-PARP1 K486R, p300, SUMO1, SUMO3,
and Ubc9 proteins were purified by 1-step affinity chromatog-
raphy using ProBond resin, according to the manufacturer‘s
recommendations (Invitrogen, Carlsbad, CA, USA). GST-
SUMO3, SUMO3, SENP2 (aa 364-569), and SENP2 (aa
364-569 C548S) were cloned in pGEX-vectors, expressed
and purified with glutathione sepharose, according to the
manufacturer‘s recommendations (GE Healthcare). The
double-tagged heterodimeric human E1-activating enzyme
was expressed from the pGEX-E1H6 vector and purified by
sequential GST beads and nickel beads; GST-cleavage was
performed through thrombin, and the recombinant pro-
tein was loaded and eluted from nickel beads using stan-
dard protocols.
In vitro sumoylation assay
The reaction was carried out in standard SUMO reaction
buffer (50 mM Tris-HCl, pH 8.0; 50 mM NaCl; 5 mM MgCl2;
10% glycerol; and 0.5 mM DTT). 5 mM ATP was added to
start the reaction. Incubation time was 30 min at 30°C, unless
otherwise indicated. The final concentration of proteins was
100 nM for SAE1/SAE2, 500 nM Ubc9, 5 !M SUMO1/
SUMO3, and 500 nM HA-PARP1.
Purification of sumoylated PARP1
The sumoylation reaction was 15" scaled up, and the incu-
bation time was increased to 120 min at 30°C. Instead of
SUMO3, a GST-tagged SUMO3 at a final concentration of 10
!M was used. After sumoylation, the sample was diluted with
2" the volume with SUMO-purification buffer (50 mM
Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA; and 1 mM
DTT) and bound to glutathione sepharose beads. After 60
min of incubation on rolls at 4°C, the supernatant was washed
away with the same buffer, and 2 U of PreScission protease
was added to the beads and incubated 16 h at 4°C. The
supernatant was used for experiments with sumoylated
PARP1.
Desumoylation of PARP1 in vitro
Purified sumoylated PARP1 was subjected to active recombi-
nant SENP2 (aa 364-569) or inactive SENP2 (aa 364-569
C548S) treatment in SUMO-purification buffer (50 mM Tris-
HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA; and 1 mM DTT) for
15 min at 30°C with a concentration of 10 ng SENP2/!l.
32P-NAD automodification
Sumoylated or desumoylated PARP1 in SUMO-purification
buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA;
and 1 mM DTT) was supplemented with 4 mM MgCl2 and 5
pmol of annealed double-stranded oligomer (5#-GGAATTCC-
3#). The reaction was started by adding 32P-NAD$ at a final
concentration of 100 nM NAD$. Automodification was al-
lowed for 5 min at 30°C. Reactions were stopped by the
addition of SDS-PAGE-loading buffer and boiling for 5 min at
95°C. Samples were subjected to SDS-PAGE, followed by
detection of automodification by autoradiography.
PAR detection by silver staining
Following synthesis of PAR in the presence of 400 !M NAD$
and 5 pmol EcoRI-linker DNA for 20 min, PAR chains were
purified and separated by modified DNA-sequencing gel
electrophoresis, as described previously (22).
Immunoprecipitation and nickel-NTA pulldown
Sumoylated or desumoylated PARP1 was bound to protein G
sepharose beads with anti-HA antibody in SUMO-purification
buffer. The beads were washed and adjusted to IP buffer (50
mM Tris-HCL, pH 8.0; 100 mM NaCl; 0.25% Nonidet P-40;
and 1 !g/ml protease inhibitors). Recombinant p300 (2 !g)
was added to the beads and incubated for 2 h at 4°C on rolls.
Washing of the beads with the same buffer removed unbound
p300. Immunoprecipitation of nuclear extracts was done with
HA antibody with IP-binding buffer (20 mM HEPES, 150 mM
NaCl, and 0.25% Nonidet P-40; 1 !g/ml), protease inhibitors,
and HDAC inhibitors (2 !M TSA, 5 mM NAM, 1 mM
Na-butyrate). The salt concentration was increased with 50
mM KCl for washing steps. Elution of bound proteins was
done with SDS-PAGE loading buffer and boiled for 5 min
at 95°C. Nickel-NTA pulldown was done as described
previously (23).
HAT Assay
Sumoylated or desumoylated PARP1 was subjected to in vitro
acetylation assay with recombinant p300 as described else-
where (24).
Knockdown and complementation of PARP1 in K562 cells
Generation of viruses and transduction of cells was done as
described earlier (25). shRNA was cloned into pRDI vector
and transduced to K562 cells. The short hairpin RNA was
designed against 5#UTR region of PARP1 mRNA. Transduced
cells were selected through puromycine resistance gene.
Complementation of cells was done with pRRL-myc-PARP1
vectors containing a blasticidine resistance marker and sub-
sequently selected with this antibiotic.
RNA preparation
Total RNA was isolated from 3 biological replicates of com-
plemented K562 cells with the Total RNA Isolation kit (Agi-
lent Technologies, Santa Clara, CA, USA). Reverse transcrip-
tion was achieved with the High-Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA, USA).
Quantitative PCR
Total reverse-transcribed cDNA from untreated or treated
K562 cells was used for q-PCR with primers against carbonic
anhydrase IX, LOXL2, and Pdk1. Amplification products
were analyzed by SYBR Green (Quantace, London, UK), and
ribosomal protein L28 was used to normalize for differences
in RNA input. Rotor-Gene3000A (Qiagen, Basel, Switzerland)
was used to perform the real-time PCR reactions.
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RESULTS
PARP1 is sumoylated in vivo
Because PARP1 was identified as a SUMO modification
target in proteomic studies, we aimed to confirm that
PARP1 is indeed sumoylated in vivo. HA-tagged PARP1
was coexpressed with myc-tagged SUMO1 or SUMO3 in
HEK293T cells, and extracts were analyzed by Western
blot. Ectopic expression of SUMO1 or SUMO3 per se
induced the modification of a multitude of proteins
(Fig. 1A, bottom). Expression of SUMO induced a
higher molecular form of PARP1 (depicted as Su-
PARP1), which was more prominent in the presence of
SUMO3 as compared to SUMO1, suggesting that
PARP1 is preferentially conjugated with SUMO3 (Fig.
1A). Expressing His-tagged SUMO, we could enrich an
anti-PARP1-reactive species on Ni-NTA beads, thus val-
idating that the higher molecular form corresponds,
indeed, to a covalent SUMO-PARP1 conjugate (Fig.
1B). Only one distinctive band of sumoylated PARP1
was detected, suggesting that PARP1 is monosumoy-
lated at a single lysine residue under the tested condi-
tions. Similar results were obtained when PARP1 was
expressed as fusion protein with Ubc9/E2 conjugation
protein, although the overall modification rate was
clearly enhanced (Supplemental Fig. 1A). Mutation of
the catalytic cysteine of the fused Ubc9 resulted in a
strong reduction of the modification, indicating that
the Ubc9 fused to PARP1 catalyzes the sumoylation of
PARP1 (Supplemental Fig. 1B). Immunoprecipitation
of this fusion protein in extracts of cells expressing
myc-tagged SUMO3 and subsequent Western blot anal-
ysis using an anti-myc antibody revealed SUMO moi-
eties on PARP1, providing additional evidence for
covalent modification of PARP1 with SUMO (Supple-
mental Fig. 1C). To test whether PARP1 would bind to
SUMO noncovalently via a SUMO-interacting motif
(SIM), GST pulldowns were performed with conjuga-
tion-deficient SUMO1-4 and RelA/p65 as a positive
control (Supplemental Fig. 2A–C). Although PARP1
was able to interact with RelA/p65, no interaction was
detectable with GST or all tested SUMOs. Thus, we
conclude that PARP1 is covalently modified by SUMO.
SENP1 and SENP3 are able to desumoylate PARP1
SUMO proteases are known to reverse sumoylation of
proteins. To test whether SUMO proteases act on
Figure 1. PARP1 is sumoylated in vivo. A) HA-PARP1,
myc-SUMO1, or myc-SUMO3 expression plasmids were
transfected in HEK293T. Whole-cell extracts were taken
in presence of 10 mM NEM and resolved on SDS-PAGE
and subsequently analyzed through Western blotting
with the indicated antibodies. Sumoylated PARP1 is
indicated as Su-PARP1. B) Denaturating nickel pulldown
of whole-cell extracts from transfected HEK293T cells.
Cells were transfected with SUMO2 alone or with
His-tagged SUMO2. Detection of sumoylated PARP1
was performed with anti-PARP1 antibody. C) HEK293T
cells were transfected with a mix of HA-PARP1, His-
SUMO3, and myc-Ubc9 expression plasmids and the indi-
cated plasmids for expression of SUMO proteases SENP1
and SENP3, or the catalytically inactive mutant counter-
part, respectively. Expression levels of the SENPs were
monitoredwith anti-Flag antibody.D)HEK293T cells were cotransfectedwith flag-tagged expression plasmids for SENP1 or SENP3
and pSUPER vector with shRNAs against SENPs. Knockdown efficiency after 28-h expression was examined with anti-Flag
antibody. E) Knockdown of SENP1 and SENP3 was achieved as in D, but in addition, a mix of HA-PARP1, His-SUMO3,
and myc-Ubc9 was cotransfected in HEK293T cells. Cell extracts were prepared and examined with the anti-PARP1 and
anti-His antibodies.
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SUMO-modified PARP1, we coexpressed wild-type or
catalytically inactive SENP1 and SENP3 with PARP1 and
SUMO3 in HEK293T cells (Fig. 1C). This showed that
coexpression of catalytically active SENP1 and SENP3
deconjugated SUMO3 from PARP1 (Fig. 1C). Corre-
spondingly, knockdown of SENP1 and SENP3 with
transiently transfected shRNAs (Fig. 1D) resulted in the
accumulation of sumoylated PARP1, as compared to
the control (Fig. 1E), indicating that SENP1 and SENP3
can act on PARP1-SUMO conjugates at physiological
expression levels. Taken together, our results illustrate
that PARP1 is preferably modified by SUMO3 and
desumoylated by the isopeptidases SENP1 and SENP3.
Furthermore, sumoylation of PARP1 seems thus to be a
transient and reversible modification.
PARP1 is sumoylated at K486 in vitro and in vivo
The consensus sumoylation site sequence is !KxE/D
(8). As determined by the SUMOsp analysis program
(http://sumosp.biocuckoo.org), the highest score
matched to lysine 486 in human PARP1 (Fig. 2A),
which is located in proximity to previously described
sites of acetylation and ADP ribosylation. To confirm
PARP1 sumoylation in vitro and to map the modifica-
tion site, we established an in vitro sumoylation system
reconstituted with recombinant human E1 (SAE1/
SAE2 heterodimer), E2 (Ubc9), wild-type SUMO1, or
SUMO3 and wild-type PARP1 (Fig. 2B). PARP1 sumoy-
lation was efficiently reconstituted in vitro with purified
proteins: reactions containing all components pro-
duced slower migrating PARP1 forms, consistent with
conjugated SUMO moieties. Attachment of a single
moiety was detected with low E2 concentrations (run-
ning at "140 kDa), whereas multiple SUMO moieties
were attached only at higher E2 concentrations (Fig.
2B). One additional band between 120 and 140 kDa was
observed at elevated Ubc9 concentrations and likely rep-
resents the modification of a degradation product of
PARP1 by SUMO3. To test for putative sumoylation sites
in PARP1, lysine 486 of PARP1 was substituted with
arginine (PARP1 K486R) and analyzed in vitro. Substitu-
tion did completely prevent the sumoylation of PARP1 in
vitro with SUMO1, SUMO3, or GST-tagged SUMO3, as
monitored by Western blot analysis (Fig. 2C, D), indicat-
ing that K486 is the major SUMO acceptor site of PARP1.
Figure 2. PARP1 is sumoylated at K486 in vitro and in vivo. A) Schematic
overview of human PARP1 domains. Putative sumoylation consensus
motif around lysine 486 is highlighted. Reported post-translational
modifications are shown in bold. ac, acetylation; ADPR, ADP-ribosyla-
tion. B) In vitro sumoylation assay with recombinant ATP-dependent
SUMO E1 (SAE1, SAE2)-activating enzyme, SUMO E2-conjugating
enzyme Ubc9, and SUMO3. Sumoylation reaction was carried out under
standard assay conditions for 30 min. PARP1 was detected with anti-
PARP1 antibody. C) In vitro sumoylation with purified HA-PARP1
wild-type or HA-PARP1 K486R as in B for the indicated time. D) In vitro
sumoylation assay with GST-tagged SUMO3 or with SUMO1, either with
HA-PARP1 wild-type or HA-PARP1 K486R for the indicated incubation
time. E) HEK293T cells were transfected with expression plasmids for HA-PARP1, HA-PARP1 K486R, or myc-SUMO3,
respectively. Whole-cell extracts were analyzed with anti-HA antibody and anti-myc antibody. Saturated levels of unbound
myc-SUMO3 were detected in the control Western blot.
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To verify sumoylation of PARP1 at K486 in vivo, we
coexpressed wild-type or the K486R mutant of PARP1
with myc-tagged SUMO3. Sumoylation of wild-type
PARP1 could be detected but not of the K486R mutant
(Fig. 2E), confirming K486 as the main sumoylated
residue in vivo.
Sumoylation of PARP1 does not affect its ADP
ribosylation activity
To explore a potential interplay of PARP1 sumoylation
with PARP1 function, we modified the established in
vitro sumoylation system to purify sumoylated PARP1. A
large-scale sumoylation reaction was performed with
GST-tagged SUMO3, E1–E2 enzymes, and HA-PARP1,
followed by GST affinity purification and subsequent
protease digestion to remove the GST tag and to purify
Su-PARP1, specifically modified at K486 (Fig. 3A). On
purification, only Su-PARP1 could be detected, indi-
cating that no unmodified PARP1 was in the purified
complex (Fig. 3B). Because PARP1 was described to
form a homodimer, this result suggests that both
subunits are equally accessible for SUMO-conjuga-
tion. PARP1 was also efficiently sumoylated in the
presence of double-stranded DNA ends, suggesting
that binding of PARP1 to DNA does not affect its
sumoylation in vitro (Supplemental Fig. 3A). Simi-
larly, Su-PARP1 was still able to bind specifically to
DNA fragments that mimic damaged DNA (Supple-
mental Fig. 3B).
To determine whether sumoylation regulates the
intrinsic ADP-ribosylation activity of PARP1, mono-
ADP-ribosylation of purified Su-PARP1 was measured
using an in vitro ADP-ribosylation assay in the presence
of 100 nM 32P-NAD!. Sumoylation of PARP1 still allows
its mono-ADP-ribosylation activity (Fig. 3B, lane 1). To
compare the extent of ADP ribosylation, Su-PARP1 was
either desumoylated by recombinant SENP2 (aa 364-
569) before or after ADP ribosylation took place (Fig.
3B, lanes 2 and 3). Quantification of the detected
radioactivity confirmed that both proteins were modi-
fied to the same extent. Similar experiments were
repeated with 400 "M NAD!, a concentration that
allows detection of poly(ADP-ribosyl)ation of PARP1.
PAR polymers synthesized by Su-PARP1 and desumoy-
lated PARP1 were isolated and analyzed with silver-
stained PAGE (Fig. 3C). Neither the amount nor the
distribution of freshly synthesized PAR was altered by
sumoylated PARP1, indicating that SUMOmodification
neither alters the ability of PARP1 to initiate nor to
extend PAR synthesis. In addition, overexpression of
SUMO3 in HEK293T cells per se did not stimulate PAR
formation (Supplemental Fig. 4A), although PARP1 is
sumoylated under these conditions (see Fig. 1A, last
lane). Furthermore, H2O2-treated cells showed PAR
formation (Supplemental Fig. 4B), which was indepen-
dent of SUMO3 levels, indicating that SUMO modifi-
cation of PARP1 does not enhance its poly(ADP-ribo-
syl)ation activity. To test the possibility of differential
localization of PARP1 upon sumoylation, we overex-
Figure 3. Sumoylation of PARP1 does
not affect its ADP-ribosylation activity.
A) Purification of sumoylated PARP1.
Purified HA-PARP1 from insect cells
was sumoylated in vitro with GST-
SUMO3 (a), which occurred site-spe-
cific on lysine 486. GST-SUMO3-con-
jugated PARP1 was captured on
glutathione sepharose beads (b). GST
tag was removed using a GST-tagged
PreScission protease (c), which was added to the beads. Supernatant consisted of sumoylated PARP1, which was either
incubated with active recombinant SENP2 fragment (aa 364-569) or the inactive mutant SENP2 C548S. B) Sumoylated
PARP1 (lanes 1 and 2) or desumoylated PARP1 (lane 3) was incubated with 100 nM radiolabeled 32P-NAD! and 5 pmol
EcoRI-linker DNA. Reaction was stopped with PARP-inhibitor 3AB, and active SENP2 was added to deconjugate SUMO3
from PARP1 (lane 2), thus generating free PARP1. Mono(ADP-ribosyl)ation was monitored with autoradiography.
C) Silver stain of isolated PAR generated by sumoylated PARP1 (lanes 1 and 3) or by desumoylated PARP1 (lanes 2 and
4). Reaction was carried out in the absence (lanes 1 and 2) or in the presence (lanes 3 and 4) of EcoRI-linker DNA at 400
"M NAD!. D) Mono(ADP-ribosyl)ation of PARP1 in the presence or absence of PARP-inhibitor 3AB with 100 nM NAD!.
Each sample was supplemented with E1, E2, and SUMO3 proteins. Reaction was stopped after a 5-min incubation time
with 3AB (lanes 3 and 4), and ATP was added (lanes 2 and 4). After the sumoylation reaction, proteins were separated
by SDS-PAGE and analyzed by autoradiography.
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pressed SUMO3 in cells and monitored PARP1 local-
ization by immunofluorescence. However, we did not
observe differential localization of PARP1 within the
nucleus upon ectopic SUMO3 expression (Supplemen-
tal Fig. 4C).
We recently reported that PARP1 is auto-ADP-
ribosylated at several lysines adjacent to the identi-
fied sumoylation site (26). To exclude that ADP-
ribosylation would affect sumoylation, we mono-ADP-
ribosylated PARP1 in vitro with radioactive NAD! and
subsequently sumoylated the labeled PARP1 fraction
(Fig. 3D). PARP1 was sumoylated in an ATP-depen-
dent manner independent of its ADP-ribosylation.
Consistently, in vivo treatment of cells with the PARP
inhibitor 3-amino-benzamide (3AB) did not affect
sumoylation (data not shown). Taken together, this
suggests that although the sumoylated and ADP-
ribosylated lysines are rather close within the PARP1
amino acid sequence, their modifications do not
interfere with each other.
Sumoylation counteracts p300-induced acetylation of
PARP1
As p300 is critical for PARP1 transcriptional coactiva-
tion and acetylates PARP1 at distinct lysines (6), we first
examined whether acetylated PARP1 would still be
sumoylated in vitro. Acetylation of PARP1 was moni-
tored with a specific anti-acetyl PARP1 (E4) antibody
(Supplemental Fig. 5A), while sumoylation was assessed
by the migration difference between unmodified
PARP1 and Su-PARP1. Acetylation with the indicated
control and subsequent addition of sumoylation en-
zymes, followed by the sumoylation reaction, revealed
that similar to the mono-ADP-ribosylated PARP1, acety-
lated PARP1 could also be efficiently modified with
SUMO (Fig. 4A, lane 4).
Moreover, we tested whether sumoylation of PARP1
would affect acetylation. Purified Su-PARP1 or de-
sumoylated PARP1 by recombinant SENP2 was both
incubated with p300 and acetyl-CoA in vitro. Western
blot analysis using the specific anti-acetyl PARP1 (E4)
antibody revealed that PARP1 is acetylated only when
PARP1 was desumoylated prior to acetylation (Fig. 4B,
lane 2), suggesting that the SUMO-modification inhib-
its p300-mediated PARP1 acetylation. To substantiate
this, we examined protein interactions with p300,
PARP1, or Su-PARP1. p300 could interact efficiently
with PARP1 but not with Su-PARP1, as demonstrated by
coimmunoprecipitation of p300 (Fig. 4C). Thus, the
absence of detectable acetylation of Su-PARP1 (see Fig.
4B) suggests that SUMO modification at K486 prevents
p300-mediated acetylation of PARP1, likely because of
steric hindrance of the bulky SUMO conjugate block-
ing p300 binding and acetylation at the adjacent lysine
residues. To explore whether the inhibitory effect of
PARP1 sumoylation on acetylation is also observed in
vivo, we coexpressed wild-type PARP1 or the sumoyla-
tion-deficient PARP1 mutant (K486R) with p300 and
monitored acetylation with the E4 antibody on Western
blots. This revealed lower levels of acetylation for the
wild-type PARP1 compared to the sumoylation-defi-
Figure 4. Sumoylation counteracts p300-induced acetylation of PARP1. A) In vitro
acetylation of PARP1 through p300 was done in the absence (lanes 1 and 3) or the
presence (lanes 2 and 4) of acetyl-CoA. Proteins necessary for sumoylation (E1,
E2, SUMO3) were added after the acetylation reaction. Proteins were separated
with SDS-PAGE and analyzed with anti-PARP1 and anti-acetyl-PARP1 (E4) anti-
body. B) In vitro acetylation reaction was done with p300 and sumoylated PARP1
(lane 1) or PARP1 desumoylated prior to the acetylation reaction (lane 2). After
acetylation reaction, sumoylated PARP1 was desumoylated with SENP2 (lane 1),
which allowed direct comparison of acetylation status of equal amounts of PARP1.
C) Coimmunoprecipitation of p300 with PARP1 was carried out on protein G
sepharose beads, using HA antibody to capture HA-tagged PARP1, either sumoy-
lated (Su-PARP1) or desumoylated (deSu-PARP1). As control, only the HA
antibody was bound to the matrix (no PARP1). Beads were incubated with purified p300, and the unbound fraction was
removed by extensive washing. D) HEK293T cells were transfected with either HA-PARP1 wt or HA-PARP1 K486R mutant
along with p300 expression plasmid. Cells were incubated with HDAC inhibitors 2 h prior to lysis, and HDAC inhibitors
were present at all steps of manipulation. Nuclear extracts were taken and subjected to immunoprecipitation using an HA
antibody. After SDS-PAGE, proteins were detected by anti-acetyl-PARP1 (E4), anti-HA, or anti-p300 antibody.
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cient PARP1 mutant (Fig. 4D). Together, these results
provide evidence for a crosstalk between these modifi-
cations.
The sumoylation-deficient K486R PARP1 mutant
exhibits higher coactivator function compared to
wild-type PARP1
To explore a possible mechanism by which sumoyla-
tion affects PARP1-dependent transcriptional coacti-
vator function in vivo, we first knocked down endog-
enous PARP1 protein levels in K562 cells with an
shRNA approach directed against the untranslated
region of PARP1’s mRNA and subsequently comple-
mented these cells with wild-type or sumoylation-
deficient K486R PARP1 mutant (Fig. 5A, B). The
expression levels of the complemented cells were
comparable to the endogenous wild-type counter-
part. Hypoxia treatment of these cells for 28 h and
subsequent profiling of the gene expression of de-
fined hypoxia-inducible genes revealed that certain
genes, such as CAIX, LOXL2 or Pdk1, are dependent
on PARP1, but only a subset was affected by the
sumoylation-deficient K486R mutation (Fig. 5C).
Similar results were obtained when PARP1!/! mouse
lung fibroblasts were complemented with wild-type
or sumoylation-deficient K486R PARP1 mutant and
stimulated by the hypoxia-mimicking drug ciclopir-
oxolamine (Supplemental Fig. 5B). Sumoylation-de-
ficient K486R PARP1 mutant not only enhanced
CAIX mRNA levels in K562 cells, but also CAIX
protein levels in vivo (Fig. 5D). Furthermore, hypoxia
treatment of K562 cells very strongly correlated with
protein sumoylation and enhanced SUMO modifica-
tion of PARP1 in HEK293T cells (Supplemental Fig.
5C, D). Thus, we conclude that sumoylation of PARP1
reduces its coactivator activity and thus regulates
gene expression in vivo.
Figure 5. Sumoylation-deficient K486R PARP1 mutant ex-
hibits higher coactivator function compared to wild-type
PARP1. A) Stable knockdown of PARP1 in human chronic
myelogenous leukemia cell line K562 using a lentiviral
system. shRNA against PARP1 targets the 5" untranslated
region of PARP1 mRNA. B) Stable complementation of
PARP1 with either pRRL-empty vector, myc-tagged wild-
type PARP1, and sumoylation-deficient PARP1 K486R mu-
tant. C) Hypoxic induction of complemented K562 cells at
0.2% O2 for 28 h. RNA was isolated, and the quantitative
PCR was done using primers for carbonic anhydrase IX
(CAIX), lysyl oxidase-like 2 (LOXL2), and pyruvate dehy-
drogenase kinase, isenzyme 1 (Pdk1) and normalized by
using L28 ribosomal protein. Normoxic samples were set to
1; fold induction of hypoxic samples is depicted. Three
biological replicates are shown. Statistical analysis was done with unpaired t test between biological replicates. Data are
represented as means # se. D) Complemented K562 cells were exposed for 29 h to 0.2% O2 hypoxia. Whole-cell extracts
were prepared and Western blotted with monoclonal anti-CAIX antibody and anti-tubulin antibody.
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DISCUSSION
The aim of this study was to characterize and investigate
the role of PARP1 sumoylation in the cellular context.
We provide biochemical and cellular evidence for
SUMO modification of PARP at lysine 486 within its
automodification domain. Mutation of K486 enhances
the transcriptional activity of PARP1, suggesting that
sumoylation restrains its transcriptional activity.
PARP1 is covalently sumoylated
Noncovalent interactions of proteins can occur
through SUMO interaction motifs (SIMs) (27). Pro-
teins like the DNA repair enzyme TDG and the tumor
suppressor PML were shown to interact with SUMOs
via SIMs, and such interactions were associated with
important biological activities (28–30). Although
PARP1 exhibits several putative SIMs, we did not
observe any direct noncovalent interaction of PARP1
with SUMOs, indicating that the interaction of
PARP1 with SUMO is exclusively covalent. Pulldown
experiments of sumoylated PARP1 under denaturat-
ing conditions and site-directed mutagenesis re-
vealed that sumoylation of PARP1 is indeed a cova-
lent and site-specific modification. A possible in-
volvement of SUMO E3 ligases for the sumoylation of
PARP1 needs further investigations. Although PIAS
family members are attractive candidates, overex-
pression of different PIAS proteins did not enhance
PARP1 sumoylation (data not shown).
Notably, we observed only monosumoylation of
PARP1 in vivo, but do not exclude that under specific
conditions, PARP1 may also be polysumoylated. In
support of this idea, heat shock has been reported to
induce a pattern of PARP1 sumoylation, which would
be consistent with polysumoylation (18). Understand-
ing the balance between monosumoylation and poly-
sumoylation of PARP1, as well as their functional
differences will remain an exciting issue.
Crosstalk between sumoylation and other
post-translational modifications
The crosstalk of post-translational modification systems
is an emerging concept (31). Sumoylation of target
proteins can be regulated through crosstalks with other
post-translational modification events. Phosphoryla-
tion, for instance, was shown to regulate SUMO conju-
gation through a highly conserved motif, which is
called phosphorylation-dependent sumoylation motif
(PDSM) (32). The PDSM motif, which contains a
SUMO consensus site and an adjacent proline-directed
phosphorylation site (!KxExxSP, where ! represents
large hydrophobic residue and x is any amino acid),
regulates phosphorylation-dependent sumoylation of
multiple transcription factors (33–35). Lysine residues
are targeted by several other post-translational modifi-
cations, including ubiquitination, acetylation, methyl-
ation, and ADP-ribosylation. It has been documented
that SUMO conjugation can occur on the same lysine
residue as ubiquitination or acetylation in some pro-
teins. For example, the competition between sumoyla-
tion and ubiquitination of the same lysine regulates the
stability of I"B# (36), whereas in other cases, sumoyla-
tion acts as a recognition signal for a ubiquitin ligase
(37). An interplay between sumoylation and acetylation
has been observed in the regulation of proteins, such as
MEF2, the core histones, and hypermethylation in
cancer 1 (HIC1) (38, 39). In the case of MEF2, the
sumoylation-acetylation switch is regulated by phos-
phorylation (40). These studies demonstrate the impor-
tance of signaling crosstalk in the regulation of protein
sumoylation.
Mechanisms of SUMO-mediated repression of PARP1
coactivator function
First, sumoylation may directly affect PARP1’s binding
to DNA by promoting its dissociation from specific
chromatin regions. This possibility seems unlikely,
since sumoylation of PARP1 did not alter its ability to
recognize and bind damaged DNA in vitro. Second,
SUMO modification could also affect enzymatic activi-
ties of PARP1, which is important for gene expression.
Also, this seems unlikely, since we have shown that
SUMO modification of PARP1 does not interfere with
DNA-dependent ADP-ribosylation activity in vitro. In
addition, increased SUMO3 levels do not correspond to
elevated poly(ADP-ribosyl)ation in cells on hydrogen
peroxide-induced DNA damage, suggesting that sumoy-
lation of PARP1 does not have a stimulatory effect on its
enzymatic activity. However, it was shown that poly-
(ADP-ribosyl)ation is not required for NF-"B-depen-
dent gene expression (41). Neither the enzymatic
activity of PARP1 nor its binding to DNA was required
for full activation of NF-"B in response to various
stimuli in vivo when tested on transiently transfected
reporter plasmids (21, 42). Consistently, the enzymatic
activity of PARP1 was not required for full transcrip-
tional activation of NF-"B in the presence of the
histone acetyltransferase p300 (6). Because sumoyla-
tion of PARP1 inhibits its acetylation at adjacent lysine
residues and because these residues are also targets of
ADP-ribosylation, a potential acetylation-ADP-ribosyla-
tion switch, which is controlled through sumoylation of
PARP1, is very likely. Third, the SUMO modification
could promote or inhibit protein-protein interactions
through protein complex formation. This scenario
seems to be the most relevant for PARP1, since the
interaction of PARP1 with p300 and subsequent PARP1
acetylation was impaired after sumoylation of PARP1 at
K486. This lysine residue lies within the domain of
PARP1, which contributes to most protein-protein in-
teractions such as XRCC1 (6). However, we did not
observe a general SUMO-dependent inhibition of pro-
tein interactions in this region since HIF1-# and
XRCC1 binding does not seem to be affected by
sumoylation of PARP1 (Supplemental Fig. 5E and un-
published results). In addition to the inhibition of p300
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binding, SUMO modification of PARP1 may facilitate
the recruitment of a transcriptional corepressor. Cur-
rently, several chromatin-modifying enzymes and chro-
matin-binding proteins have been implicated as effec-
tors of SUMO-mediated repression. For example,
SUMO modification of the transcription factor Elk-1
promotes recruitment of HDAC2, associated with his-
tone deacetylation and transcriptional repression of the
c-fos promoter (43). Very recently, CoREST1 and Mi2
were identified as SUMO-dependent corepressors, and
evidence was provided that CoREST1 binds directly and
noncovalently to SUMO2/3, but not to SUMO1 (44,
45). Notably, the aforementioned interaction of PARP1
with PIAS family members could contribute to gene
silencing.
Desumoylation of PARP1 by SENP1 and SENP3
We observed that SENP1 and SENP3 are able to
catalyze PARP1’s SUMO deconjugation. The nucleo-
plasmic SENP1 relieves SUMO-dependent repression
of Ets1, c-Jun, and the androgen receptor, the latter
effect being through desumoylation of histone deacety-
lase 1 (46). Recent data also implicate the nucleolus in
dynamic cycles of sumoylation and desumoylation. For
example, nucleolar SENP3 is able to catalyze desumoy-
lation of various proteins in this compartment, with
specificity to SUMO2/3 (15, 46). In addition, it seems
that SENPs regulate SUMO paralog preference of
substrate proteins by deconjugation of specific SUMOs,
as shown for RanGAP1 (47). This could also explain the
higher steady-state level of SUMO3-modified than
SUMO1-modified PARP1.
Only a subset of PARP1-dependent genes are
affected by sumoylation
Analyses of the role of SUMO in transcriptional regu-
lation have mainly relied on the use of protein overex-
pession and transiently transfected reporter genes,
which may not give a true reflection of the physiological
situation. Therefore, we have established a system
where we complement cells depleted from endogenous
PARP1 with sumoylation deficient PARP1 or wild-type
PARP1 and analyzed the expression of endogenous
target genes. Known HIF1-! dependent genes with a
high induction upon hypoxia were tested. Of these,
CAIX and LOXL2 showed increased transcript levels in
sumoylation deficient K486R mutant cell line, whereas
other genes were solely dependent on PARP1, but not
on its sumoylation. Consistent with the qPCR data, the
expression levels of CAIX were increased in cells ex-
pressing sumoylation-deficient PARP1. Previous studies
on PARP1’s coactivator function revealed that this
function is heavily dependent on its acetylation
through p300. Here, we showed that acetylation is
abrogated if the SUMO moiety is present on PARP1.
Consistently, the sumoylation-deficient mutant showed
a higher acetylation status, which corresponded to
higher gene expression status for some genes. Collec-
tively, these data support the mechanistic studies per-
formed in vitro, unraveling an important role of sumoy-
lation in regulating PARP1-dependent transcriptional
coactivation through regulation of its acetylation. It is
largely accepted that post-translational modifications
fine tune and regulate the requirement of certain
transcriptional cofactors for gene expression by tran-
scription factors and might thus influence only a subset
of genes (48).
Hypoxia-induced gene expression is affected by
PARP1 sumoylation
The role of sumoylation in the regulation of hypoxia-
induced gene expression and HIF-1! stability is
controversial (49). Hypoxia can induce the expres-
sion of SUMO1 (50) and an RWD-containing sumoy-
lation enhancer (RSUME) that functions as a promoter
of protein sumoylation (51). RSUME expression is in-
duced by hypoxia, which leads to the enhanced
sumoylation and stabilization of HIF-1!. Alterna-
tively, a recent study indicates that the hypoxia-
induced sumoylation of HIF-1! targets HIF-1! for
degradation through the von Hippel–Lindau (VHL)
protein-mediated ubiquitin-proteasome pathway
(37). Clearly, further studies are needed to clarify
these controversial findings on the role of sumoyla-
tion in the regulation of HIF-1! stability during
hypoxia. In this study, we have investigated the
regulation of the known HIF1-!-dependent genes
CAIX and LOXL2 and provide novel insights to
understand the complex transcriptional regulation
of these emerging tumor markers. The expression of
these genes is restrained through SUMO modifica-
tion of the transcriptional coactivator PARP1, indi-
cating that sumoylation of PARP1 dampens HIF1-!
signaling for these genes. Thus, this pathway may
have an important regulatory role in the regulation
of intracellular pH and hypoxia-induced metastasis
(52, 53). Moreover, it remains to be elucidated
whether sumoylation of PARP1 is also affecting tran-
scription mediated by other transcription factors and
whether SUMO modification is associated with the
role of PARP1 in several pathophysiological disease
models. Further studies of the sumoylation of PARP1
will determine the role of SUMO modification/
deconjugation in these pathological states.
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Supplementary Methods: 
 
DNA binding assay 
For in vitro DNA binding assays a biotinylated oligonucleotide (5´-
GCTGTGGACCCTGCTGTGGGCTGGAGAACAAGGTGATCTGCG-3´) was annealed 
with a fully complementary oligonucleotide 5´-
CGCAGATCACCTCCAGCCCACAGCAGGGTCCACAGC-3´ (control a). To mimic 
nicked or gapped DNA the biotinylated oligonucleotide was annealed with the 
oligonucleotide 5´-CGCAGATCACCTTGTTCTCCA-3´ and either 5´-
GCGCACAGCAGGGTCCACAGC-3´ (control b, nicked fragment) or 5´-
CGCAGATCACCTTGTTCT-P (gapped fragment). Biotinylated oligonucleotides were 
captured on Streptavidin Agarose beads (Novagen). 
 
Immunofluorescence 
For detection of proteins by immunofluorescence, HEK293T cells were fixed with freshly 
prepared Methanol:Acetic acid (3:1) mix for 5 min on ice, and washed with PBS. 
Unspecific binding sites were blocked with 0.05% Tween20 and 5% non-fat dry milk in 
PBS for 30 min at room temperature prior to staining with primary and FITC-conjugated 
secondary antibodies in the presence of blocking buffer. Pictures were taken with standard 
fluorescence microscope (Olympus Mx51, 40x, NA 1.3). 
 
Reporter gene Assay 
Mouse PARP1
+/+ 
or PARP1
!/!
 mouse lung fibroblasts (MLF) cells were isolated from 
129S/EV-PARP1+/+ and 129S/EV-PARP1!/! mice (Wang, Morrison, 1997). Only cell 
passages 2 to 10 were used for experiments. MLF were grown in DMEM Glutamax-I 
(Invitrogen) containing 4.5 g/L glucose, supplemented with 10% FCS (Invitrogen), 50 
units/mL penicillin, 50 µg/mL streptomycin (Sigma), and "-naphthylacetic acid 
(Invitrogen). Cells were grown in 5% CO2 at 37°C in a humidified incubator. MLF were 
transfected with polyethylenimine as previously described. Because of differences in 
transfection efficiencies, an expression plasmid of CMV driven Renilla luceriferase was 
cotransfected as a transfection efficiency control, and luciferase activities were normalized 
based on Renilla light units. Luciferase activity was measured with the pSG5C-CA9 
reporter gene (described in Kopacek J, et al. (2005). Biochim Biophys Acta 1729: 41-49). 
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Plasmids 
Human HIF1-! (aa 365-805) was amplified from pENTR-d hHIF1-! (aa 5-805) and cloned 
into a pGEX6P3 vector with BamHI and XhoI restriction enzymes. 
 
Protein purification 
GST-hHIF1-! (aa 365-805) was expressed in bacteria and purified according to standard 
protocols using glutathione sepharose 4B  (GE healthcare). 
 
Immunoprecipitation 
Sumoylated PARP1 was purified as described in the material and methods section. Either 
sumoylated HA-PARP1 or desumoylated HA-PARP1 was incubated on protein G 
sepharose beads (GE healthcare) together with anti-HA antibody. After 1.5 h incubation 
time, the beads were washed and 5 ug of purified GST-HIF1-! (aa 365-805) was added for 
2h. The beads were washed with IP-buffer (50 mM Tris pH 8.0, 170 mM NaCl, 0.5% NP-
40, Protease inhibitors) and subjected to SDS-PAGE, followed by western blot analysis. 
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Supplementary Figures: 
 
Supplementary Figure 1:  
(A) HA-PARP1-Ubc9 fusion protein was ectopically expressed with either myc-SUMO1 or 
myc-SUMO3 in HEK293T. Cell extracts were examined with anti-HA and anti-myc 
antibody. (B) HA-PARP1-Ubc9 or HA-PARP1-Ubc9 C93S were transfected along with 
myc-SUMO3 into HEK293T cells. Whole cell extracts were taken and analyzed with anti-
HA antibody (C) Immunoprecipitation of ectopically expressed HA-PARP1-Ubc9 fusion 
protein, expressed in HEK293T with or without myc-SUMO3. Cell extracts were examined 
with anti-HA and anti-myc antibody. 
 
Supplementary Figure 2: 
(A) GST-pulldown with GST alone, conjugation deficient GST-SUMO-AA, or GST-p65 
against whole cell extracts from HEK293T. Detection of PARP1-binding was done with 
PARP1 western blot. GST was used as negative control, GST-p65 as positive control for 
PARP1 interaction. A coomassie stain of the western blot membrane is shown. (B) GST-
pulldown as in (A), but with purified PARP1. (C) GST-pulldown with more stringent 
conditions than in (B), but with recombinant purified TDG as positive control for non-
covalent interaction.  
 
Supplementary Figure 3:  
(A) An in vitro sumoylation assay with purified PARP1 was carried out without or with 
EcoRI-linker DNA in the reaction. (B) Three different biotin-tagged oligonucleotides were 
bound to in vitro translated 
35
S-Methionine labeled and sumoylated PARP1. Precipitation 
of the oligonucleotides was performed with Streptavidin-Agarose. Bound proteins were 
separated through SDS-PAGE and detected with autoradiography. 
 
Supplementary Figure 4:  
(A) Immunofluorescence staining of untransfected or with myc-SUMO3 transfected 
HEK293T cells. The cells were fixed 28 h after transfection and stained with the anti-
SUMO2/3 (18H8) or anti-PAR (10H) antibody. (B) Immunofluorescence staining of 
untransfected or with myc-SUMO3 transfected HEK293T cells. The cells were treated with 
0.5 mM H2O2 for 10 min, fixed and stained with the anti-SUMO2/3 (18H8) or anti-PAR 
(10H) antibody. (C) Immunofluorescence staining of untransfected or with myc-SUMO3 
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transfected HEK293T cells. Cells were fixed 28 h after transfection and stained with anit-
PARP1 (H250) or anti-myc (9E10) antibody.  
  
Supplementary Figure 5:  
(A) In vitro acetylation assay with PARP1 wild-type or with acetylation-deficient PARP1 
KQR (K498R, K505R, K521R, K524R) mutant. Western blot was done with monoclonal 
E4 antibody and anti-PARP1 antibody. The antibody was generated against an acetylated 
peptide corresponding to residues K498, K505 and K508 in human PARP1 sequence. 
Control of equal inputs of PARP1 was done through coomassie stain of the western blot 
membrane. (B) CAIX reporter plasmid is induced with SUMOylation deficient PARP1. 
Primary mouse lung fibroblasts (MLF) were transfected with HA-PARP1 wt or HA-
PARP1 K486R along with CAIX reporter plasmids and Renilla-Luciferase for 
normalization. Cells were induced with hypoxia mimicking drug Ciclopirox-olamine for 
8h. (C) SUMO2/3 conjugation is induced after hypoxia. K562 whole cell extracts were 
examined with SUMO 2/3 antibody after hypoxic induction for 28h at 0.2% O2. (D) 
HEK293T cells were transfected with HA-PARP1 and myc-SUMO3 expression plasmids. 
20 hours after transfection, cells were exposed to hypoxia (0.2%O2) for 28 h. Whole cell 
extracts were examined by western blot using anti-myc and anti-PARP1 antibodies. (E) 
HA-PARP1 was sumoylated (Su-PARP1) or desumoylated (deSu-PARP1) in vitro as 
described in Fig. 3A, and subsequently immunoprecipitated using anti-HA antibody. As 
control, only beads with the anti-HA antibody was used (no protein). After extensive 
washing, beads were incubated with purified GST-HIF1-! (aa 365-805). Co-
immunoprecipitated GST-HIF1-! was detected by western blot using an anti-GST 
antibody. 
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Supplementary Fig. 3!
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WB E4    
(acetyl-PARP1) !
WB PARP1!
Coomassie!
PARP1 wt                             +            +              -             - !
PARP1 KQR                         -             -              +            +!
p300 wt, Acetyl CoA            -             +               -            +!
A 
B C 
Messner et al.!
!
 m
yc
-P
AR
P1
 K
48
6R
!
 m
yc
-P
AR
P1
 !
 m
yc
-P
AR
P1
 K
48
6R
!
 e
m
pt
y v
ec
to
r!
 m
yc
-P
AR
P1
 !
 e
m
pt
y v
ec
to
r!
hypoxia! normoxia!
WB !-SUMO 2/3!
WB !-tubulin!
36!
50!
64!
98!
64!
50!
  112 
  
  113 
5.4. Inflammasome activated caspase 7 cleaves PARP1 to enhance the expression of 
a subset of NF-!B target genes 
  
Molecular Cell
Article
Inflammasome-Activated Caspase 7
Cleaves PARP1 to Enhance the Expression
of a Subset of NF-kB Target Genes
Su¨heda Erener,1,2 Virginie Pe´trilli,3,4 Ingrid Kassner,1,2 Roberta Minotti,1 Rosa Castillo,3 Raffaella Santoro,1
Paul O. Hassa,1 Ju¨rg Tschopp,3 and Michael O. Hottiger1,*
1Institute of Veterinary Biochemistry and Molecular Biology
2Molecular Life Science Program, Life Science Zurich Graduate School
University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
3Department of Biochemistry, University of Lausanne, Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
4Present address: Universite´ de Lyon, F-69000 Lyon, France; CNRS, UMR5286, Centre de Recherche en Cance´rologie de Lyon, F-69000
Lyon, France; InsermU1052, Centre de Recherche en Cance´rologie de Lyon, F-69000 Lyon, France; Universite´ Lyon 1, F-69000 Lyon, France
*Correspondence: hottiger@vetbio.uzh.ch
DOI 10.1016/j.molcel.2012.02.016
SUMMARY
Caspase 1 is part of the inflammasome, which is
assembled upon pathogen recognition, while cas-
pases 3 and/or 7 aremediators of apoptotic and non-
apoptotic functions. PARP1 cleavage is a hallmark
of apoptosis yet not essential, suggesting it has
another physiological role. Here we show that after
LPS stimulation, caspase 7 is activated by caspase
1, translocates to the nucleus, and cleaves PARP1
at the promoters of a subset of NF-kB target genes
negatively regulated by PARP1. Mutating the PARP1
cleavage site D214 renders PARP1 uncleavable
and inhibits PARP1 release from chromatin and
chromatin decondensation, thereby restraining the
expression of cleavage-dependent NF-kB target
genes. These findings propose an apoptosis-inde-
pendent regulatory role for caspase 7-mediated
PARP1 cleavage in proinflammatory gene expression
and provide insight into inflammasome signaling.
INTRODUCTION
The nuclear factor kappaB (NF-kB) signal transduction pathway
is induced in response to a wide range of stimuli and regulates
the cellular response to stress, inflammation, infections, and
cytokines (Mankan et al., 2009). The transcription factor activity
of NF-kB can be regulated by reversible posttranslational
modification of NF-kB itself (e.g., acetylation), by the recruitment
of cofactors (e.g., CBP/p300), or by the modification of chro-
matin structure (Lomvardas and Thanos, 2002; Natoli, 2006;
Ramirez-Carrozzi et al., 2009).
Caspases are highly conserved cysteine-dependent aspar-
tate-specific proteases. The human caspase family consists
of 12 members that can be grouped into inflammatory and
apoptotic caspases (Chowdhury et al., 2008). Caspase 1 is the
prototypical member of the inflammatory caspases that mediate
the maturation of inflammatory cytokines like proIL-1b and
proIL-18 (Ghayur et al., 1997; Martinon et al., 2004; Thornberry
et al., 1992). Caspase-1 is activated within a cytoplasmic multi-
protein complex named the inflammasome, which consists
of a receptor, an adaptor (e.g., ASC), and caspase 1 (Schroder
and Tschopp, 2010). Genetic studies in mice suggest at least
four inflammasomes with distinct receptors detecting different
PAMPs (pathogen-associated molecular patterns) and DAMPs
(danger-associated molecular patterns).
Active caspase 3 and 7 cleave a large set of substrates, which
ultimately results in apoptosis or necrosis (Kuida et al., 1996;
Malireddi et al., 2010). Whereas caspase 3 knockout mice die
prematurely (Kuida et al., 1996), caspase 7 knockout mice
show no phenotypic abnormalities (Lakhani et al., 2006). Cas-
pase 3/7 double-knockout mice suffer from early perinatal
lethality (Lakhani et al., 2006). Accumulating evidence also
suggests nonredundant roles and nonapoptotic functions for
caspase 3 and caspase 7 in different cellular processes such
as cell proliferation, cell-cycle regulation, and cell differentiation
and inflammation (Algeciras-Schimnich et al., 2002; Denis et al.,
1998; Lamkanfi et al., 2008).
Poly(ADP-ribose) polymerase 1 (PARP1, recently renamed
ARTD1 [Hottiger et al., 2010]) is a nuclear chromatin-associated
multifunctional enzyme found in most eukaryotes apart from
yeast and catalyzes the polymerization of ADP-ribose units
from donor NAD+ molecules (Hassa et al., 2006; Kim et al.,
2005). During apoptosis, PARP1 is cleaved by caspases 3
and 7, yielding two enzymatically inactive fragments (24 and
89 kDa) (D’Amours et al., 2001). Interestingly, PARP1 knockin
mice, which harbor a mutated caspase cleavage site (D214N),
develop normally, indicating that cleavage of PARP1 is not
required during apoptosis (Pe´trilli et al., 2004). This observation
raises the fundamental question why such an elaborate mecha-
nism for selective degradation of a subset of cellular proteins
exists, when eventually all the cellular components need to be
destroyed. Important regulatory functions other than apoptosis
that are mediated by PARP1 cleavage could explain the devel-
opment of this intricate mechanism.
Although historically studied in the context of genotoxic stress
signaling, PARP1 has more recently been linked to the regula-
tion of chromatin structure, transcription, and chromosome
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organization (Kraus and Lis, 2003; Krishnakumar and Kraus,
2010). Based on the analysis of gene expression profiles in
PARP1 knockout or siRNA treated cells, genes can be classified
as PARP1-independent or PARP1-dependent (Frizzell et al.,
2009), although the molecular basis that determines PARP1
dependency is not yet understood. Furthermore, PARP1-depen-
dent genes can be regulated positively or negatively by PARP1
(Carrillo et al., 2004; Krishnakumar et al., 2008). Earlier studies
from our laboratory provide evidence that in mouse lung fibro-
blasts (MLFs) the stimulus-dependent transcriptional activation
of transiently transfected reporter plasmids containing the
NF-kB sites of the iNOS and MIP2 genes depends on PARP1
(Hassa et al., 2006; Hassa and Hottiger, 1999). Further studies
revealed that the stimulus-induced gene expression of the
iNOS (NF-kB) reporter plasmid containing the nos-2 promoter
was severely reduced in the presence of noncleavable (D214N)
PARP1, while the presence of a cleavable PARP1 (WT or enzy-
matically inactive) was beneficial (Pe´trilli et al., 2004). This ob-
servation was confirmed for endogenous nos-2 and strongly
suggests that PARP1 is most likely processed upon stimulation
and that cleavage of PARP1 at D214 is beneficial for full tran-
scriptional activation of certain NF-kB target genes. Here, we
elucidate the cellular signaling mechanism that leads to PARP1
cleavage under inflammatory conditions and the consequence
of this cleavage event for proinflammatory gene expression.
RESULTS
Induction of a Subset of NF-kB Target Genes
Is Compromised in Peritoneal Macrophages Isolated
from D214N PARP1 Mice
To investigate the regulatory function of PARP1 cleavage for
NF-kB-dependent gene expression at the molecular level during
inflammation, peritoneal macrophages expressing either WT or
noncleavable D214N PARP1 were stimulated for 1 hr with LPS.
Gene expression analysis by customized NF-kB microarrays
(Jayne et al., 2009) identified ten genes that were less stimulated
by LPS in D214N PARP1 cells as compared to WT cells (data
not shown). Real-time RT-PCR revealed that the LPS-induced
expression of CSF2, IL-6, and LIF was indeed dependent on
PARP1 cleavage (reduced in D214N) (Figure 1A). IL-6 levels
were also reduced at the protein level in LPS-induced D214N
cells (Figure S1A). Interestingly, the three genes were highly ex-
pressed in PARP1 !/! macrophages, indicating a repressory
function of PARP1 for these genes (Carrillo et al., 2004) (data
not shown). IP-10 was also negatively regulated by PARP1
(PARP1-dependent), but in contrast to the other three genes
comparably induced in WT and D214N PARP1 cells (Figure 1A)
and was therefore included as a control gene, which is not ex-
pressed in a PARP1 cleavage-dependent manner. Together,
these data show that only a subset of PARP1-dependent genes
was additionally regulated by PARP1 cleavage.
PARP1 Cleavage at D214 Regulates the LPS-Induced
Expression of NF-kB Target Genes Also in Human
THP1 Cells
To further investigate the physiological relevance of LPS-
induced PARP1 cleavage, we expressed WT or noncleavable
D214N PARP1 in human THP1 cells depleted of endogenous
PARP1 (Figure S1B). LPS stimulation (1 hr) of THP1 cells com-
plemented with noncleavable D214N PARP1 (as compared to
THP1 cells complemented with WT PARP1) resulted in signifi-
cantly reduced IL-6 gene induction, while IP-10 induction was
not affected (Figure 1B), and thus implied that PARP1 cleavage
is important for the transcriptional activation of IL-6 and
confirmed the results obtained with primary cells.
Since PARP1 cleavage is considered a hallmark of apoptosis,
we tested whether LPS treatment of THP1 cells would induce
cell death under the tested conditions by two independent
methods. While the control treatment with camptothecin (CPT)
induced a significant increase of dead cells, LPS stimulation
did not induce any detectable increase in cell death for the
indicated time period as measured by staining with ethidium
homodimer and calcein or LDH release (Figures 1C and 1D).
Moreover, treatment of complemented THP1 cells with CPT
induced an 89 kDa cleavage fragment in WT-complemented
cells, but not in cells expressing D214N PARP1, confirming
that the mutant D214N PARP1 was indeed protected from
caspase cleavage (Figure 1E).
The PARP1 D214N Mutation Does Not Affect NF-kB
Function or Biochemical Properties of PARP1
The observation that CSF2 and IL-6 induction were both abol-
ished upon knockdown of the large NF-kB subunit p65 (Figures
S1C and S1D) suggested that stimulus-induced expression of
these genes is mainly dependent on p65 signaling. Therefore,
we performed ChIP experiments with an antibody against p65
to investigate whether the reduced gene induction in D214N
PARP1 cells was due to hampered recruitment of p65 to target
DNA sequences. p65 recruitment to the promoters of CSF2,
IL-6, and IP-10, but not to the promoter of the control gene
Prolactin, occurred as soon as 30 min after LPS stimulation of
peritoneal macrophages isolated from WT and D214N animals
(Figure 2A). After 1 hr, p65 dissociated from the IL-6 and IP-10
promoters and exhibited a comparable distribution in WT and
D214N cells (Figure 2A). These results clearly suggested that
the differential expression of the studied NF-kB target genes
was not due to differential p65 recruitment.
In order to exclude that the above-described expression
changes were due to altered biochemical properties of D214N
PARP1, additional analyses were performed. The enzymatic
activity of WT and D214N PARP1 was induced by DNA to the
same extent in vitro (Figure 2B). Since the stimulation by DNA
is known to induce a conformational change that brings the
N-terminal DNA-binding domain to the C-terminal catalytic
domain of PARP1 proteins (Messner et al., 2010), the D214N
mutation is unlikely to alter the overall configuration of PARP1.
We have previously described that PARP1 can bind and be
acetylated by p300 (Hassa et al., 2005). Acetylation of PARP1
by p300 revealed that D214N and WT PARP1 can be acetylated
in vitro to the same extent (Figure 2C), implicating that complex
formation with other proteins was not affected. Complex forma-
tion between p65 and PARP1 was also not affected by the
D214N mutation in vivo as well as in vitro (Figures 2D and 2E).
These results furthermore implied that the reduced induction
of gene expression observed in D214N cells was neither due to
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hampered NF-kB signaling nor caused by altered biochemical
properties of D214N PARP1.
PARP1 Is Cleaved by Caspases after LPS Induction
To confirm that PARP1 cleavage indeed occurs upon LPS induc-
tion, the presence of the enzymatically inactive, C-terminal, large
PARP1 fragment (p89; resulting from cleavage at D214) was
assessed in stimulated bone marrow-derived macrophages
(BMDM) from wild-type mice. PARP1 cleavage was distinctly
observed after 2 hr of LPS treatment (Figure 2F) and similarly
detected in THP1 cells (Figures S2A and S2B). The observation
that PARP1 cleavage affected transcript levels already after
1 hr of LPS induction (Figure 1A) suggested that the cleaved
PARP1 fragments might be immediately degraded by the pro-
teasomal machinery and thus rendered undetectable for western
blot analysis at early time points. Upon inhibition of the protea-
some activity by MG132 and stimulation of the cells with LPS,
the p89 fragment could be consistently detected already at the
1 hr time point, and the cleaved PARP1 fragment was exclusively
found in the nuclear fraction (Figures S2C and S2D). MG132
Figure 1. PARP1 Cleavage at D214 Regulates Expression of a Subset of NF-kB Target Genes
(A) LPS-stimulated induction of CSF2, IL-6, LIF, and IP-10 expression in peritoneal macrophages isolated from WT and D214N PARP1 mice. Cells were stim-
ulated with LPS for 1 hr and mRNA levels were determined by real-time RT-PCR analysis. Samples were normalized to Rps12 expression levels and expressed
as fold increase relative to unstimulated mRNA levels. Data are means ± SEM of at least four independent representative experiments.
(B) Induction of IL-6 and IP-10 expression in stably complemented THP1 cells. Cells were stimulated with LPS for 1 hr and mRNA levels were determined by
real-time RT-PCR analysis. Samples were normalized to Rpl28 expression levels and expressed as fold increase relative to unstimulated mRNA levels. Data are
means ± SD, n = 2.
(C and D) LPS stimulation does not affect cell viability. THP1 macrophages were stimulated with LPS for the indicated times and (C) stained with calcein and
ethidium homodimer and analyzed by immunofluorescence microscopy (n = 3–7, mean ± SEM) or (D) assayed for LDH release as indicated in the experimental
procedures (n = 3, mean ± SEM).
(E) THP1 cells were stimulated with camptothethcin (CPT; 10 mM for 6 hr), total cell extracts were prepared and proteins were analyzed by western blot. Ctrl* is
the sample treated with etoposide for 16 hr.
Molecular Cell
Casp7-induced PARP1 cleavage regulates NF-kB
Molecular Cell 46, 1–12, April 27, 2012 ª2012 Elsevier Inc. 3
Please cite this article in press as: Erener et al., Inflammasome-Activated Caspase 7 Cleaves PARP1 to Enhance the Expression of a Subset of NF-kB
Target Genes, Molecular Cell (2012), doi:10.1016/j.molcel.2012.02.016
  116 
  
Figure 2. Characterization of WT and D214N PARP1
(A) ChIP analysis of p65 recruitment upon LPS stimulation on the target promoters. WT (white bars) and D214N (gray bars) PARP1 peritoneal macrophages
were stimulatedwith LPS for the indicated times. p65 was immunoprecipitated, and the occupancy on the indicated promoters wasmeasured by qRT-PCR. Data
are represented as bound/input and normalized to values corresponding to unstimulated conditions. Unstimulated levels were arbitrarily set as 1. Prolactin
promoter was assessed as negative control. Data represent means from 3–4 independent experiments ± SEM.
(B) Enzymatic activity of recombinant PARP1 proteins. WT, D214N, and E988K PARP1 baculovirus generated proteins were incubated with or without DNA for
5 min, and ribosylation was analyzed by autoradiography.
(C) Acetylation of WT and D214N PARP1 (AcCoA=Acetyl coenzyme A).
(D) PARP1 interaction with p65 after LPS stimulation in WT and D214N peritoneal macrophages. Cells were stimulated with LPS and then fractionated. Nuclear
extracts were subjected to western blotting.
(E) Interaction of PARP1 fragments with GST-p65. GST-p65 recombinant protein purified from insect cells was incubated with full-length WT and D214N PARP1
proteins. Interaction was analyzed by western blot.
(F) Bone marrow-derived macrophages from wild-typemice were stimulated with LPS for different times in the presence or absence of Z-VAD-fmk (50 mM). Total
cell extracts were prepared, and PARP1 cleavage was analyzed by western blot.
(G) Gene expression profiles of CSF2, IL-6, and IP-10 in Raw 264.7 cells. Cells were treated with LPS (1 mg/ml) and/or Z-VAD-fmk (10 mM) for 4 hr and mRNA
levels were determined by real-time RT-PCR analysis. Samples were normalized to Rps12 expression levels and expressed as fold increase relative to
unstimulated mRNA levels. Data are means ± SEM of three independent experiments.
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alone had no effect on PARP1 cleavage (Figures S2C and S2D)
and did not induce apoptosis under the tested conditions (Fig-
ure S2E). These results suggested that PARP1 is cleaved upon
LPS stimulation and that the C-terminal p89 cleavage fragment
is subject to proteasomal degradation and reduced to levels
below the detection limit for western blot analysis at early time
points after LPS treatment.
Moreover, the caspase inhibitor Z-VAD abrogated LPS-
dependent PARP1 cleavage as shown by western blot analysis
(Figure 2F). Z-VAD treatment also reduced LPS induced CSF2
and IL-6 transcription but not IP-10 transcription in Raw 264.7
cells (Figure 2G), although LPS-induced nuclear translocation
of NF-kB was not affected (Figure S3A). These data strongly
suggested that Z-VAD treatment per se did not affect LPS
signaling and that caspases were responsible for the cleavage
of PARP1.
Caspase 7 Cleaves PARP1 at D214 In Vitro and
Enhances NF-kB-Dependent Gene Induction In Vivo
In order to identify which of the caspases 1–10 cleaves PARP1
upon LPS stimulation, purified recombinant WT and D214N
PARP1 were incubated with active human caspases (caspase
1–10; expressed and purified with a baculovirus expression
system). Western blot analysis with an antibody directed against
the catalytic domain of PARP1 confirmed that PARP1 is predom-
inantly cleaved at D214 by caspase 3 and 7 and to a lesser extent
by caspases 1, 6, 8, 9, and 10 (Figure 3A).
Since PARP1 is localized in the nucleus, we investigated
whether the homologous and highly similar caspases 3 and 7
translocate to the nucleus upon LPS induction. THP1monocytes
were stimulated with LPS for 1.5 or 3.5 hr, and cytoplasmic and
nuclear fractions were prepared. Western blot analysis with an
antibody that detects only the activated caspase 7 resulting
from cleavage at D198 (p19) revealed that aminor but detectable
amount of active caspase 7 translocated to the nucleus after
stimulation (Figure 3B). Although we could observe caspase 3
activation upon LPS stimulation, we were unable to detect cas-
pase 3 in the nucleus under our experimental conditions and in
our cell lines (Figure S3B), suggesting that caspase 7 is mainly
responsible for the observed PARP1 cleavage in vivo.
To confirm that caspase 7 has a functional role in LPS-depen-
dent NF-kB gene induction, we transfected peritoneal macro-
phages and THP1 cells with caspase 7 or caspase 3 (as a control)
siRNAs and confirmed siRNA specificity by western blot and
quantitative RT-PCR (Figures S4A and S4B and data not shown).
LPS-induction of CSF2 and LIF was reduced in macrophages
transfected with caspase 7 siRNA, while it was increased or
not affected in cells transfectedwith caspase 3 siRNA (Figure 3C;
similar for THP1 cells in Figure S4C). The control gene IP-10was
not affected (Figure 3C), indicating that mainly caspase 7 was
responsible for the cleavage of PARP1 and the induction of
PARP1-cleavage-dependent NF-kB target genes. The strongly
reduced IL-6 protein levels secreted by LPS-treated peritoneal
macrophages of caspase 7 !/! mice, as compared to cells
from WT animals, supported the above observation for IL-6
gene expression at the protein level (Figure 3D).
To confirm that this LPS-dependent role of caspase 7 on
NF-kB is linked to PARP1 cleavage, THP1 cells expressing WT
or D214N PARP1 were transiently transfected with mock or
caspase 7 siRNA and stimulated 1 hr with LPS. Indeed, real-
time RT-PCR analysis revealed that caspase 7 knockdown led
to a 50% reduction of IL-6 gene induction in WT PARP1-
expressing THP1 cells, whereas no significant increase was
observed upon caspase 7 knockdown in D214N PARP1-
expressing THP1 cells (Figure 3E). Since the caspase 7 knock-
down did not affect nuclear translocation of the large subunit
of NF-kB p65 (Figure S4D), we concluded that caspase 7 has
a proinflammatory role in NF-kB-mediated gene induction that
is mainly mediated by PARP1 cleavage at D214.
Caspase 7 Is a Target of the NLRP3 Inflammasome
Theproinflammatory effects seen for caspase7encouragedus to
test the link between PARP1 cleavage, inflammatory caspase 1,
and caspase 7. Peritoneal macrophages isolated from WT,
caspase 1 !/!, and caspase 7 !/! mice were stimulated with
LPS for different times ranging from 1 hr to 16 hr. LPS treatment
of WT cells induced PARP1, caspase 1, and caspase 7 cleavage
(Figure 4A). In WT cells, PARP1 cleavage was visible as early as
1 hr after stimulation, but it was not observed in caspase 7 !/!
cells, confirming the proposed role for caspase 7 in cleaving
PARP1 upon LPS stimulation in vivo (Figure 4A). Similarly, PARP1
and caspase 7 cleavage was not detected in caspase 1 !/!
cells (Figure 4A). In caspase 7 !/! cell extracts, LPS-dependent
caspase 1 activation was not affected, providing evidence that
caspase 1 is upstream of caspase 7 activation, not vice versa.
Based on these findings, we further investigated caspase 1,
inflammasome formation, and caspase 7 activation. Caspase 7
was not required for inflammasome formation and IL-1bmatura-
tion in response to classical inflammasome activators (Figures
S5A and S5B). Remarkably, IL-1b levels in WT and D214N
macrophages were comparable (Figure S5C), suggesting that
observed changes in IL-1b serum levels after LPS treatment
in mice are the result of a more complex response in vivo (Pe´trilli
et al., 2004). Next, we tested whether the essential inflamma-
some adaptor protein ASC is required to activate caspase 1 in
response to LPS stimulation. Indeed, in peritoneal macrophages
lacking ASC, LPS-dependent caspase 1 activation, caspase 7
activation, and PARP1 cleavage were abolished (Figure S5D).
Moreover, IL-6 protein release upon LPS stimulation of ASC!/!
cells was reduced (Figure 4B). LPS dependent caspase 1 activa-
tion and caspase 7 activation were also abolished in BMDMs
lacking the NLRP3 inflammasome component NLRP3 (Fig-
ure 4C). The NLRP3 inflammasome can be activated by expo-
sure to bacterial products as well as danger signals (Mariathasan
et al., 2004; Pe´trilli et al., 2007; Tschopp and Schroder, 2010). In
WTmacrophages, LPS stimulation induced intracellular caspase
1 maturation (XT), whereas a typical NLRP3 inflammasome
inducer like monosodium urate (MSU) led to release of active
caspase 1 into the cell culture media (Figure 4D). Western blot
analysis also confirmed that caspase 1 and 7 were similarly
activated in WT and D214 PARP1 cell lines (Figure 4E). We
thus concluded that the transcriptional effects caused by the
PARP1 D214N mutation were not caused by altered caspase 7
activation.
These results indicate that LPS-dependent caspase 7 activa-
tion is mediated by the NLRP3 inflammasome and highlight
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a role for activated intracellular caspase 1 that is also supported
by other recent observations (Malireddi et al., 2010).
LPS Induces PARP1 Dissociation from the CSF2, IL-6,
and IP-10 Transcription Start Site upon Recruitment
of Caspase 7
To elucidate the chromatin association of PARP1 after LPS stim-
ulation at the transcriptional start site (TSS) of the indicated
genes, ChIP experiments with antibodies that recognize the
C-terminal part of PARP1 (p89) were performed. PARP1 was
associated with the TSS of the three indicated genes under un-
stimulated conditions (Figure 5A). Stimulation with LPS for 2 hr
or more lead to reduced PARP1 occupancy on the CSF2 and
IL-6 promoters, while PARP1 dissociation could not be detected
at earlier time points (Figure 5A). The chromatin association of
PARP1 was lost immediately after LPS stimulation at the TSS
Figure 3. Caspase 7 Cleaves PARP1 at D214 In Vitro and Controls NF-kB Gene Induction
(A) Screening of caspase family members (1–10) for PARP1 cleavage at D214 in vitro. Recombinant PARP1 WT or D214N mutant recombinant proteins were
incubated with active caspases (1–10) for 20 min at 30!C in a caspase cleavage buffer. Reaction products were analyzed by SDS gel followed by western blot
using PARP1 antibody.
(B) THP1 cells were stimulated with LPS for the indicated times. Cells were then fractionated, and cytoplasmic and nuclear extracts were subjected to western
blotting.
(C) CSF2, LIF, and IP10 fold induction upon LPS stimulation of caspase 3 and 7 knockdown macrophages. Cells were stimulated with LPS for 1 hr and gene
expression was analyzed by real-time RT-PCR. Samples were normalized to Rps12 and expressed as fold increase relative to unstimulated mRNA levels. Data
are means ± SD, n = 2.
(D) IL-6 protein levels released by IP macrophages were determined by ELISA after 5 hr of LPS induction (IL-6 could not be detected in uninduced peritoneal
macrophages). Values represent means ± SD of two measurements.
(E) IL-6 expression is significantly reduced in siCasp7-treated THP1 cells. Changes in gene expression upon LPS stimulation were expressed as fold response.
Fold response was set arbitrarily as 100% in simock transfected cells. Data are means ± SD, n = 2.
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of IP-10 (Figure 5A), indicating differences in the chromatin
dissociation of PARP1 for different NF-kB target genes. Stimula-
tion of Raw 264.7 macrophages for 2 hr in presence of Z-VAD
inhibited the chromatin dissociation of PARP1 from the CSF2
and IL-6 (but not IP-10) promoters and thus implied that the
release of PARP1 at these sites is dependent on caspase activity
(Figure 5B). In agreement with this finding, we could detect
a small but distinct caspase 7 recruitment to the promoter of
the cleavage-dependent gene IL-6, but not to the promoter of
IP-10 (Figures 5C and S5E).
Next we compared chromatin association of PARP1 in THP1
cells complemented with N-terminally myc-tagged WT or
D214N PARP1. The uncleaved or enzymatically inactive p24
PARP1 cleavage fragment was immunoprecipitated with an
anti-myc antibody (Figure S1B). Already, after 1 hr of LPS stimu-
lation, myc-PARP1 chromatin association was reduced at the
TSS of IL-6 in THP1 cells complemented with WT PARP1 (Fig-
Figure 4. Caspase 7 Is a Target of the
NLRP3 Inflammasome
(A) PARP1 cleavage upon LPS stimulation is
mediated by caspase 1 and caspase 7. Peritoneal
macrophages from wild-type, caspase 1!/!, and
caspase 7 !/! mice were stimulated for the indi-
cated times with LPS, total cell extracts were
prepared, and PARP1 cleavage and caspase 1
and caspase 7 activation were analyzed by
western blot.
(B) In IP macrophages lacking the essential in-
flammasome adaptor ASC, IL-6 protein levels
upon LPS stimulation were strongly reduced as
determined by ELISA (means ± SEM).
(C) BMDM cells from wild-type and NLRP3 !/!
mice were stimulated for the indicated times with
LPS, total cell extracts were prepared, and PARP1
cleavage and caspase 1 and caspase 7 activation
were analyzed by western blot.
(D) Peritoneal macrophages from wild-type mice
were stimulated for the indicated timeswith LPS or
MSU. Total cell extracts (XT) or the culture media
(SN) were analyzed by western blot.
(E) Uncleavable PARP1 (D214N) does not interfere
with caspase activation by LPS. Peritoneal
macrophages from wild-type and D214N PARP1
mice were stimulated for the indicated time with
LPS, total cell extracts were prepared, and PARP1
cleavage and caspase 1 and caspase 7 activation
were analyzed by western blot.
ure 5D). In contrast, the myc-tagged
PARP1 was still detectable in cells com-
plemented with noncleavable D214N
PARP1 (Figure 5D). Interestingly, PARP1
seemed even enriched at the IL-6 TSS
upon LPS stimulation of these cells. This
was not observed for the TSS of H2B,
which served as a control gene not
regulated by PARP1. Together, these
data suggested that PARP1 is associ-
ated with chromatin and that upon LPS
stimulation and recruitment of caspase
7 both the N-terminal (myc-tagged) and the C-terminal PARP1
fragments dissociate from chromatin at the TSS (Figures 5B
and 5D).
LPS-Induced PARP1 Chromatin Dissociation Leads
to Chromatin Decondensation
Previous studies have shown that PARP1 can regulate nucleo-
some compaction and the accessibility of DNA in chromatin
(Gottschalk et al., 2009; Timinszky et al., 2009). To gain more
insight into the functional consequences of PARP1 cleavage
and dissociation at the chromatin level, we performed a chro-
matin accessibility assay for CSF2, as a representative PARP1
cleavage-dependent gene. Chromatin from unstimulated or
1 hr LPS-stimulated cells were isolated, digested with MNase,
and subsequently analyzed by CHART-PCR. The chromatin at
the TSS of CSF2 became more accessible upon LPS stimulation
(Figure 5E). This effect on chromatin accessibility was more
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Figure 5. PARP1 Cleavage Regulates the Expression of IL-6 in THP1 Cells
(A) Kinetics of PARP1 occupancy upon LPS stimulation on the target promoters by ChIP analysis. Raw 264.7 cells were stimulated with LPS for different times.
PARP1 was immunoprecipitated with a PARP1 antibody, and the occupancy on the indicated promoters was measured by real-time RT-PCR. Results are
normalized to values corresponding to the beads control (0 hr time point), and the means ± SEM are shown.
(B) Effect of Z-VAD-fmk on PARP1 occupancy on the target promoters after LPS stimulation. Raw 264.7 cells were treated for 2 hr with LPS and Z-VAD-fmk.
The same analysis was performed as in (A). Results are from two independent experiments, ± SD.
(C) Kinetics of caspase 7 occupancy at the IL-6 promoter. Values are represented as bound/input and were normalized to the IgG control. The mean ± SD of
two RT-PCR quantifications is shown, and two independent experiments were performed.
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pronounced around the TSS than 1 kb upstream of this site (Fig-
ure 5E). Interestingly, analysis of the corresponding site in cells
isolated from D214N PARP1 mice revealed that the extent of
chromatin decompaction was significantly reduced upon LPS
stimulation (Figure 5E), which correlated with the observed
gene expression levels for CSF2 upon LPS stimulation (Fig-
ure 5F). Together, these data provided strong evidence that
PARP1 cleavage decreased chromatin compaction at the TSS
in vivo and enhanced LPS induction of defined NF-kB target
genes.
DISCUSSION
The results presented here demonstrate that (1) upon LPS stim-
ulation and after activation of the NLRP3 inflammasome and of
caspase 1, caspase 7 translocates to the nucleus; (2) caspase
7 is recruited to the transcription start site of specific NF-kB
target genes; (3) caspase 7 cleaves mainly PARP1 at D214;
and (4) release of the PARP1 cleavage fragments leads to sub-
sequent chromatin decondensation and enhanced gene ex-
pression. Our conclusions are based on several observations:
(1) on differential gene expression in mouse primary cells and
human THP1 cells genetically complemented with WT or non-
cleavable D214N PARP1; (2) on different mouse models lacking
caspase 7 or individual components of the NLRP3 inflamma-
some; (3) on differential chromatin accessibilities based on
MNase experiments; and (4) on ChIP experiments for p65, cas-
pase 7, and PARP1. These results may have broad implications
for the regulation of the inflammatory response, since several
NF-kB target genes involved in inflammation are regulated by
PARP1 cleavage.
Nuclear Translocation of Caspase 7 upon LPS
Stimulation
Our experiments show that LPS-activated caspase 7 and PARP1
cleavage stimulated the expression of PARP1 negatively regu-
lated NF-kB target genes in the tested cells. This tight regulation
could be achieved by LPS-induced activation of a very distinct
cytoplasmic complex containing caspase 7 and/or the induction
of a posttranslational modification, which would allow caspase 7
to translocate to the nucleus and to be recruited to the TSS,
where mainly PARP1 seems processed. However, the protein
responsible for recruiting caspase 7 is currently not known. An
LPS-induced factor that translocates to the nucleus could func-
tion as a carrier or regulator for caspase 7, since caspase 7 lacks
a classical NLS. Such a mechanism could also cause alternative
shuttling and targeting of caspase 7 and thus explain the biolog-
ically different functions of the highly similar caspases 3 and 7.
Different Kinetics of PARP1 Release from NF-kB Target
Genes
Chromatin dissociation and the release of the p89 PARP1 frag-
ment (Figure 5A) was only observed after 2 hr of LPS stimulation
for CSF-2 and IL-6, while the p89 fragment dissociated within
minutes from the promoter of the control gene IP-10 (Figure 5A).
The observation that PARP1 can dissociate from some NF-kB
target genes either within minutes and even in the presence of
Z-VAD (IP-10) or only 2 hr after LPS induction (CSF-2, IL-6) hints
at different mechanisms that mediate release of PARP1: fast,
PARP1 cleavage-independent (observed for IP-10) and slow,
PARP1 cleavage-dependent chromatin release.
PARP1 (C- and N-terminal fragments) was released from the
chromatin of a subset of genes in a caspase-dependent manner
(Figure 5), but a certain amount of PARP1 remained associated
with the promoters (Figure 5A). This observation implies that
transcriptional initiation does not require full dissociation of
PARP1. The functional relevance of this residual PARP1 is
currently not understood.
Caspases 3 and 7 Have Distinct Functions Independent
of Apoptosis
Caspases are important effectors of programmed cell death and
their function in apoptosis has been extensively studied (Thorn-
berry and Lazebnik, 1998). For example, the activations of the
NLRP3 and NLRC4 inflammasomes and of caspase 7 was
described upon induction of pyroptosis (Malireddi et al., 2010).
Similarly, the infection of macrophages with L. pneumophila
results in cell death due to the NLRC4/IPAF inflammasome and
to activation of caspase 7 (Akhter et al., 2009). During apoptosis,
caspases also cleave PARP1 (Germain et al., 1999). To our
knowledge, there are currently no publications describing the
activation of the NLRP3, caspase 1, caspase 7 signaling axis
independent of any type of programmed cell death.
Upon LPS stimulation, we did not detect ADP-ribose polymer
formation (sign of genotoxic stress signaling) with the available
antibodies against ADP-ribose polymers, and the amount of
activated caspases 3/7 during LPS treatment was very low
compared to apoptotic conditions. It is therefore likely that the
herein described processing of PARP1 by caspases 1/7 repre-
sents a direct mechanism of chromatin regulation. However,
we cannot exclude that active caspase 7 is cleaving additional
proteins important for other cellular processes during LPS stim-
ulation or that other caspases are also able to cleave PARP1
upon LPS stimulation (e.g., caspase 6, 8, 9, or 10) (Figure 3A).
Reports documenting functions of caspases in nonapoptotic
cellular processes are accumulating. For example, stimulation
of microglia with various inflammogens activates caspase 8
(D) ChIP analysis of PARP1 occupancy upon LPS stimulation on the target promoters inWT and D214NPARP1-complemented THP1 cells. Cells were stimulated
with LPS for 1 hr. PARP1 was immunoprecipitated with a myc antibody, and the occupancy on the indicated promoters was measured by real-time RT-PCR.
Results are corrected for the input controls and expressed as relative occupancy, unstimulated levels being set arbitrarily as 1. H2B promoter was assessed as
negative control. Data are means ± SD, n = 2.
(E) Chromatin accessibility was assessed by real-time PCR (CHART-PCR). Nuclei from unstimulated and LPS-stimulated BMDMs were incubated with MNase.
(!1) kb upstream promoter and TSS of CSF2 were analyzed. Results are expressed as uncut over cut genomic DNA and normalized to unstimulated levels.
Unstimulated uncut/cut genomic DNA level around TSS was arbitrarily set as 100. Data are from a pool of six mice, and means ± SD are shown (n = 2).
(F) After stimulation of BMDMs with LPS for 1 hr, mRNA levels were determined by real-time RT-PCR analysis. Samples were normalized to Rps12 expression
levels and expressed as fold increase relative to unstimulated mRNA levels. Data are means ± SEM, three independent mice groups where each group contains
two mice, n = 6.
Molecular Cell
Casp7-induced PARP1 cleavage regulates NF-kB
Molecular Cell 46, 1–12, April 27, 2012 ª2012 Elsevier Inc. 9
Please cite this article in press as: Erener et al., Inflammasome-Activated Caspase 7 Cleaves PARP1 to Enhance the Expression of a Subset of NF-kB
Target Genes, Molecular Cell (2012), doi:10.1016/j.molcel.2012.02.016
  122 
  
and caspase 3/7 without triggering cell death in vitro or in vivo,
providing another example for a nonapoptotic function (Burguil-
los et al., 2011). The results presented here are also in agreement
with the recently published finding that caspase 7 (but not
caspase 3) is a downstream target of caspase 1, which provides
evidence for distinct activation mechanisms for caspase 3
and 7 in response to microbial stimuli and bacterial infection
(Lamkanfi et al., 2008). Interestingly, PARP1 cleavage was
also observed in extracts of differentiating cells, implicating
PARP1 cleavage in other cellular processes and emphasizing
its physiological relevance (Fujita et al., 2008).
PARP1 Cleavage-Dependent Regulation of NF-kB
Target Gene Expression Is Not Due to Altered p65
Recruitment
At present, the molecular basis of the PARP1 and PARP1
cleavage dependency leading to differential NF-kB transcrip-
tional activation is not understood. The observation that the
recruitment of p65 to the promoters of CSF2, IL-6, and IP-10
was comparable in WT and D214N PARP1 cells underlines the
notion that these genes have an inherent competence to
respond to NF-kB (Smale, 2011). PARP1 may thus be involved
in maintaining and fine-tuning the extent of the NF-kB response,
likely due to a stimulation of RNA polymerase II-dependent
transcription.
The changes in gene expression (mRNA and protein levels)
could also be influenced at the posttranscriptional level, but so
far PARP1 has not been implicated in such a regulatory mecha-
nism. Although poly-ADP-ribose regulates stress responses
and microRNA activity in the cytoplasm, PARP1 was neither de-
tected in stress granules nor involved in any kind of regulation
(Leung et al., 2011). Together, we think that our data on
PARP1 cleavage and chromatin association, chromatin decon-
densation, and mRNA levels are all in agreement and do not
hint at a posttranscriptional effect of PARP1 cleavage on
mRNA stability.
It also remains to be determined if PARP1 positively regulated
genes respond similarly to caspase-induced PARP1 cleavage.
Our previous findings provide evidence that PARP1 is present
as a chromatin regulator in different biochemically induced
NF-kB complexes and is required for at least a subset of NF-
kB gene expression (Hassa et al., 2008). Such a differential
NF-kB-specific promoter regulation has been described for
other transcriptional cofactors, such as CARM1 (Covic et al.,
2005), or as the result of sumoylation of PARP1 (Messner et al.,
2009). PARP1 association in different regulatory complexes
or PARP1 posttranslational modification may thus result in differ-
ential susceptibility to caspase cleavage and thereby limit the
regulatory function of PARP1 cleavage to a specific subset of
NF-kB target genes.
In this study we explored the signaling and molecular
mechanism by which PARP1 cleavage contributes to NF-kB-
dependent transcriptional regulation. We provide evidence that
LPS-activated nonapoptotic PARP1 cleavage by caspase 7
releases PARP1 from chromatin, reduces chromatin com-
paction, and enhances the expression of a subset of NF-kB-
dependent genes. Mutation of the PARP1 cleavage site
(D214) or absence of activated caspase 7 abolishes LPS-
stimulated PARP1 cleavage, prevents release of PARP1 from
chromatin, maintains chromatin compaction, and compromises
the induction of a subset of PARP1 negatively regulated
NF-kB target genes. These results functionally link the
NLRP3 inflammasome-activated caspase 7 to inflammation
and transcription.
EXPERIMENTAL PROCEDURES
A brief description of the experimental procedures is given below. A more
detailed delineation of the methods is provided in the supplemental material.
All experiments shown and discussed were performed at least twice and
one representative result is shown.
Mice and Cell Isolation
WT and transgenic mice were maintained in a specific pathogen-free facility
and were from the same genetic background (C57BL/6). For the generation
of bone marrow macrophages, 6- to 8-week-old mice were sacrificed, and
the cells were isolated as described elsewhere (Pe´trilli et al., 2007). Cells
were plated in 10 cm uncharged plastic plates (Petri dish) and incubated for
full differentiation in RPMI medium supplemented with 10% FCS, 100 units/ml
penicillin/streptomycin (GIBCO), 13 nonessential amino acids (GIBCO), 1 mM
sodium pyruvate (GIBCO), 50 mM b-mercaptoethanol (GIBCO), and 20% L929
conditioned medium for 10 days in a humidified incubator (with 5% CO2 at
37!C). After 10 days, cells were counted and seeded in 6-well tissue culture
plates. After 16 hr, cells were stimulated with 10 mg/ml LPS for 1 hr and
harvested for RNA extraction.
For the isolation of peritoneal macrophages, 8- to 10-week-oldmicewere i.p
injected with 1 ml of 10% Brewer thioglycollate medium for 3 days. Mice were
sacrificed, and cells were collected as described previously (Pe´trilli et al.,
2004). Briefly, cells were collected in RPMI medium by abdominal lavage,
washed with PBS, and seeded at a cell density of 13106 cells/ml in tissue
culture plates in full-RPMI medium containing 10% FCS, 100 units/ml
penicillin/streptomycin (GIBCO), 13 nonessential amino acids (GIBCO), and
1mM sodium pyruvate (GIBCO). Cells were cultured in full-RPMI medium.
Animal experiments were performed according to the regulations of the
cantonal veterinary office.
RNA Extraction and Gene Expression Analysis by Real-Time RT-PCR
Unless stated otherwise, subconfluent (50%) cells were stimulated with
10 mg/ml LPS for 1 hr. Total RNA was isolated using kits according to the
manufacturers’ recommendation (Macherey-Nagel and Ambion). RNA was
reverse-transcribed (kit from Applied Biosystems) and real-time PCR was
performed using the Rotor-Gene 3000 (Corbett Life Science/QIAGEN) and
TaqMan assays or SYBR Green (primers listed in Tables S1 and S2).
Transient Transfections
THP1 cells were primed with PMA (10 ng/ml) for 24 hr and transfected with
30 pmol siRNA oligos (QIAGEN) with 4 ml Lipofectamine RNAiMAX reagent
(Invitrogen) according to the manufacturer’s protocol. Transfection into
HEK293 cells was described elsewhere (Hassa et al., 2005).
Chromatin Immunoprecipitation
Cells were crosslinked with 1% formaldehyde (Calbiochem) or with formalde-
hyde and dimethyl 3,30-DTBP (Kurdistani and Grunstein, 2003). Chromatin
was fragmented with the Bioruptor (Diagenode), incubated with specific
antibodies, and collected with Protein A Agarose/salmon sperm DNA
(Millipore). DNA was extracted and measured by real-time PCR using SYBR
Green (see above). Primers are listed in Table S3.
Chromatin Accessibility by Real-Time PCR
Accessibility of DNA to MNase was analyzed by real-time PCR (CHART-PCR)
as described elsewhere (Rao et al., 2001). The genomic DNA was isolated
using a mammalian Genomic DNA miniprep kit (Sigma). Primers used in
real-time PCR analysis are listed in Table S3.
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SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, three tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.molcel.2012.02.016.
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F igure S1. Genetic Complementation of T HP1 Cells 
(A) IL-6 levels in the supernatant of IP macrophages were determined by ELISA 
before and after 5h of LPS induction.  
(B) Stable complementation of THP1 PARP1 knockdown cells either with PRRL-
empty vector, myc-tagged WT PARP1 or uncleavable PARP1 D214N mutant. Total 
cell extracts were prepared and proteins were immunoprecipitated with a myc 
antibody and analyzed by western blot using PARP1 antibody. Gapdh was used as 
loading control.  
(C and D) p65 knock-down abolishes LPS induced gene induction. THP1 cells were 
transiently transfected with the p65 siRNA oligos and (C) analyzed by western blot or 
(D) real-time RT-PCR analysis was performed after one hour LPS stimulation. 
Samples were normalized to Rpl28 and expressed as fold increase relative to 
unstimulated mRNA levels.  
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F igure S2. LPS Stimulation Induces PA RP1 C leavage and Inhibition of Caspase 
Activity Does Not A ffect LPS Induced p65 Shuttling to Nucleus 
(A) PARP1 cleavage profile in LPS treated THP1 macrophages. Total cell extracts 
were prepared and analyzed by western blot using indicated antibodies.  
(B) THP1 monocytes were stimulated with LPS for different times, total cell extracts 
were prepared from and analyzed by western blot using antibodies against the full-
length and cleaved C-terminal fragment of PARP1 (p89) and Tubulin as loading 
control. A short and long exposure (s.e and l.e, respectively) of the same blot are 
shown. Ctrl* is the sample treated with Etoposide for 16 hours. 
(C) Total cell extracts were prepared and proteins were analyzed by western blot 
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using the indicated antibodies.  
(D) Cells were fractionated and cytoplasmic and nuclear extracts were subjected to 
western blotting with the indicated antibodies.  
(E) Cells were assayed for LDH release as indicated in the experimental procedures. 
Camptothethcin (CPT) was assessed as positive control. n=3, ± SEM. 
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F igure S3. PA RP1 C leavage at D214 Occurs after One Hour of LPS Stimulation 
(A) Raw 264.7 cells were stimulated with LPS in the presence or absence of z-VAD-
???????????????? ??????????????????????????????????????? ????????????????????????????
and DAPI and analyzed by immunofluroscence microscopy.  
(B) THP1 cells were stimulated with LPS for the indicated times. Cells were then 
fractionated and cytoplasmic and nuclear extracts were subjected to western blotting. 
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F igure S4. Caspase 3 and 7 K nock-down in IP Cells and Caspase 7 K nock-down 
E ffect on LPS Induced p65 Shuttling to Nucleus 
(A and B) IP cells were transiently transfected with the indicated siRNA oligos. (A) 
Knock-down efficiency was confirmed with western blot. (B) THP1 cells 
complemented with WT or D214N PARP1 were PMA primed, transfected with mock 
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or caspase 7 siRNA oligos, total cell extracts were prepared and subjected to western 
blotting using the indicated antibodies.  
(C) Effect of caspase knockdown on LPS dependent NF-??? ??????? ????? ??????????
THP1 cells were transiently transfected with the indicated siRNA oligos, stimulated 
with LPS for one hour and gene expression was analyzed by real-time RT-PCR. 
Samples were normalized to Rpl28 and expressed as fold increase relative to 
unstimulated mRNA levels. Data are means of ± SD, n=2.  
(D) THP1 cells were PMA primed, transiently transfected with the mock or caspase 7 
siRNA oligos and stimulated with LPS for the indicated times. Cells were fixed, 
incubated with p65 antibody and DAPI and analyzed by immunofluorescence 
microscopy. 
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F igure S5.  
(A and B) Absence of caspase 7 does not affect inflammasome activation. Peritoneal 
macrophages from WT and caspase 7 -/- mice were were primed overnight with LPS 
then incubated with with different inflammasome activators. Cell supernatants (A) 
and cell extracts (B) were prepared, IL-1? secretion and caspase 1 activation was 
analyzed by western blot.  
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(C) IL-1b levels in WT and D214N PARP1 expressing macrophages after stimulation 
by LPS for 0-16 hours.  
(D) The inflammasome adaptor protein ASC is required for LPS-dependent caspase 1 
and caspase 7 activation and for PARP1 cleavage. IP cells from wild-type and ASC -/- 
mice were stimulated for the indicated times with LPS, total cell extracts were 
prepared and PARP1 cleavage, caspase 1 and caspase 7 activation was analyzed by 
western blot.  
(E) As a control, the kinetics of caspase 7 occupancy at the IP-10  promoter was 
determined. Cells were stimulated with LPS for different times. Caspase 7 was 
immunoprecipitated with a Caspase 7 antibody and the occupancy on the IP-10 
promoter was measured by real time RT-PCR. Results are normalized to values 
corresponding to the beads control (0h time-point). 
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Tables S1, S2, and S3. PC R Primers Used in This Study  
The sequences of forward (F) and reverse (R) primers used for PCR are given in 5`-
3`direction. 
 
T A B L E S1. SyBr G reen Primers Used in Real-T ime R T-PC R Analysis 
Gene  Species Sequence (F , R; 5`-3`) 
CSF2 Mus musculus ACATGCCTGTCACGTTGAAT 
TTGAGTTTGGTGAAATTGCC 
IP-10 Mus musculus GCACGAACTTAACCACCATCTTCC 
CTACCCATTGATACATACTTGATGACAC 
IL-6 Mus musculus ACTGACAATATGAATGTTGGGACAC 
ACCATCTGGCTAGGTAACAGAA 
MIP2 Mus musculus ACATCCCACCCACACAGTGAAAGA 
TCCTTCCATGAAAGCCATCCGACT 
LIF Mus musculus CCATAGATGCAGCAAGGAGA 
CAGTCCTGAGATGAGCCTGA 
RPS12 Mus musculus GAAGCTGCCAAAGCCTTAGA 
AACTGCAACCAACCACCTTC 
RPL28 Homo Sapiens GCAATTCCTTCCGCTACAAC 
TGTTCTTGCGGATCATGTGT 
IL-6 Homo Sapiens GGCACTGGCAGAAAACAACC 
GCAAGTCTCCTCATTGAATCC 
 
T A B L E S2. Taqman Probes Used in Real-T ime R T-PC R Analysis 
Gene  Species Taqman-Number 
NOS-2 Mus musculus Mm00440485 
CALNEXIN Mus musculus Mm00500330_m1 
IP-1O Homo Sapiens Hs00171042_m1 
CSF2 Homo Sapiens Hs99999044_m1 
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T A B L E S3. SyBr G reen Primers Used in ChIP and C H A R T R T-PC R Analysis 
Gene  Species Sequence (F , R; 5`-3`) 
IP-10 Mus 
musculus 
GCAATGCCCTCGGTTTACAG 
GGCTGACTTTGGAGATGACTCA 
IL-6 Mus 
musculus 
CCCCACCCTCCAACAAAGATTTT 
CCCCAGTCTCATATTTATTAGGAGTCAAC 
CSF2 Mus 
musculus 
AATTCTGCAGCCACATCCTC 
GCCAGGAGATTCCACAACTC 
CSF2(-1KB) Mus 
musculus 
CTTGAGACCATGCTGCCTTT 
GCTTCCCTGGCAAGTTCTC 
NOS-2 Mus 
musculus 
ATGGCCTTGCATGAGGATAC 
GCAGCAGCCATCAGGTATTT 
NOS-2  
(-1KB) 
Mus 
musculus 
GGGTGTTGCCTGGATAAAGA 
CACTTGCACACACACACAGC 
Prolactin Mus 
musculus 
CCTTCATTTCTGGCCAATGT 
GCCTGAGAGAACCACAGCTT 
IL-6 Homo 
Sapiens 
CCTCACCCTCCAACAAAGAT 
GCCTCAGACATCTCCAGTCC 
H2B Homo 
Sapiens 
TTGCATAAGCGATTCTATATAAAAGCG 
ATAAAGCGCCAACGAAAAGG 
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Supplemental Experimental Procedures 
 
T issue Culture 
THP1 monocytic cells were grown in suspension and maintained in RPMI 
supplemented with 10% FCS, 1mM sodium pyruvate (Gibco), 1x non-essential amino 
acids (Gibco) and 100units/ml penicillin/streptomycin (Gibco), 50 ?M ?-
mercaptoethanol (Gibco) at a cell density of 0.3 to 1.0x106/mL. For differentiation 
into macrophages, cells were plated at a density of 1x106/6-cm dish in RPMI with 10 
ng/ml PMA for 18 hours to become fully differentiated macrophages before use in 
experiments. HEK 293 cells were maintained in DMEM supplemented with 10% FCS 
and 100 units/ml penicillin/streptomycin. All cells were maintained at 37°C in 5% 
CO2. 
Plasmids  
Plasmid for the mammalian expression of human PARP1 was generated by cloning 
human PARP1 cDNA into XhoI cloning site of pCDNA 3 with a hemagglutinin-tag at 
the C-terminus. Corresponding D214N PARP1 mutant was generated by site directed 
mutagenesis and confirmed by sequencing. Plasmids for the mammalian expression of 
HDAC 1-2 were described elsewhere (Hassa et al., 2005). myc-PARP1(WT), myc-
PARP1 (89 kDa), myc-PARP1 (24 kDa) were cloned into pCMV vector and the latter 
two constructs had a nuclear localization signal at the N-terminus. 
Reagents and Antibodies 
Lipopolysaccharide (LPS, 055:B5) was purchased from Sigma. Active recombinant 
human caspase Set IV was purchased from Biovision. Etoposide was purchased from 
Calbiochem. Ethidium homodimer and Calcein AM were purchased from Fluka. 
SyBR Green was purchased from Quantace. The following antibodies were purchased 
from Santa Cruz Biotechnologies: anti-RelA (sc-372), anti-PARP1 (sc-7150), anti-
GAPDH (FL-335), anti-caspase 7 (sc-28295). The anti-PARP1 (89) and active-
caspase 7 (9491) antibodies were from Cell Signaling. Anti-mouse caspase-1 was 
obtained from Peter Vandernabele. The anti-myc antibodies were either purchased 
from Roche (11-667-149-001) or purified from hybridoma cells. The anti-Tubulin and 
anti-Flag (M2) antibodies were purchased from Sigma and the anti-HA was from 
Covance (MMS-101P). The anti-caspase 7 from Epitomics (1032-1) antibody was 
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purchased was used for ChIP experiments. The p65 antibody from Enzo Lifesciences 
(ALX-210-574) was used for immunohistochemistry. 
Generation of Recombinant Proteins  
The recombinant proteins were expressed by baculovirus in Sf21 cells using either the 
FastBac (Invitrogen) or the BacPAK systems (Clontech). His-tagged proteins were 
purified over Ni2+-beads (ProBond, Invitrogen) and GST-tagged proteins over L-
Glutathione beads (Sigma). All purified proteins were analyzed by coomassie staining 
and confirmed by western blot analysis using the corresponding antibodies.  
Stable PA RP1 K nockdown and Complementation in T HP1 Cells 
Generation of viruses and transduction of cells was done as described earlier (Ariumi 
et al., 2005). Briefly, pRDI vector containing PARP1 shRNA (#5) was used to 
transduce THP1 cells. The short hairpin RNA was against 5`UTR region of PARP1 
mRNA. Transduced cells were selected through puromycin resistance gene. 
Complementation of cells was done with pRRL-myc-PARP1 vectors containing a 
blasticidin resistance marker and complemented cells were subsequently selected for 
three weeks with 2 µg/ml blasticidin. 
32P- N A D Automodification 
Experiment was performed as described elsewhere (Altmeyer et al., 2009). 
In Vitro T ranslation 
HA-tagged WT and D214N mutant PARP1 were in vitro translated using the `TNT 
coupl??? ????????????? ??????? ????????? ?????????? ?????????? ???? ???????????????
instructions. 
In Vitro PA RP1 C leavage Assay 
10 pmol recombinant or 125 ng in vitro translated 35S labeled WT or D214N PARP1 
proteins were incubated for 20 minutes at 37°C with 1U of recombinant caspases in 
caspase cleavage buffer (50 mM Hepes pH 7.2, 50 mM NaCl, 0.1% Chaps, 10 mM 
EDTA, 5% Glycerol, 10 mM DTT). Proteins were subsequently resolved by SDS-
PAGE and analyzed by western blot. 
In Vitro Interaction and GST Pull-Down Assays 
GST-p65 expressed in insect cells was immobilized on glutathione-sepharose beads 
(Amersham Biosciences) and incubated with recombinant PARP1 proteins (WT, 
D214N mutant) in binding buffer (50 mM Tris pH 8, 100 mM NaCl, 0.5% NP-40, 5 
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mM DTT, 1 mM PMSF) for 2 h at 4°C rolling. Glutathione beads were washed three 
times with precission buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1mM EDTA, 1 
mM DTT) and incubated with precission enzyme in 50 ul precission buffer overnight. 
Proteins in the supernatant were boiled, resolved on SDS-PAGE and subjected to 
western blot using anti-PARP1 or anti-HA antibodies. 
Immune F luorescence Microscopy 
For immune fluorescence stainings, cells were grown on cover slips and fixed with 
icecold methanol for 10min at 4°C, followed by washing with PBS. 10% FCS in PBS 
was used for blocking at RT for 30min. Cells were then incubated with the primary 
antibody directed against RelA (C20, Santa Cruz sc-372) and the secondary antibody 
(CyTM3-conjugated AffiniPure Goat Anti-Rabbit, Jackson ImmunoResearch 
Laboratories). Both antibodies were used in a dilution of 1:250 in 5%FCS in PBS for 
1hr at RT. Cells were mounted with Vectashield containing DAPI and analyzed by 
fluorescence microscopy using a Leica DMI 6000B. 
Whole Cell Extract and Immunoprecipitation for Myc-PA RP1 
Unless stated otherwise, whole cell extracts were prepared by lyzing the cells for 15 
minutes in lysis buffer (50 mM Tris pH 8, 500 mM NaCl, 1% Triton X-100, 1?g/ml 
pepstatin, 1?g/ml bestatin, 1?g/ml leupeptin, 2 mM PMSF) at 4°C. One milligram of 
whole cell extract was incubated with anti-myc antibody for 2 hours at 4°C. 
Immunocomplexes were collected with Protein A agarose beads (GE Healthcare) for 
1 hour at 4°C and washed three times with wash buffer containing 120 mM NaCl. 
Immunocomplexes were analyzed by standard western blot analysis using anti-
PARP1 and anti-GAPDH antibodies.  
Nuclear Extract Preparation  
Cells were stimulated with 10 µg/ml LPS for the indicated times, washed with PBS, 
harvested and washed again three times in buffer A (10 mM HEPES KOH pH7.9, 1.5 
mM MgCl2, 10 mM KCl, 1?g/ml pepstatin, 1?g/ml bestatin, 1?g/ml leupeptin, 2 mM 
PMSF, 5mM DTT). Cells were lysed with A+ buffer (Buffer A+ 0.06 % NP-40) and 
centrifuged for 5 minutes at 5000 rpm. Supernatant corresponding to cytoplasm was 
saved for western blot analysis. Pellet was washed three times with buffer A and 
subsequently resuspended in three volumes of Buffer C (20 mM HEPES KOH pH7.9, 
0.42 M NaCl, 1.5 mM MgCl2, 25% v/v glycerol, 1?g/ml pepstatin, 1?g/ml bestatin, 
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1?g/ml leupeptin, 2 mM PMSF, 5 mM DTT) and incubated for 15 minutes at 4°C on 
rotating wheels. Lysate was centrifuged for 10 minutes at 4°C at 14000 rpm with the 
supernatant corresponding to the nuclear fraction.150 ?g cytoplasmic extracts and 50 
?g nuclear extracts were boiled with Laemmli buffer, resolved on 15% SDS-PAGE 
and subjected to western blot using different antibodies. 
Cell V iability Assay 
THP1 macrophages stimulated with 10 µg/ml LPS for the indicated times were 
incubated with 4 ?M Ethidium homodimer and 2 ?M Calcein mix in PBS for 30 
minutes at 37°C incubator. Ethidium homodimer positive and Calcein positive  cells 
were visualized using Olympus BX51 microscope.  
In Vitro Inflammasome Formation  
Peritoneal macrophages were primed overnight with 100 ng/ml of ultra-pure LPS and 
stimulated as indicated asbestos (150 ?g/ml), MSU (150 ?g/ml), R837 (10 ?g/ml), 
Nigericin (20?M) for 6hr except ATP 5???????(Pétrilli et al., 2007). 
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6. Unpublished Results 
6.1. ARTD1 recruitment, release and PAR formation at laser-induced DNA 
lesions in live cells 
As described in section 5.1, SET7/9 methylates ARTD1 at K508 and influences its 
H2O2-induced PAR formation. One mechanism to regulate ARTD1 activity in vivo is 
to alter its recruitment and affinity to damaged chromatin. Therefore, we wanted to 
study the effects of SET7/9-mediated methylation on ARTD1 activity in live cells. 
This was done in collaboration with the group of Elisa May at the Bioimaging Center 
in Konstanz, who have established methods for DNA damage induction with near 
infrared short laser pulses [222,223]. The binding characteristics of ARTD1 wildtype 
and the methylation deficient mutant K508R were compared in presence and absence 
of SET7/9. Strinkingly, both EGFP-ARTD1 wildtype and K508R are recruited less 
efficiently to DNA lesions induced with a 1050 nm laser, when SET7/9 is depleted 
(Fig. 6a and b). The K508R mutation itself had no effect on ARTD1 recruitment to 
DNA damage sites induced at this wavelength. Furthermore, the release of PAGFP-
ARTD1 wildtype and K508R from laser-induced DNA lesions was comparable (Fig. 
6c and d). 
PAR formation at irradiated sites can be monitored in real-time by using the 
macrodomain of macroH2A fused to EGFP. This protein domain is known to bind 
PAR resulting in a time-dependent increase of fluorescence signal in the damaged 
area, when PAR is formed. Live cell microscopy showed that less PAR is formed at 
laser-irradiated sites in SET7/9 knockdown cells than in cells treated with a control 
siRNA (Fig. 6e). No differences in PAR formation were observed between ARTD1 
knockdown cells complemented with ARTD1 wildtype or K508R (data not shown). 
These results indicate that under the tested conditions (multiphoton laser irradiation 
with ' = 1050 nm) ARTD1 recruitment to and activation by DNA damage is 
enhanced by SET7/9 independent of the methylation at K508. The data described here 
suggest that SET7/9 regulates ARTD1 by other mechanisms in addition to the 
methylation at K508. This could be achieved in several ways, e.g. (1) by methylating 
other chromatin-associated factors and thereby inducing chromatin changes leading to 
enhanced DNA damage or better access for ARTD1, (2) by methylating other proteins 
that in turn activate ARTD1 and (3) by methylation independent mechanisms e.g. 
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Figure 6. ARTD1 binding and PAR formation kinetics at multiphoton laser induced DNA lesions. 
(a and b) ARTD1 wildtype (wt) and K508R recruitment to DNA lesions induced with a 1050 nm laser 
was measured and analyzed as described elsewhere [223]. Briedfly, U2OS cells were transfected with 
siRNA directed against SET7/9 or a control siRNA (scr) using RNAiMAX according to the 
manufacturer’s instructions. One day later, medium was changed and EGFP-ARTD1 plasmids were 
transfected by calcium phosphate transfection in a BES-buffered system. One-and-a-half or two days 
later, confocal microscopy was performed in phenol-red free DMEM and fluorescence intensity 
increase was measured at DNA lesions. (c and d) ARTD1 release from DNA lesions was analyzed 
using ARTD1 proteins fused to photoactivatable GFP. Cells were transfected with siRNA against 
ARTD1 and PAGFP-ARTD1 plasmids as described in (a and b). At the indicated times after DNA 
damage induction with a 1050 nm laser, PAGFP was photoactivated in the same area with a short laser 
pulse at 775 nm and fluorescence intensity decay was measured over time. (e) Recruitment of the 
macrodomain of macroH2A was examined as in (a and b).   
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direct interaction and recruitment of ARTD1. One possible factor that might influence 
ARTD1 in a SET7/9 methylation-dependent manner is histone H1, which was 
previously reported to activate ARTD1 [224]. 
The comparable binding dynamics and PAR formation kinetics of ARTD1 wildtype 
and K508R can be explained by the following possibilities: (1) Endogenous wildtype 
ARTD1 levels (at least in the recruitment studies with SET7/9 knockdown) might 
mask a methylation-dependent effect. (2) At this wavelength the methylation might 
not influence ARTD1 activity (compare section 8). (3) SET7/9 might methylate 
another lysine residue close-by if K508 is mutated. The last point is strengthened by 
the fact that in vitro methylation of ARTD1 K508R was observed at some conditions 
(e.g. low salt stringency).  
 
6.2. ARTD1 demethylation 
Lysine methylation is a reversible modification. Demethylation is catalyzed by 
proteins of the LSD and JmjC domain families. LSD1 and LSD2 were shown to 
demethylate other SET7/9 targets such as H3 [210,225] and E2F1 [203]. Therefore, 
we tried if they also remove the methyl group from monomethylated ARTD1 K508. 
H3 was used as a positive control. The substrate proteins were first methylated with 
radioactive SAM and then incubated with GST (as a negative control), LSD1 or 
LSD2 after residual SAM had been removed by spin-column chromatography. 
Incubation with LSD1 and LSD2 clearly decreased the radioactive signal of H3 as 
well as full-length ARTD1 and the fragment 373-524 (Fig. 7). This could indicate that 
both LSD1 and LSD2 are indeed able to remove the [14C]-labeled methyl group from 
K508.   
However, it has to be noted that the LSD1 and LSD2 preparations might have been 
contaminated by bacterial proteases as their expression in E. coli did not yield high 
amounts of full-length protein and generated many truncated products. Thus, 
demethylation of ARTD1 has to be studied in more detail with other LSD protein 
preparations and in presence of high amounts of protease inhibitors to elucidate if 
LSD1 and LSD2 indeed reverse the SET7/9-dependent methylation. Other 
demethylases from the JmjC domain family could be included in future studies.  
It will also be interesting to investigate the effect of demethylase knockdown and 
overexpression on ARTD1 activity in vivo. 
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Figure 7. Demethylation of histones and ARTD1 by LSDs. His-tagged LSD1 and LSD2 were 
expressed in E. coli in presence of 10 %M riboflavin and purified by one-step nickel affinity 
chromatography. 1 %g ARTD1 or 2.5 %g histone mix were methylated with [14C]-labeled SAM by 
SET7/9 as described in section 5.1. To remove residual SAM, proteins were then purified over a G-50 
column (GE Healthcare) according to the manufacturer’s recommendations. The same volume of 1x 
demethylation buffer (50 mM Tris pH8.0, 50 mM KCl, 5 mM MgCl2, 5% glycerol, 1 mM DTT, 
0.2mM PMSF) and LSD proteins or GST were added. Demethylation was allowed to proceed for 3 hrs 
at 37°C. Proteins were then separated by SDS-PAGE, stained with Coomassie and analyzed by 
autoradiography. 
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6.3. Mutation of SET7/9 target lysine residues does not change the nuclear 
distribution of H1.4 
SET7/9 methylates the residues K121, K129, K159, K171, K177 and K192 in the C-
terminal domain of H1.4 (see section 5.2). To investigate the influence of SET7/9-
dependent methylation on H1.4, we mutated these residues to arginines and analyzed 
the nuclear distribution of N-terminally EGFP-tagged H1.4 in U2OS cells. Neither the 
combined mutation of the four last target residues (K4R) nor the mutation of all six 
residues (K6R) had an influence on the localization pattern of H1.4 in the nucleus 
(Fig. 8). H1.4 wildtype, K4R and K6R were preferentially localized to hetero-
chromatin as described previously [28]. 
 
 
 
Figure 8. H1.4 distribution in the nucleus. U2OS cells were transfected with EGFP-H1.4 expression 
plasmids and analyzed by live cell microscopy in phenol-red free medium two days later. wt: wildtype, 
K4R: K159/171/172/192R mutant, K6R: K121/129/159/171/172/192R mutant  
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6.4. SET7/9 is modified by ARTD1 
During our studies, we realized that ARTD1 was not only methylated by SET7/9 but 
that SET7/9 was also modified by ARTD1 in radioactive trans-ADP-ribosylation 
assays (Fig. 9). As ADP-ribosylation might also occur in the N-terminal GST-tag of 
SET7/9, the GST fusion protein was cleaved with PreScission protease and GST was 
removed. This revealed that SET7/9 itself and not the GST tag was modified by 
ARTD1. It will be exciting to see if and under which conditions ADP-ribosylation of 
SET7/9 occurs in cells and how this modification affects SET7/9 activity and 
substrate specificity.  
 
                       
 
Figure 9. SET7/9 is ADP-ribosylated by ARTD1. GST and GST-SET7/9 were expressed in E. coli 
and purified using glutathione sepharose according to the manufacturer’s instructions (GE Healthcare).  
1 %g of each purified GST protein was incubated with recombinant ARTD1 in presence of 100 nM 32P-
labeled NAD+ and 5 pmol EcoRI DNA for 15 min at 30°C. Poly-(ADP-ribosyl)ation was visualized by 
autoradiography and protein levels by Coomassie staining. (Lane 1: GST, Lane 2: GST-SET7/9 
without EcoRI, Lane 3:  GST-SET7/9, Lane 4: GST-SET7/9 cleaved by PreScission, Lane 5: SET7/9 
after PreScission cleavage and removal of GST)  
 
 
6.5. SET7/9 is mainly localized in the nucleus 
As most cellular target proteins of SET7/9 are nuclear proteins, at least a fraction of 
SET7/9 has to be localized in the nucleus despite the lack of any DNA binding motifs 
or nuclear localization signals [185]. Interestingly, SET7/9 was mainly found in the 
cytoplasmic extracts of MCF7 human breast cancer cells (Fig. 10a). Cytoplasmic 
localization was similarly seen for other cell types such as U2OS cells, T24 human 
bladder carcinoma cells, HEK 293T cells and mouse lung fibroblasts (data not shown). 
Adriamycin treatment, which induces DNA DSBs by topoisomerase II inhibition, had 
no effects on the observed SET7/9 distribution in MCF7 cells (Fig. 10a). 
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To identify the localization of SET7/9 in intact cells, we expressed a GFP-tagged 
version of SET7/9 in U2OS cells and performed live cell imaging under different 
conditions. In contrast to cell extracts, in untreated cells, GFP-SET7/9 was found in 
the cytosol and even more abundantly in the nucleus, but was completely absent from 
the nucleoli (Fig. 10b). This distribution did not change upon treatment with the DSB 
inducer etoposide, the inflammatory cytokine TNF" or the nuclear export inhibitor 
leptomycin B. We thus speculate that in living cells a decent amount of SET7/9 
resides in the nucleus, but that during the preparation of nuclear extracts SET7/9 is 
lost from this fraction, as it is not tightly bound to the chromatin.  
 
 
 
Figure 10. SET7/9 is mainly localized to the nucleus but not tightly associated with the chromatin. 
(a) MCF7 cells were treated with 0.5 %M Adriamycin for the indicated times and fractionated into 
cytoplasmic (CE) and nuclear extracts (NE). SET7/9 localization was then analyzed by Western blot 
(low and high exposure). Preparation of the cellular fractions was controlled by ARTD1 and tubulin. 
(b) U2OS cells were treated with 50 %M etoposide, 10 ng/ml TNF" or 10 ng/ml leptomycin B (LMB) 
for 1 hr and GFP-SET7/9 localization was visualized by live cell microscopy. PC: phase contrast. Note: 
The phase contrast image of the control cells looks different because it was taken in a different area of 
the well, the microscope settings were kept equal for all images. 
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6.6. Role of ARTD1 in NF-!B-dependent gene expression after DNA damage 
ARTD1 plays a role as a cofactor for several transcription factors such as NF-!B 
[103,106,226]. NF-!B is a widely expressed, hetero-dimeric transcription factor that 
is activated by many inflammatory and immunological stimuli like TNF" and LPS. In 
unstimulated cells, it is usually sequestered in the cytosol through its interaction with 
one of several inhibitors of NF-!B (I!Bs). Most exogenous stimuli activate NF-!B 
via a canonical pathway involving rapid I!B kinase (IKK) dependent phosphorylation 
of I!Bs and their degradation by the proteasome, which allows the subsequent 
translocation of NF-!B to the nucleus, where it induces its target genes [227,228].  
Apart from this classical stimulation by exogenous factors, NF-!B can also be 
triggered by endogenous stimuli like genotoxic stress [229]. NF-!B activation by 
these stimuli occurs through an atypical pathway with much slower kinetics and a 
weaker response. The exact mechanisms of NF-!B activation and the set of genes 
induced by DNA damage vary among different cell lines and depend on the DNA 
damage inducing agent and the dose applied [230,231]. Many of the genes induced by 
NF-!B upon DNA damage are anti-apoptotic genes (e.g. cIAPs, XIAP, BCL-XL) and 
genes involved in cell cycle regulation (e.g. Gadd45!) [230,232,233]. NF-!B 
induction and the resulting activation of pro-survival factors is an important 
mechanism how malignant cells develop chemo- and radioresistance and thereby 
evade effective cancer treatment.  
As ARTD1 was shown to act as a coactivator for NF-!B-dependent gene expression 
and its enzymatic activity is strongly induced upon DNA damage, it might play a role 
in DNA damage induced NF-!B activation. Reporter gene assays revealing that NF-
!B-dependent gene expression is severely impaired in ARTD1 knockout cells treated 
with etoposide strengthen this hypothesis [103,111].  
We investigated the functional relevance of ARTD1 in DNA damage induced NF-!B-
dependent gene expression by addressing two different aspects: (i) The role of 
ARTD1 in DNA damage induced nuclear translocation of NF-!B (role of ARTD1 as 
sensor/inducer). (ii) The role of ARTD1 as transcriptional cofactor in DNA damage 
induced gene expression of endogenous NF-!B target genes. 
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6.6.1. ARTD1 is not required for DNA damage induced nuclear shuttling of NF-"B 
X-radiation was used to induce DSBs in MLFs isolated from ARTD1 wildtype (+/+) 
and ARTD1 knockout (-/-) cells. This resulted in the formation of $-H2AX foci that 
gradually decreased over time as a result of DSB repair. Some DNA damage 
independent speckles were detected by the $-H2AX antibody in untreated cells, but 
these were clearly different from the ones induced upon X-radiation. The induction of 
$-H2AX foci as well as the DSB repair was comparable in both cell lines (Fig. 11a).  
This indicated that ARTD1 -/- cells were not more susceptible to the induction of 
DSBs by X-radiation and that ARTD1 was not required for the repair of these DSBs.  
X-radiation also resulted in the formation of PAR in ARTD1 +/+ cells in a dose-
dependent manner. This could be inhibited by the addition of the PARP inhibitor 
DAM-TIQ-A. ARTD1 was the enzyme responsible for PAR formation upon X-
radiation, as PAR was not induced in ARTD1 -/- cells (Fig. 11b). 
In order to address the aspect, if ARTD1 is required for the translocation of NF-!B to 
the nucleus after DNA damage, the shuttling of NF-!B subunit RelA was compared in 
ARTD1 -/- and +/+ cells (Fig. 11c). The inflammatory cytokine TNF" induced a fast 
and robust nuclear translocation of RelA in all cells. X-radiation on the other hand 
induced a much weaker response that developed over a much longer time. Only a 
fraction of RelA shuttled to the nucleus and this was seen in only about 25% of the 
cells. NF-!B shuttling was equal in both cells lines, suggesting that ARTD1 is not 
required for the observed redistribution of RelA upon X-radiation or TNF" treatment.  
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Figure 11. DNA damage induced RelA shuttling to the nucleus is not impaired in ARTD1 
knockout cells. (a) MLFs isolated from ARTD1 wildtype (+/+) and ARTD1 knockout (-/-) mice were 
X-radiated with 3 Gy and afterwards allowed to recover for the indicated times. DSBs were then 
visualized by immunofluorescence staining of $-H2AX. (b) ARTD1 +/+ and -/- MLFs were X-radiated 
with the indicated dose, fixed 5 min later and PAR formation was detected by immunofluorescence 
microscopy. Cells were preincubated with 10 %M DAM-TIQ-A for 2 hrs to inhibit ARTD1 activity. (c) 
ARTD1 +/+ and -/- MLFs were treated with 30 ng/ml murine TNF" for 20 min or X-radiated (IR) and 
fixed after 3 hrs. NF-!B shuttling was then analyzed by immunofluorescence staining of the RelA 
subunit. DAPI was used to stain the DNA. 
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6.6.2. DNA damage induced NF-"B-dependent gene expression is impaired in 
ARTD1 knockout cells 
ARTD1 could also play a role in NF-!B signaling after it has been activated and 
shuttled to the nucleus for example as a transcriptional cofactor of NF-!B or by 
changing the local chromatin architecture. To investigate this possibility, NF-!B-
dependent gene expression was analyzed in ARTD1 +/+ cells after stimulation with 
different DNA damage inducing agents and compared to the response in ARTD1 -/-
cells.  
I"B# was used as a target gene that is usually activated upon NF-!B activation by a 
negative feedback loop independent from the stimulus. The ribosomal gene RPS12 
was used as a negative control whose expression should not change after the 
treatments. Gene expression analysis of I"B# and several anti-apoptotic and cell-cycle 
regulatory genes (GADD45!, cIAP1, XIAP, BCL-XL) in ARTD1 +/+ MLFs confirmed 
that genotoxic stress induces the expression of endogenous NF-!B target genes. As 
expected, the response to DNA damage was much weaker than the one to TNF" 
treatment (induction: 3-4 versus 20 fold) and occurred at later time points (4-6 hours 
instead of 1 hour)(Fig. 12). Although ARTD1 -/- and ARTD1 +/+ cells were treated in 
parallel, the expression of I"B# and other NF-!B-dependent target genes was 
impaired in cells lacking ARTD1. Since ARTD1 is not required for the nuclear 
shuttling of NF-!B after DNA damage in MLFs, these results suggest that ARTD1 
rather regulates downstream events (such as transcription initiation).  
ARTD1 -/- cells were then complemented with human and mouse ARTD1  (Fig. 13a) 
to verify if the impaired PAR formation and NF-!B-dependent gene expression are 
indeed caused by the absence of ARTD1 and not by unspecific variation between the 
two cell lines due to clonal selection. Complementation with human and mouse 
ARTD1 restored PAR formation upon X-radiation but NF-!B-dependent gene 
expression was not reconstituted (Fig. 13b and c).  
This result can be explained by two scenarios: Either the gene expression differences 
between ARTD1 +/+ and -/- cells are generated by cell line variations apart from the 
ARTD1 deficiency or the expression levels of ARTD1 in the complemented cells are 
not high enough to restore NF-!B-dependent gene expression. Although the 
complemented cells were maintained under selection pressure by the antibiotic 
blasticidine, they had a high cell-to-cell variability in ARTD1 protein expression. 
While some cells expressed very high levels of ARTD1, in others ARTD1 expression 
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was almost not detectable. It is thus possible that the amount of cells expressing the 
correct levels of ARTD1 was not high enough to detect an effect on the expression of 
NF-!B target genes. 
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Figure 12. DNA damage induced expression of endogenous NF-!B target genes is impaired in 
ARTD1 -/- MLFs. ARTD1 +/+ and -/- MLFs were treated with 30 ng/ml mTNF", 50 J/m2, 10 and 25 
Gy X-IR, 15 %M CPT, 50 %M etoposide, 0.5 mM H2O2 or 0.5 mM MMS in FCS-free medium and 
harvested after 1 and 4 hrs. Total RNA was then extracted and reverse transcribed with poly-A primers. 
(a) Gene expression was analyzed by conventional RT-PCR and agarose gel electrophoresis. 
Ribosomal gene RPS12 was used as control gene. PCR reactions omitting reverse transcriptase (-RT) 
were used as negative controls. (b) Expression of I"B# and GADD45! was analyzed by real-time RT-
PCR. Values were normalized with the expression of RPS12. The mean ± SEM of technical duplicates 
are shown as fold inductions to the expression in untreated cells.  
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 Figure 13. ARTD1 complementation does not restore NF-!B-dependent gene expression in 
ARTD1 -/- cells. (a) Whole cells extracts of ARTD1 -/- and +/+ cells as well as ARTD1 -/- cells 
complemented with an emty vector (+ pRRL), hARTD1 or mARTD1 were analyzed by Western blot 
using antibodies directed against ARTD1, RelA and tubulin. (b) Immunofluorescence images of 
complemented cells showing ARTD1 expression levels and PAR generation upon X-radiation. (c-f) 
Complemented cells were treated as indicated and expression of I"B# (c), GADD45! (d), BCL-XL (e) 
and cIAP1 (f) was analyzed by real-time RT-PCR (compare Fig. 12). Open bars: + pRRL, solid bars: + 
hARTD1. 
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6.6.3. Discussion 
While it is widely accepted that ARTD1 is involved the regulation of NF-!B target 
gene expression upon DNA damage, the underlying mechanisms are still under debate. 
This has been investigated in many studies with partially contradictory results. Our 
results suggest that ARTD1 is not required for the nuclear translocation of NF-!B, but 
might regulate downstream events during the activation of NF-!B-dependent genes. 
In agreement with this, B. Durkacz et al. show that I!B" degradation and nuclear 
translocation of NF-!B subunits p50 and RelA (measured by immunoblotting of 
nuclear extracts) are not affected by the PARP inhibitor AG14361 or in ARTD1 -/- 
mouse embryonic fibroblasts, but that IR-induced DNA binding and target gene 
activation of NF-!B are disturbed [149]. Another study from this group suggests that 
PARP inhibitor AG-014699 radio-sensitizes cells in an NF-!B-dependent manner by 
preventing ARTD1 downstream signaling to NF-!B [150]. Also in this study, NF-!B 
shuttling after IR was not affected by ARTD1 inhibition or knockdown.  
In contrast to our results, C. Scheidereit and colleagues suggest a model in which 
ARTD1 and its enzymatic activity are required for the formation of a nucleoplasmic 
signalosome that promotes the SUMOylation of IKK subunit NEMO [234]. Modified 
NEMO then translocates to the cytoplasm where it induces the activation of NF-!B 
[235]. This implies a role of ARTD1 upstream of NF-!B translocation to the nucleus. 
The discrepancy between the described study and our own results can be addressed in 
several ways. First of all, the dosage of the genotoxic agents used in this study was 
extremely high (80 Gy or 100 %M etoposide) which might induce other signaling 
pathways than the stimuli we applied (maximum 25 Gy or 50 %M etoposide). 
Furthermore, the results are mainly based on differences between ARTD1 -/- and +/+ 
cells, which could potentially differ in more parameters than the ARTD1 deficiency. 
And finally, the conclusions are also based on the application of the first generation 
PARP inhibitor 3-AB, which is known to inhibit many cellular targets apart from 
ARTD1 [236,237]. Due to this lack in specificity, it is very well possible that 3-AB 
influences NF-!B activation via ARTD1 independent mechanisms. 
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6.7. Phosphorylation of ARTD1 by AMPK 
AMPK is a key player in the regulation of energy metabolism. It is activated by a rise 
in the AMP/ATP ratio within the cell and influences the cellular energy homeostasis 
by phosphorylating many downstream targets. It was shown that ARTD1 is 
phosphorylated by AMPK in vitro and that this phosphorylation is stimulated by the 
addition of AMP [140]. In cells, ARTD1 and AMPK were shown to physically 
interact and overexpression of a constitutively active form of AMPK lead to increased 
ARTD1 automodification [140].  This positive regulation of ARTD1 activity could be 
a direct effect of ARTD1 phosphorylation by AMPK or an indirect effect as AMPK 
activation also increases cellular NAD+ levels [238]. 
We were interested to determine where ARTD1 is phosphorylated by AMPK and if 
the phosphorylation has a direct effect on ARTD1 activity in vitro. In order to identify 
the phosphorylation site in ARTD1, ARTD1 and fragments covering the whole 
protein were subjected to an in vitro kinase assay with AMPK (Fig. 14a). The assay 
confirmed that ARTD1 is phosphorylated by AMPK. The phosphorylation increased 
upon addition of AMP. ARTD1(1-373) was strongly phosphorylated, indicating that 
AMPK phosphorylates ARTD1 in its DBD. ARTD1(373-525) was also modified by 
AMPK, but as ARTD1(373-1014) was not phosphorylated, this site is probably not 
accessible for AMPK in the context of the whole protein. In an attempt to identify the 
sub-domain of the DBD that is phosphorylated by AMPK, ARTD1 deletion mutants 
lacking either the ZFI (aa 1-111), the ZFII (aa 117-201) or the ZBDIII (aa 279-333) 
were in vitro modified with AMPK (Fig. 14b). Deletion of either one of the two zinc 
fingers of ARTD1 almost completely abolished its phosphorylation by AMPK. 
Interestingly, the deletion of the ZBDIII had the opposite effect and markedly 
increased the phosphorylation efficiency. These data suggest that AMPK 
phosphorylates ARTD1 in its first 279 aa and that this phosphorylation requires the 
presence of two intact zinc fingers. Furthermore, it seems that the ZBDIII has an 
inhibitory effect on the phosphorylation maybe by limiting the access of AMPK to its 
phosphorylation site(s) in ARTD1.  
The localization of the AMPK target site within the DBD of ARTD1 prompted us to 
investigate if the phosphorylation was influenced by the presence of DNA, but pre-
incubation of ARTD1 with an annealed double-stranded oligomer had no effect on its 
phosphorylation by AMPK (Fig. 14c). 
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Figure 14. AMPK phosphorylates ARTD1 in its DNA binding domain. (a) Recombinant ARTD1 
full-length and fragments covering the whole protein were incubated with AMPK in an in vitro 
phosphorylation assay with 32P-$-ATP. AMP was used to stimulate AMPK activity. The asterisk 
indicates AMPK autophosphorylation. (b) ARTD1 full-length and DBD sub-domain deletion mutants 
were phosphorylated as in (a). &ZFI: ARTD1 lacking aa 1-111, &ZFII: ARTD1 lacking aa 117-201, 
&ZBDIII: ARTD1 lacking aa 279-333. (c) ARTD1 phosphorylation by AMPK as in (b) but ARTD1 
proteins were preincubated with and without 5 pmol activating DNA for 15 min on ice. 
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The phosphorylation of ARTD1 introduces a negative charge into its DBD and might 
thus change its interaction with DNA by electrostatic repulsion. This in turn could 
affect its DNA-dependent enzymatic activity. This hypothesis was tested by first 
phosphorylating ARTD1 with AMPK and then inducing auto-ADP-ribosylation. Pre-
incubation of ARTD1 with AMPK and ATP had no influence on its PARylation 
activity at different NAD+ concentrations (Fig. 15a). ARTD1 was purified from insect 
cells and might therefore be post-translationally modified already. To rule out that a 
pre-existing phosphorylation of ARTD1 might mask an effect of the in vitro 
phosphorylation by AMPK, a new batch of ARTD1 was purified including a 
dephosphorylation step with calf intestinal alkaline phosphatase (CIP). Pre-incubation 
with CIP had no effect on the PARylation activity of ARTD1 (Fig. 15b). ARTD1 
mono-ADP-ribosylation at very low NAD+ concentrations (10 nM) was also not 
influenced by AMPK-dependent phosphorylation (Fig. 15c).  
We therefore conclude that ARTD1 phosphorylation by AMPK has no influence on 
ARTD1 activity under the conditions tested. It is possible, however, that an effect on 
ARTD1 automodification was missed due to insufficient in vitro phosphorylation 
efficiency.  
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Figure 15. ARTD1 activity does not change upon phosphorylation by AMPK. (a) ARTD1 was in 
vitro phosphorylated with AMPK, purified by nickel affinity chromatography and in vitro PARylation 
was performed on the nickel beads by addition of activating DNA and the indicated concentrations of 
cold NAD+. Automodification was analyzed by immunoblotting with a PAR-specific antibody (LP96). 
(b) Automodification activity of recombinant ARTD1 that was treated with and without CIP during 
purification was examined in an in vitro PARylation assay in solution [89] followed by 
immunoblotting. (c) ARTD1 activity after phosphorylation by AMPK was assessed as in (a) but with 
10 nM 32P-labeled NAD+. Mono-ADP-ribosylation of ARTD1 was visualized by autoradiography. 
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6.8. Growth defect in cells complemented with ARTD1 E988K 
The catalytic glutamate E988 in ARTD1 is important for its ability to synthesize 
ADP-ribose polymers. The ARTD1 mutant E988K thus displays only weak 
monoART activity, but is not able to attach further ADP-ribose units to the initially 
transferred ADP-ribose molecules. Complementation of MLFs isolated from 
ARTD1 -/- mice with ARTD1 E988K induced a severe growth defect although 
ARTD1 deficient cells (complemented with an empty vector) or cells complemented 
with wildtype ARTD1 grew normally (Table 2). The doubling time of E988K 
complemented cells was 2-3 times longer than the one of wildtype complemented 
cells.  
 
 
  Growth rate in 48 hrs Doubling time (hrs) 
  1x105 5x105 1x105  5x105 
pRRL 2.85 3.21 31.77 28.53 
ARTD1 wt 2.65 3.52 34.14 26.44 
ARTD1 E988K 1.46 1.625 87.92 68.53 
 
 
Table 2. Proliferation of ARTD1 -/- cells complemented with wildtype (wt) ARTD1 or the E998K 
mutant. ARTD1 -/- MLFs were complemented with an empty vector (pRRL), hARTD1 wt or hARTD1 
E988K. To determine proliferation rates and duplication times, 1x105 and 5x105 cells were seeded, 
grown in presence of 5 %g/ml blasticidine for 48 hrs and then harvested and counted using a Neubauer 
hemocytometer. 
 
 
 
The reduced proliferation rates were not caused by cell cycle defects as E988K cells 
displayed similar cell cycle profiles as cells complemented with an empty vector or 
wildtype ARTD1 in early as well as in later passages (Fig. 16b and c). E988K cells 
were also not positive for senescense-associated #-galactosidase activity (Fig. 16d) 
indicating that E988K expression did not induce senescence. The negative effect of 
ARTD1 E988K on cell growth was further emphasized by the finding that E988K 
expression levels at later passages were much lower than wildtype expression levels 
(Fig. 16a) concomitant with the recovery of normal proliferation rates. This suggested 
that silencing of the E988K construct e.g. by epigenetic mechanisms conferred a 
growth advantage to the outgrowing clones. 
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Figure 16. Characterization of E988K complemented cells. (a) Protein expression levels of ARTD1 
in ARTD1 complemented stable cell lines (compare Table 1) were analyzed by Western blot. (b) Cell 
cycle profiles of ARTD1 complemented cells (passage 4 post transduction) were analyzed by flow 
cytometry. Cells were fixed, RNA was digested and DNA content was determined by propidium iodide 
staining and flow cytometry. (c) Same as in (b), but the experiment was performed with cells that were 
frozen and thawed after the transduction (passage 7 after thawing). (d) Senescence-associated #-
galactosidase activity was analyzed by acidic #-galactosidase staining [239]. Briefly, cells were fixed 
with 0.2% glutaraldehyde in PBS for 5 min and then stained with 1 mg/ml X-gal at pH 6.0 and 37°C 
for 24 hrs. HEK293T cells overexpressing #-galactosidase were used as positive control. 
Representative light-microscopy images are shown. 
 
The phenomenon that mutations interfering with the enzymatic activity of ARTD1 
cause prolonged doubling times has been reported previously [240,241]. Cells 
completely lacking ARTD1 grow normally indicating that ARTD1-dependent PAR 
formation per se is not required for cell proliferation. This suggests that the 
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unprocessive ARTD1 protein itself disturbs normal cell growth. It is possible that 
E988K binds to certain DNA structures e.g. nick and DSBs, but unlike wildtype 
ARTD1, it cannot dissociate upon activation and thus blocks the access for other 
factors such as ARTD2 and proteins of the transcription and DNA repair machinery. 
This dominant-negative effect was also seen for the ARTD1 DBD alone whose 
overexpression in cells markedly inhibited PAR formation, induced hypersensitivity 
to alkylating agents and in some studies also reduced cell growth [242-245]. The 
hypothesis is challenged by the fact that ARTD1 inhibition by small-molecule 
inhibitors is compatible with normal cell growth in most cell lines. This inhibition, 
however, is reversible in most cases and thus might have other effects than the 
irreversible inactivation of ARTD1’s PAR activity by certain mutations. The exact 
mechanisms of cell growth inhibition by unprocessive ARTD1 and its cellular targets 
have to be elucidated in future studies.  
 
6.9. Materials and methods 
6.9.1. Mouse cell lines and complementations 
MLFs were isolated from ARTD1 +/+ and -/- mice and immortalized using the 3T3 
protocol [246]. Established MLF cell lines were grown in Dulbecco’s Modified Eagle 
medium supplemented with 10% (v/v) fetal calf serum, penicillin/streptomycin and 
1X Non Essential Amino Acids (Gibco). Lentivirus production in HEK293T cells and 
transduction of MLFs was performed as described elsewhere [247]. Briefly, HEK 
293T cells were pretreated with 25 %M chloroquine for 5 min and transfected with 3.5 
%g envelope plasmid, 6.5 %g packaging plasmid and 10 %g transfer vector (pRRL 
backbone) using the calcium phosphate method. Medium was replaced 6 hrs later and 
virus was harvested 40 hrs post transfection.  
For transductions, 1 x 105 MLFs were seeded in sixwell plates and one day later, cells 
were incubated with the virus in presence of 4 %g/ml polybrene overnight. Selection 
was started with 5 %g/ml blasticidine two days after the transduction and stable cell 
lines were maintained in presence of the antibiotic. 
6.9.2. Live cell microscopy and immunofluorescence 
Images were taken with an Olympus BX51 microscope or a Leica DMI6000 B 
inverted microscope. For immunofluorescence analysis, cells were fixed with 4% 
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paraformaldehyde in PBS for 15 min at RT. Samples were then blocked with 2% BSA 
in PBS with 0.1% Triton and afterwards incubated with the indicated antibodies in 
blocking solution. For anti-PAR immunofluorescence staining, cells were fixed in 
methanol:acetic acid 3:1 for 5 min on ice. Blocking and antibody incubation were 
then performed in 5% milk in PBS-T (0.05% Tween-20). Mounting was done in 
Vectashield with DAPI (Vector Labs). 
6.9.3. Gene expression analysis by conventional and real-time RT-PCR 
Total RNA was extracted using the NucleoSpin® RNA II kit (Macherey Nagel). 1 – 2 
%g total RNA were reverse transcribed with the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems). For conventional RT-PCR, 150 ng cDNA 
were amplified with 0.6 u GoTaq® DNA Polymerase (Promega) using 0.4 %M primers 
in a 25 %l reaction. Real-time PCR was performed in duplicates in a Rotor-Gene 
3000A thermal cycler (Corbett Research) using the SensiMix SYBR & Fluorescein 
kit (Bioline). 10 ng cDNA were used in each reaction and a standard curve ranging 
from 0.05 to 50 ng cDNA was done to calculate primer efficiencies. Statistical 
analysis was performed with REST© software, version 2 [248]. 
6.9.4. In vitro phosphorylation assay 
1 %g recombinant ARTD1 was incubated with 100 ng active AMPK (A1/B1/G2, 
SignalChem) in presence of 10 %M ATP spiked with 1%Ci 32P-$-ATP (Hartmann 
Analytic) in kinase buffer (20 mM HEPES pH7.5, 5 mM MgCl2, 0.01% Brij-35, 0.4 
mM DTT, 300 %M AMP, 1 mM NaF, 0.1 mM NaV3O4, 20 mM #-glycerophosphate) 
for 15 min at 30°C. Reactions were stopped by addition of 5X SDS-sample buffer, 
denatured at 95°C for 5 min and separated by SDS-PAGE. Gels were stained with 
Coomassie, dried and autoradiographed. 
For sequential phosphorylation/ADP-ribosylation assays, CIPped ARTD1 was 
phosphorylated as described above but using 20 %M cold ATP, bound to nickel 
affinity resin after phosphorylation, washed and modified in PAR buffer (50 mM Tris 
pH8.0, 150 mM NaCl, 4 mM MgCl2, 5 pmol activating DNA, 1 mg/ml pepstatin, 1 
mg/ml bestatin, 1 mg/ml leupeptin) after addition of hot or cold NAD+ as indicated.  
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DISCUSSION AND PERSPECTIVES 
7. Summary of results 
We have investigated the influence of the KMT SET7/9 on the two chromatin-
associated proteins ARTD1 and linker histone H1. In vitro methylation assays 
demonstrated that SET7/9 specifically methylates ARTD1, but not ARTD2, another 
member of the ARTD family. Using in silico analysis and mass spectrometry, K508 
of ARTD1 was identified as the target site for SET7/9-dependent methylation. This 
was confirmed by site-directed mutagenesis of this residue to arginine. Interestingly, 
K508 is located close to confirmed acetylation and PARylation sites within the AMD 
of ARTD1 [89,142]. This prompted us to investigate the reciprocal influence of 
ARTD1 methylation and other post-translational modifications within this region. 
While methylation of ARTD1 did not interfere with its automodification, ARTD1 
PARylation strongly inhibited its subsequent methylation by SET7/9. In contrast, we 
did not observe differences in p300-dependent acetylation of methylated and 
unmethylated ARTD1.  
Using a newly generated antibody directed against the monomethylated lysine residue 
K508 in ARTD1, we were able to detect ARTD1 K508 methylation in U2OS cells 
overexpressing wildtype SET7/9, but not after overexpression of the enzymatically 
inactive mutant H297A. Interestingly, we found that PAR formation after H2O2 
treatment was decreased after SET7/9 knockdown, while we could see enhanced 
H2O2–induced PAR formation after overexpression of wildtype but not H297A 
SET7/9. Reduced ARTD1 activity in nuclear extracts from SET7/9 knockdown cells 
was also observed in radioactive PARylation assays.  
In radioactive PARylation assays, we observed that ARTD1 activity was higher in 
nuclear extracts of cells complemented with wildtype ARTD1 compared to cell lines 
complemented with methylation deficient ARTD1 mutants. This effect was reduced 
in presence of exogenous ARTD1-activating DNA. These results indicate that 
SET7/9-dependent methylation of K508 is important for ARTD1 activity in cells, 
especially under conditions where ARTD1 is only weakly activated. We then 
monitored ARTD1 recruitment to locally induced DNA lesions by live cell 
microscopy and found that ARTD1 K508R is recruited less efficiently to DNA 
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damage sites induced with a 775 nm laser than the wildtype protein. This difference 
was not observed at 1050 nm.  
Finally, we observed that H1 is also monomethylated by SET7/9 at several lysine 
residues in its CTD. We used deletion and cluster mutation strategies to identify six 
KAK motifs in H1 that are methylated by SET7/9 at the last lysine residue (K121, 
K129, K159, K171, K177 and K192). The addition of plasmid DNA completely 
abolished SET7/9-dependent methylation of H1. Furthermore, we found that ARTD1-
dependent PARylation of H1 and H3 prevents their subsequent methylation by 
SET7/9. In a histone mix, H3 is the preferred target for ARTD1 as well as for SET7/9, 
but prior PARylation of the histones can shift the substrate specificity of SET7/9 from 
H3 to H1.  
 
8. ARTD1 regulation by SET7/9-dependent methylation 
The addition of a methyl group to lysine residues of target proteins can affect the 
protein function by different mechanisms. While methylation does not change the 
positive charge of the lysine residue, it increases the size and hydrophobicity of the 
side chain and might thus directly influence the enzymatic activity if the target site 
lies in or close to the catalytic center or if the methylation induces or inhibits 
intramolecular interactions. In vivo, methylation can also indirectly regulate the 
function of a protein by inducing or inhibiting the interaction with other proteins or 
partner molecules, by changing its subcellular localization or by influencing its 
stability.  
In the presented work, it was discovered that SET7/9 methylates ARTD1 at a specific 
lysine residue in its AMD (K508) and that this modification increases ARTD1 
activity in vitro and in vivo. This positive effect on the enzymatic activity of ARTD1 
was mainly observed at sub-optimal conditions i.e. at non-saturating DNA (compare 
Fig. 4B and C in section 5.1) or low NAD+ concentrations (100 nM, data not shown). 
These results indicate that SET7/9-dependent methylation lowers the activation 
threshold for ARTD1 by weak triggers rather than being an absolute requirement for 
its activity. We thus became interested in the mechanism by which methylation at 
K508 sensitizes ARTD1 for stimulation by low DNA damage. To address this 
question we analyzed the nuclear distribution of ARTD1 as a function of its 
methylation. The affinity of ARTD1 for undamaged chromatin did not change upon 
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SET7/9 knockdown. However, ARTD1 wildtype was recruited more efficiently to 
laser-induced DNA damage than ARTD1 K508R at 775 nm, but not at 1050 nm (Fig. 
1D and S1D in section 5.1).  
These different observations at 775 and 1050 nm wavelengths can be explained in two 
ways: (1) Fewer DSBs are formed at 1050 nm than at 775 nm and thus overall less 
ARTD1 protein is recruited to the laser damaged site. At this wavelength, the 
sensitivity of the system might thus not be high enough to detect differences between 
ARTD1 wildtype and K508R. (2) It is known that the setup at 1050 nm selectively 
produces DNA strand breaks while multiphoton absorption at 775 nm generates UV 
photo products (cyclobutane-pyrimidine dimers and 6-4 photoproducts) and oxidative 
base damage in addition to DNA strand breaks [222]. Thus, it is possible that ARTD1 
methylation regulates its recruitment to specific types of DNA damage that are only 
induced at 775 but not at 1050 nm. Several lines of evidence indicate that ARTD1-
dependent PAR formation is triggered by UV damage or exposure to reactive oxygen 
species (although the exact molecular structures responsible for ARTD1 activation by 
these stresses remain to be determined) and that ARTD1 modulates the induction of 
cell death upon these stresses [249-251]. Therefore, it will be interesting to see if 
methylation sensitizes ARTD1 for the activation by these types of DNA damage. 
This could be further investigated by in vitro PARylation assays in which DNA 
structures containing different types of lesions with protected ends are used to activate 
methylated and unmethylated ARTD1. Another approach to test this hypothesis 
would be to directly measure the affinity of unmethylated and methylated ARTD1 to 
different DNA structures e.g. by DNA-pulldown assays, by microplate capture assays 
with immobilized DNA probes or by surface plasmon resonance spectroscopy.  
If SET7/9-dependent monomethylation indeed increases the response of ARTD1 to 
certain types of stress, it might also influence the cellular fate induced by these 
stresses. In fact, SET7/9 has been previously implicated in the modulation of cell 
cycle regulation and apoptosis in response to diverse stresses such as treatment with 
the inflammatory cytokine TNF" or DNA intercalator doxorubicin by methylating 
different factors e.g. p53, E2F1 and pRb [195,201-203]. ARTD1 methylation might 
thus be an additional level of cell fate regulation by SET7/9 in response to particular 
stresses. However, the role of SET7/9 at least in p53-induced cell cycle arrest and 
apoptosis after topoisomerase inhibitor treatment was not confirmed in SET7/9 
knockout mice [187,196]. A detailed characterization of SET7/9 knockout mice and 
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derived cell lines will elucidate if and how SET7/9 might influence the sensitivity to 
other cellular insults such as UV irradiation or reactive oxygen species. In this respect, 
it is also important to note that SAH, which is generated as a byproduct of 
methylation reactions, is a potent inhibitor of all methyltransferases [252,253]. To 
prevent accumulation of SAH and resynthesize SAM, SAH is cleaved by the enzyme 
SAH hydrolase, which requires NAD+ as essential cofactor. Thus, it is very likely that 
cellular stresses that influence nutrient supply and energy consumption (and thereby 
indirectly the cellular SAM/SAH ratio critical for the methylation potential) will also 
influence the methylation processes within a cell [254]. As ARTD1 is a NAD+-
consuming enzyme, this might create a feedback loop between ARTD1 methylation 
and ARTD1 activity. ARTD1 might not be methylated under conditions that do not 
favor methylation i.e. when NAD+ levels and hence SAM/SAH ratio are low. As a 
result, ARTD1 would only be activated by high genotoxic stress at these conditions in 
order to preserve the cellular NAD+ levels. Methylation might thus be a fine-tuning 
mechanism to facilitate ARTD1 activation when NAD+ levels are high enough. 
The results described here provide first insights for the regulation of ARTD1 
enzymatic activity by SET7/9-dependent methylation. We show that SET7/9 
methylates ARTD1 in its AMD, but neither in its DBD nor in its catalytic and NAD+-
binding domain (Fig. 2B in section 5.1), which would have supported an involvement 
in substrate or activator binding. The catalytic mechanism of ARTD1 is little 
understood. It is known that the DBD of ARTD1 interacts with its catalytic domain in 
a DNA-dependent manner and that this interaction increases the affinity of ARTD1 
for its co-substrate NAD+ [89]. Furthermore, several studies suggest that ARTD1 acts 
as a catalytic dimer [89,255,256]. It is thus tempting to speculate that the methylation 
at K508 enhances the dimerization or intramolecular interactions of ARTD1 and 
thereby modulates its activity.  
In vivo, the methylation of ARTD1 might alternatively influence its function by 
promoting the interaction with other proteins. HP1 proteins are known to interact with 
ARTD1 [257] and contain a chromodomain, which binds trimethylated H3K9. 
However, it is unlikely that this domain also recognizes monomethylated ARTD1, as 
both the methyl state and the sequence context of this site are quite different from 
H3K9. Yet, the list of protein domains specifically recognizing individual protein 
modifications or their combinations is constantly increasing and it is very well 
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possible that future work will identify interaction partners of ARTD1 that are 
dependent on the methylation of K508. 
Finally, it remains to be determined if ARTD1 is constitutively methylated in vivo or 
if it is only methylated in response to certain conditions. We have tried to tackle this 
question by treating cells with different stimuli (LPS, TNF", etoposide, UV 
irradiation, H2O2), using different cell types in varying differentiation stages and by 
analyzing cells in different cell cycle phases (data not shown). So far, ARTD1 
methylation could only be detected in cells overexpressing SET7/9 (Fig. 2E and F in 
section 5.1) and none of the treatments or cell cycle phases led to specific differences. 
It could be that endogenous K508 methylation levels are very low and cannot be 
detected by the generated antibody. Alternatively, SET7/9-dependent 
monomethylation of ARTD1 might be the rate-limiting step for further methylation 
events in vivo and therefore mainly di- or trimethylated ARTD1 exists under 
physiological conditions, which might not be recognized by the antibody developed 
against monomethylated ARTD1. ARTD1 monomethylation at K508 was also found 
in several mass spectrometric studies with breast cancer samples and Jurkat T cells 
cited on PhosphoSitePlus® [258], but there is no information about control tissues or 
non-cancerous cell lines.  
 
9. Putative functions of H1 methylation by SET7/9 
SET7/9 was first isolated as a mono-methyltransferase for H3K4 [182,183]. In the 
course of our studies, we found that SET7/9 is also capable of methylating linker 
histones. We identified six KAK sites in the CTD of H1.4, which are methylated at 
the last lysine residue in in vitro methylation assays with recombinant SET7/9 (Fig. 
17). However, the in vivo function and biological relevance of this modification are 
still unclear. This is partially due to the lack of specific antibodies recognizing the 
mono-methylated KAK motifs in H1.4. We found that the antibody generated against 
methylated ARTD1 showed cross-reactivity with methylated H1.4 in vitro (data not 
shown). Yet, its application for methylated linker histones in vivo is difficult, as it 
lacks specificity for H1.4 and recognizes many other potentially methylated proteins 
as well. We also tested other antibodies directed against methylated lysines, but faced 
the same limitations (data not shown).  
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One possible function of H1 methylation by SET7/9 might be the stimulation or 
repression of other post-translational modifications. Compared with core histones, 
little is known about the modifications and the corresponding modifiers of the linker 
histones. Interestingly, the four last KAK motifs, which displayed the strongest 
methylation in in vitro methylation assays with SET7/9 (Fig. 1E in section 5.2), are 
located in close proximity to well-known CDK phosphorylation sites (Fig. 17). 
Crosstalk between K26 dimethylation and AuroraB-mediated phosphorylation of S27 
has been reported previously [259]. A similar crosstalk might exist between SET7/9-
dependent H1 methylation and phosphorylation by CDKs. Two of these sites (S172 
and S187) are not exclusively phosphorylated during mitosis and their 
phosphorylation in interphase correlated with transcription and chromatin relaxation 
[48].  
Based on in vitro experiments showing that H3K4 monomethylation precludes 
repressive histone modifiers, H3K4 methylation by SET7/9 was linked to 
transcriptional activation. Several studies confirmed a positive role of SET7/9 on 
expression and H3K4 methylation of specific subsets of genes [184-186,260].  
SET7/9 knockout mice on the other hand show no change in global H3K4 
methylation levels. The same gene-specific function could hold true for H1 
methylation by SET7/9. A prerequisite to test this hypothesis is the generation of an 
antibody specific for this modification. With such a tool one could analyze the 
methylation of H1 on individual genes and promoters in a SET7/9-dependent manner. 
Moreover, ChIP-sequencing could be used to map the global distribution of this 
Figure 17. Human H1.4 amino acid sequence with known post-translational modification sites. 
The grey box marks the central globular domain. The six newly identified KAK motifs that are 
methylated by SET7/9 are highlighted in red. Blue: PARylation (PAR), red: phosphorylation (P), 
green: methylation (me, number indicates methylation state). 
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modification. In this context, it will also be exciting to assess the correlation between 
H1 methylation by SET7/9 and H1 phosphorylation at S172 and S187. 
We found that SET7/9-dependent H1 methylation is inhibited in the presence of DNA 
(Fig. 1B in section 5.2). This can be explained by DNA-induced conformational 
changes of the H1 CTD and by the charge neutralization through DNA, as SET7/9 is 
known to prefer lysine residues in a positively charged context. Likewise, methylation 
may directly influence the binding of H1 to DNA and its function in chromatin 
compaction, especially as the six lysine residues targeted by SET7/9 all reside in the 
CTD of H1.4, which is important for chromatin binding [9]. We compared the nuclear 
distribution of wildtype GFP-H1.4 and the K6R mutant by live cell microscopy (Fig. 
8) and their mobility in FRAP experiments (data not shown) but did not observe any 
differences under the tested conditions. However, it is possible that differences in 
H1.4 mobility are only detectable in cells overexpressing or lacking SET7/9 as it was 
also the case for ARTD1 methylation in vivo. We also generated H1.4 fusion proteins 
with photoactivatable GFP, which may be used in future studies to monitor the 
dynamics of H1.4 in certain nuclear regions and under specific conditions as a 
function of SET7/9-dependent methylation.  
Genome-wide binding studies revealed that H1 resides primarily on inactive genes, 
while ARTD1 displays reciprocal binding to chromatin [102]. SET7/9-mediated 
methylation might thus regulate the exchange of H1 and ARTD1 on their target 
promoters during gene activation. This could be accomplished by modulating the 
interaction of H1 and/or ARTD1 with other chromatin binding factors that facilitate 
their deposition or displacement from chromatin and thereby promote alterations in 
chromatin structure. This hypothesis could be analyzed by identifying methylation-
dependent interaction partners of H1 and ARTD1 and by mapping the global 
chromatin distribution of H1 and ARTD1 in a SET7/9-dependent manner e.g. by 
comparing SET7/9 wildtype and knockout cells. 
 
10. Crosstalk of ARTD1 and SET7/9 on chromatin 
Epigenetic modifications are DNA-sequence independent heritable changes of 
chromatin that regulate gene expression and thereby influence the specific phenotype 
of a cell. Epigenetic modifications include (1) DNA methylation, (2) histone 
modifications and (3) chromatin remodeling. ARTD1 and histone ADP-ribosylation 
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were previously suggested as components of the histone code [73,98]. The results 
described here provide a further line of evidence for this hypothesis. We show that 
ARTD1-dependent PARylation of histones influences their subsequent methylation 
by SET7/9 (Fig. 3 in section 5.2). Compared to phosphorylation, which strongly 
reduces methylation if in proximity of SET7/9 target lysine residues [191], 
PARylation is a much more bulky modification with more negative charges and 
therefore also inhibited histone methylation by SET7/9. Based on our experiments, we 
know that SET7/9 methylates both, H1 and H3. Yet, when both histones are present, 
H3 is preferably methylated over H1. Strikingly, PARylation did not merely inhibit 
SET7/9-dependent methylation of histones, but completely shifted its substrate-
specificity from H3 to H1. These observations could be explained by sequential 
PARylation events, where ARTD1 modifies H3 before H1. PARylation of H3 would 
then inhibit its subsequent methylation by SET7/9 and its competition as a SET7/9 
target with H1 (Fig. 18).  
 
Figure 18. Crosstalk of ARTD1 and SET7/9 on histone modifications. H1 and H3 compete for 
methylation by SET7/9. As soon as H3 is PARylated by ARTD1, H1 becomes methylated by SET7/9. 
If H1 is also PARylated, none of the two histones are methylated any more. Schematic representation 
of our in vitro data. 
 
This ARTD1-dependent regulation of the substrate specificity of another histone 
modifying enzyme may be an exciting mechanism to explain how ARTD1 influences 
chromatin-associated processes such as transcription. It is important to notice that 
progressive PARylation of histones also inhibited the methylation of H1, 
documenting that different outcomes for SET7/9-dependent histone methylation can 
occur depending on the extent of ARTD1 activity.  
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The complexity of ARTD1-dependent histone modifications is increased by the facts 
that (1) ARTD1 can modify all core histones and the linker histones [261] and (2) the 
size and quality (e.g. branching or length) of the polymers may differ under varying 
conditions and depending on the substrate histone. Therefore, future studies should 
not merely focus on the influence of ARTD1 and PARylation on other histone 
modifications but also on how ARTD1-dependent histone methylation itself is 
regulated. In this regard, it will also be interesting to investigate if SET7/9-dependent 
ARTD1 methylation may influence its substrate choice and trans-PARylation 
activities. 
 
11. SET7/9 - a stress sensor and tumor suppressor? 
While SET7/9 was first identified as a histone methyltransferase for H3K4, it is now 
widely accepted that its main function may be the methylation of other, non-histone 
proteins. SET7/9 has a unique SET domain structure and is found in many animals 
from zebrafish to humans. It has a broad substrate-specificity and a rather relaxed 
consensus motif (Fig. 19).  
                
 
Figure 19. SET7/9 consensus motif. The only invariable residue is the lysine at position 6, which 
becomes methylated. The sequence logo was created using WebLogo (University of California, 
Berkeley [262]). SET7/9 target sequences from known substrates are displayed in the box. H3 and H1 
target sequences were omitted from the logo generation for technical reasons. 
 
Recently, Dhayalan et al. have published a list of 91 new SET7/9 target peptides 
[191]. They applied peptide-array methylation to identify an optimized target 
sequence for SET7/9 ([GRHKPST][K> R][S>KYA RTPN][Kme]). We have now 
identified ARTD1 and H1 as additional substrates. Thus, the list of SET7/9 target 
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proteins is rapidly growing, indicating that SET7/9-dependent methylation is a widely 
spread, relevant post-translational modification. Although the localization of SET7/9 
is not confined to the nucleus, all substrates identified so far are proteins with 
important chromatin-associated functions related to gene expression, cell proliferation 
and tumor formation and progression. Yet, based on the rather mild phenotype of the 
available knockout mouse strains [187,196], an essential function of SET7/9 under 
normal, physiological conditions is very unlikely. Furthermore, although Set7/9-
dependent methylation was shown to stabilize and activate several tumor suppressor 
proteins (e.g. p53, pRb), the knockout mice did not display any increased 
predisposition to tumorigenesis. Thus, SET7/9 might be only required under certain 
stress or pathophysiological conditions or SET7/9 loss might be compensated by other 
methyltransferases or unrelated mechanisms. With the help of new tools like the 
SET7/9 knockout cell lines and more specific chemical inhibitors of SET7/9, it will 
be exciting to unravel and re-evaluate the exact functions of SET7/9 during 
tumorigenesis and normal development. !
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